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Current clinical methods for determining disease activity and treatment response in 
rheumatoid arthritis (RA) are inadequate. The aim of this thesis was to discover 
accessible circulating biomarkers of disease activity and thus treatment response in 
RA. This has the potential to aid clinical decision making at an earlier time point and 
improve long-term patient outcome. 
This study has established that the ratio between relative numbers of CD169+ 
monocytes and CD43+ Tregs, two key cells in inflammation, are positively associated 
with disease activity in RA patients. Furthermore, RA patients who have not 
responded to cDMARD treatment exhibited circulating Tregs with a lower activation 
state compared to those who have responded. Subsequent cell culture experiments 
used sialic acid (Sia) as a surrogate of CD169, because it binds to CD169 before 
ligation. Sia was found to suppress Treg activity, reducing intracellular activation 
markers FoxP3 and NFκB, and secretion of inflammatory cytokines. Thus, changes in 
levels of circulating CD169+ monocytes may be the cause of defective Treg activity in 
RA non-responders, potentially via the CD43 Treg cell surface marker. 
A range of circulating plasma proteins were identified to be associated with RA 
disease activity as well as treatment response. With further validation, a biomarker 
panel of specific plasma proteins could prove to be a reliable method of determining 
treatment response earlier than currently possible. Such a panel may also improve 




In summary, this thesis provides compelling evidence of the potential of how 
treatment response can be determined by analysing key cells and proteins in 
peripheral blood. It is postulated that with further validation, these markers could 
enable RA treatment response to be determined earlier than the current timeline of 
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1.0 Rheumatoid Arthritis 
 
Rheumatoid arthritis (RA) is a chronic, autoimmune condition that involves 
inflammation of the synovial membrane surrounding joints. Physical symptoms of RA 
vary depending on disease severity, but typically include swelling, tenderness and 
pain in affected joints. The joint pain and stiffness experienced during RA is a 
consequence of the actions of various immune cells within the synovial membrane. 
These immune cells contribute to cartilage breakdown via secretion of specific 
proteins and enzymes. As the cartilage surrounds and protects the underlying bone, 
its destruction causes the bone to become exposed and susceptible to erosion (Miller 
et al. 2009; Jung et al. 2014). Therefore, in severe cases patients may develop long 
term disabilities due to the irreversible damage caused.  
As joint damage can rapidly occur in RA, clinicians need to make robust decisions in 
prescribing an effective treatment regimen in order to dampen disease activity in a 
timely fashion. Currently however, clinicians are unable to pre-determine treatment 
efficacy for individual patients, thus it may take an extensive amount of time to reach 
remission. Additionally, current measures of disease activity are considered to be 
unreliable (Smolen et al. 2010a; Ormseth et al. 2015; Jensen Hansen et al. 2017). This 
chapter discusses current clinical measures of disease activity in RA and common 
treatment strategies. Furthermore, this thesis postulates that the action of key 
immune cells in RA may be a better representation of disease activity than current 
measures, and may therefore be more effective in determining treatment response. 
Sensitive biological markers of disease activity would vastly benefit both the patient 
and clinician as they could assist in determining treatment response earlier than 
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currently possible. Therefore, this could prevent long term damage in patients who 
do not respond to initial treatments, enabling them to move to a more effective 
treatment at an earlier time point.  
1.0.1 Prevalence of Rheumatoid Arthritis 
 
RA affects between 0.5% and 1% of the entire adult population (Gabriel and Michaud 
2009), increasing to 6% in people aged above 65 years (Davis and Matteson 2012). 
Women are approximately 3 times more likely to suffer from RA than men (The 
Arthritis Foundation 2015), which may be due to a number of factors at play as 
discussed below. Increased levels of specific female hormones may contribute, 
however conflicting evidence from previous studies suggest further work needs to 
be carried out (Pikwer et al. 2012; Beydoun et al. 2013; Alpizar-Rodriguez et al. 2017).  
Environmental factors may also play a role in RA prevalence, with trends observed 
across particular geographical populations. For example, lower prevalence is 
reported in China and Japan, whereas increased prevalence is observed in Pima 
Indians (Jacobsson et al. 1994; Shichikawa et al. 1999).  
Research to date also suggests diet and infections could play a role (Karlson and 
Deane 2012). Additionally, the human microbiome has been associated with RA 
prevalence and pathogenesis. For example, the gut microbiome in RA patients was 
previously found to contain a different bacterial composition compared to the 
control group, including a lower percentage of Bifidobacteria (Vaahtovuo et al. 2008). 
This is of importance because bacterial composition in the gut can produce butyric 
acid, leading to the differentiation of regulatory T cells (Tregs) which play a pivotal 
role in RA (Furusawa et al. 2013). Periodontal disease, caused by the oral bacteria 
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Porphyromonas gingivalis, has also been associated with RA prevalence where as 
many as 60% of RA patients exhibit symptoms (Mobini et al. 2017).  
Overall, the prevalence of RA can be a combination of many factors, not least the 
influence of predisposing genes. Interestingly, a genetic study of monozygotic twins 
demonstrates a low concordance rate of approximately 15%, which suggests a 
number of additional factors impact upon RA risk (Silman et al. 1993). However, more 
recent advances have shown a number of differences in gene expression in disease 
discordant monozygotic twins, including upregulation of laeverin and osteoclast 
stimulating factor-1 in RA (Haas et al. 2006). 
The predisposing genetics of RA has been the focus of many research efforts over the 
last decade. The human leukocyte antigen (HLA) genes in particular are associated 
with increased risk of RA (Stastny 1976). Specifically, various risk alleles that share a 
unique amino acid sequence within HLADRB1 have been associated with RA risk 
(Gregersen et al. 1987). For example, HLADR4 is linked to increased prevalence of the 
disease (Pratt et al. 2009), and has been shown to increase in RA patients compared 
to healthy controls (Stastny 1978). Further studies have associated the involvement 
of these ‘shared epitope’ HLA molecules with the production of autoantibodies such 
as anti-citrullinated peptide antibodes (ACPAs) (Arend and Firestein 2012; Viatte et 
al. 2013). Interestingly, environmental factors such as smoking have been associated 
with HLADRB1 as well as autoantibody production, thus indicating RA prevalence 
may be a combination of genetic and environmental factors (Boechat Nde et al. 2012; 
Fisher et al. 2014). 
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Advances in the ability to detect single nucleotide polymorphisms (SNPs) have greatly 
accelerated the unearthing of variants associated with RA. For example, 
polymorphisms of cytotoxic T lymphocyte protein-4 (CTLA-4), an important factor in 
T cell co-stimulation, have been related to RA risk (de Vries 2011). Further SNPs 
associated with risk include peptidyl arginine deiminase-type 4 (PADI4) and protein 
tyrosine phosphatase-non-receptor type 22 (PTPN22), the latter being one of the 
most strongly RA associated SNPs to date (Suzuki et al. 2003; Begovich et al. 2004). 
Epigenetic studies of RA have also added to the knowledge base of how the disease 
develops. DNA methylation, which can modulate gene expression, is extremely 
important due to its downstream impacts on key pathways. For example, global 
hypomethylation in T cells was previously unveiled in RA patients compared to 
healthy subjects (Richardson et al. 1990), stressing the importance of methylation in 
autoimmune responses. More recent studies observed methylation differences in RA 
patients compared to control groups, including within fibroblast-like synoviocytes 
(FLS) which are key cells involved in disease pathogenesis within the synovial 
membrane (Nile et al. 2008; Nakano et al. 2013). This type of analysis may provide 
more insight into the cellular pathology in RA patients.  
 1.0.2 Diagnosis of RA 
 
When a patient is referred to a rheumatologist, a series of tests must be carried out 
before the patient is formally diagnosed. A physical examination of the joints is 
carried out to detect any swelling or tenderness. Blood tests are also used to check 
for common biological markers that can indicate whether inflammation is present. 
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Additionally, radiographic tests may be carried out to assess any damage or 
inflammation of the joints (NICE 2009). 
The American College of Rheumatology (ACR) and the European League Against 
Rheumatism (EULAR) provide classification criteria guidelines to aid clinical diagnosis 
of RA. The 2010 ACR/EULAR guidelines describe a scoring system that takes into 
account the number of swollen and tender joints, the presence of autoantibodies in 
serum, the duration of symptoms and elevation of acute phase reactants (American 
College of Rheumatology and European League Against Rheumatism 2010). If a 





The guidelines from the National Institute for Health and Care Excellence (NICE), 
published in 2009, suggest that a patient should be urgently referred for treatment 
if synovitis persists for 3 months (NICE 2009). In order to confirm diagnosis, NICE also 
recommends testing levels of autoantibodies in the blood, as well as performing X-
Rays for patients with early onset of symptoms. 
 1.0.2.1 Autoantibodies in RA 
 
Autoantibodies are self-reactive antibodies, produced by plasma B cells in 
autoimmune conditions. Rheumatoid factor (RF) and anti-citrullinated peptide 
antibodies (ACPAs) are most commonly tested in RA and are associated with 
increased disease severity and therefore poorer outcome (Pai et al. 1998). ACPAs are 
more specific to RA than RF with approximately 65% of patients exhibiting high levels 
in the blood (Charpin et al. 2013). Patients who contain high concentrations of RF 
autoantibodies are diagnosed as sero-positive, however an RA diagnosis can still be 
made for sero-negative patients. Sero-positive patients can exhibit high 
concentrations of autoantibodies years before the onset of symptoms, which are 
associated with a poorer clinical outcome (Nielen et al. 2006). Several studies point 
to the potential role of autoantibodies in the pathogenesis of RA (Bax et al. 2014). 
 1.0.3 Treatment of RA 
 
As there is no cure for RA, the aim of treatment for patients is to reach remission or 
reduce disease activity in order to prevent permanent damage to joints and keep 
symptoms under control (Smolen et al. 2014b). The treatment pathway of RA 
patients is case dependent, however the 2009 NICE guidelines outline how to 
manage symptoms and indicate the most suitable treatments (NICE 2009). The 
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guidelines for currently available treatments are summarised in the below 
subsections.  
1.0.3.1 Symptom control 
 
Milder treatments are often recommended to control symptoms of RA. Examples 
include analgesics such as paracetamol and non-steroidal anti-inflammatory drugs 
(NSAIDS). NSAIDs work by inhibiting cyclooxygenase (COX), an enzyme that leads to 
prostaglandin production (Vane 1971). The COX enzyme has different isoforms 
including COX-1 and COX-2. COX-1 has been linked to homeostatic functions 
(Crofford 2013), whereas COX-2 is involved in inflammation (Crofford et al. 2000). 
COX-2 inhibitors work to prevent this process and are recommended to treat RA 
symptoms (NICE 2009).  
The most common side effect associated with NSAIDs is gastrointestinal problems 
(Lanas 2009). Additionally, COX inhibitors have been linked to increased cardiac risk 
(Mukherjee et al. 2001). However, side effects of these drugs are less common 
compared to disease-modifying anti-rheumatic drugs (DMARDs). NICE guidelines 
suggest DMARD treatment should be considered if the milder treatments are 
ineffective in controlling symptoms (NICE 2009). 
 1.0.3.2 Disease-modifying anti-rheumatic drugs (DMARDs) 
 
DMARDs are generally immunosuppressive and anti-inflammatory in nature, 
however the particular mode of action is drug dependent, as detailed in subsequent 
paragraphs. In cases where milder treatments are deemed ineffective, DMARDs are 
recommended as the first-line therapy for newly diagnosed patients. They can be 
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used as a monotherapy or in combination, depending on each patient’s condition. 
Drug dosage is usually increased gradually, however the guidelines recommend 
decreasing dosage if a patient is responding well (NICE 2009). Conventional DMARDs 
(cDMARDs) include drugs such as Methotrexate (MTX), Sulfasalazine (SLZ), 
Leflunomide (LFN) and Hydroxychloroquine (HCQ).  
MTX prevents folic acid metabolism by inhibiting dihydrofolate, which subsequently 
reduces tetrahydrofolate (White and Goldman 1976; Johnston et al. 1995). Previous 
studies have also shown MTX inhibits purine and pyrimidine metabolism (Eleff et al. 
1985; Tian and Cronstein 2007), prevents cell proliferation and increases T cell 
apoptosis (Cronstein 2005; Klak et al. 2016). Therefore it is suggested that these 
mechanisms are responsible for the anti-inflammatory effects of MTX (Klak et al. 
2016).  
SLZ is generally used as a substitute for MTX when clinicians decide MTX is ineffective 
or intolerable for patients. However, SLZ can also be used in combination with MTX 
to increase efficacy of treatment (Ogrendik 2013). The mechanism of action of SLZ is 
not as well known as MTX, however previous studies have shown it inhibits cell 
growth by autophagy (Guo et al. 2011). Additionally it inhibits the expression of 
tumor necrosis factor-alpha (TNFα), a key pro-inflammatory cytokine involved in RA 
pathogenesis (Rodenburg et al. 2000). 
LFN or HCQ can be used to treat RA patients when MTX and SLZ have shown no 
efficacy. LFN blocks dihydroorotate dehydrogenase, therefore inhibiting pyrimidines 
(Greene et al. 1995). Subsequently the proliferation of T cells and antibody 
production by B cells is reduced (Klak et al. 2016). HCQ has previously been used to 
10 
 
treat malaria (ter Kuile et al. 1993), but can also be effective in treating RA (Wiacek 
et al. 2012). The mechanism of HCQ includes inhibition of Toll-like receptor (TLR) 
signalling and antigen presentation to T cells, which are key steps in the immune 
response (Ziegler and Unanue 1982; Kyburz et al. 2006). It has also been described 
as an immunomodulatory drug because it inhibits pro-inflammatory cytokines such 
as interleukin-6 (IL-6) and TNFα (Wozniacka et al. 2008). 
Unfortunately, cDMARDs are commonly associated with side effects, which can 
depend on the drug prescribed, dosage, pharmacokinetics and response of the 
individual patient. Undesirable side effects include toxicity of the lungs and liver (Lee 
et al. 2012; Conway et al. 2015), as well as nausea and vomiting (Patil et al. 2014). If 
the side effects are severe, it is classed as an adverse reaction and the drug type is 
switched. A long-term study found approximately 50% of RA patients on DMARD 
medication will experience an adverse event or non-response after 2-5 years, 
depending on drug type (Grove et al. 2000). However the number of patients that 
experience adverse events alone is unclear due to the different time frames between 
longitudinal studies. For example, MTX was previously found to be less associated 
with adverse events compared to SLZ, however contraindications are more common 
with MTX when patients are followed for a longer time (Grove et al. 2000). This 
observation may be due to the drug accumulating over time. Further to the negative 
impact experienced by patients, adverse events also pose additional cost problems 




Despite the risk of severe side effects, cDMARDs have been shown to improve 
symptoms in 60-70% of patients, depending on drug type. For example, previous 
studies have shown on average 67% of patients have clinical improvement when on 
MTX (Willkens et al. 1980; Willkens and Watson 1982; Hoffmeister 1983), 
approximately 60% have improvement of symptoms on SLZ (McWilliams et al. 2013), 
and 68% of patients were shown to have a reduction of disease activity after 1 year 
on LFN (Wiacek et al. 2012). Although the majority of patients show improvement on 
cDMARD treatment, 30-40% will not respond therefore clinicians must seek 
alternative treatment options.  
The tight control of RA (TICORA) study assessed whether intensive patient 
management during cDMARD therapy would improve overall clinical outcome 
(Grigor et al. 2004). The study identified a tightly monitored dosage escalation 
programme that reduced disease activity and improved remission rates in study 
patients compared with routine management (Appendix A). In agreement with these 
findings, a further systematic review identified that 65% of TICORA study patients 
achieved remission compared to 16% of control patients (Bakker et al. 2007). This 
relatively new concept is promising in guiding clinician’s dose escalation decisions 
and improving clinical efficacy of cDMARDs. 
 1.0.3.3 Glucocorticoids 
 
Glucocorticoids (GCs) are a type of steroid hormone of which the mechanism is not 
fully understood. They are considered anti-inflammatory and have been shown to 
inhibit inflammatory gene expression (Newton 2014). The 2013 EULAR guidelines 
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recommend GCs for use in the treatment of RA in combination with one or more 
DMARD (Smolen et al. 2014b).  
Previous studies have demonstrated the benefits of GCs in combination therapy to 
treat RA. For example, supplementing with GCs reduces progression of joint damage 
(Svensson et al. 2005). In agreement with this finding, a more recent study 
demonstrated that use of GCs in combination therapy was more beneficial in 
reducing joint damage, compared to monotherapy (Goekoop-Ruiterman et al. 2008).  
However, GCs are also associated with adverse events including cataracts, fractures 
and weight gain, with the latter being the most common (Curtis et al. 2006). GCs are 
only recommended as a short-term treatment with the aim being rapid reduction of 
inflammation (Smolen et al. 2014b). Long-term treatment may be considered when 
all other treatment options have been exhausted. 
 1.0.3.4 Biological DMARDs 
 
Biological DMARDs are designed to inhibit cells and cytokines involved in the immune 
response, and are therefore anti-inflammatory and immunosuppressive. However, 
as the name would suggest biologic DMARDS are high purity recombinant proteins 
such as receptors, antibody fragments and chimeras and are therefore more 
expensive to produce than cDMARDs. For example, adalimumab costs an estimated 
£9,295 per patient per year and is one of the top grossing drugs worldwide alongside 
other biologics including etanercept, rituximab and infliximab (Malottki et al. 2011). 
In order to be eligible to receive biologic DMARD treatment, patients must have 
failed at least two cDMARDs and have a disease activity score (DAS) of ≥5.1 on two 
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occasions that are 1 month apart (National rheumatoid arthritis society (NRAS) 
2013). The use of DAS will be discussed in more detail in section 1.0.4.  
The biologic drugs approved by NICE include tumor necrosis factor (TNF) inhibitors 
known as anti-TNFs, tocilizumab (TCZ), rituximab and abatacept (NICE 2009). Anti-
TNFs are one of the first choice biologics for clinicians as they inhibit TNFα, a key pro-
inflammatory cytokine involved in RA pathogenesis (Jin et al. 2010). There are many 
anti-TNF biologics available, each with different physical attributes, including 
adalimumab, certolizumab, etanercept, infliximab and golimumab. Choice of drug is 
usually agreed between the patient and rheumatologist, and often is decided based 
on how the drug is administered and risk of side effects (Smolen et al. 2014b). The 
efficacy of anti-TNFs ranges from approximately 60-70% depending on the type of 
drug used, and whether or not it is combined with a cDMARD (Hirabara et al. 2014; 
Keystone et al. 2014; Takeuchi et al. 2014; Smolen et al. 2014a). Many studies suggest 
combination therapy improves clinical outcome compared to anti-TNF monotherapy 
(Keystone et al. 2014; Smolen et al. 2014a). However, specific combination 
treatments display a variety of responses in individual patients. 
In recent years, TCZ has been one of the first biologics considered by clinicians to 
treat RA. The reason is because it targets IL-6, one of the most important pro-
inflammatory cytokines present in the joint (Alves et al. 2011). Along with TNFα, IL-6 
is involved in T helper cell-17 (Th17) differentiation which has been directly 
associated with RA pathogenesis (Jovanovic et al. 1998). Additionally, IL-6 production 
leads to the secretion of C-reactive protein (CRP) from the liver, which is an 
inflammatory marker that can be included in the calculation of disease activity in RA 
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(section 1.0.4). The clinical efficacy of TCZ is slightly higher than other biologics, 
where approximately 80% of patients display a clinical response, however remission 
is only achieved in 50-60% of patients after 24 weeks (Ogata et al. 2014).  
Rituximab is a B cell inhibitor that targets CD20 specifically. This mechanism is 
important because of the key involvement of B cells in RA pathogenesis (Marston et 
al. 2010). Rituximab has proven to be clinically effective in improving RA symptoms 
for approximately 70% of RA patients (Edwards et al. 2004; Wendler et al. 2014). 
Interestingly some patients may not benefit from rituximab initially, but later show 
good response with further doses (National rheumatoid arthritis society (NRAS) 
2013). 
Abatacept inhibits the activation of T cells, thereby inhibiting one of the key cells 
involved in the immune response (Moreland et al. 2002). It has been shown to reduce 
the progression of RA after one year of treatment (Kremer et al. 2005). Additionally, 
approximately 60% of abatacept treated patients had reduced swollen and tender 
joints after 1 year of treatment compared to a placebo control group. 
Although biologic response differs between drug type, these drugs are generally 
associated with a response rate of 60-70%, with efficacy considered to be similar 
across each drug type (Smolen et al. 2014a). Although less common than cDMARDs, 
biological DMARDs are also associated with severe side effects, and therefore 
symptoms must be carefully monitored. Severe side effects include increased risk of 
infection (Singh et al. 2015; Curtis et al. 2015; Yun et al. 2015), and therefore 
increased risk of infectious diseases such as Hepatitis B and tuberculosis (Keane et al. 
2001; Chen et al. 2017). 
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 1.0.4 Monitoring RA 
 
The NICE guidelines state that patients with recent-onset active RA should be subject 
to a composite scoring system, such as the disease activity score in 28 joints (DAS28) 
(NICE 2009). The DAS28 is an equation (Figure 1.2) that takes into account physical 
symptoms of the disease, a blood-based marker of inflammation, and the general 
well-being of the patient. It is used to assess levels of disease activity in a consistent 
manner and guide clinicians in drug dosage as patients show response or non-
response to treatment. 
 
Review appointments are recommended to assess disease activity and damage (NICE 
2009). The EULAR guidelines recommend frequent monitoring for up to 3 months 
after commencing treatment (Smolen et al. 2014b). Improvement, as measured by a 
reduction in DAS28, must be achieved within the first 3 months. A reduction in DAS28 
score of more than 1.2 is deemed a good response, and a reduction of more than 0.6, 
but less than 1.2 is considered a moderate response (NICE 2009; Smolen et al. 
2014b). Furthermore, clinical remission in RA is when a patient achieves a DAS28 
score of less than 2.6. If a patient has not reached remission or low disease activity 
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within the first 6 months of cDMARD treatment, alternative options must be visited, 
such as the use of biological DMARDs.  
The 2010 EULAR guidelines define remission as a DAS28 score of less than 2.6 
(Smolen et al. 2010b), however the 2013 update also includes the need to account 
for maximum functional improvement and prevention of further damage (Smolen et 
al. 2009; Aletaha and Smolen 2011; Smolen et al. 2014b). The patient perspective 
can therefore be taken into account during treatment monitoring by use of a visual 
analogue scale (VAS) and health assessment questionnaire (HAQ). These disease 
scoring tools focus on pain levels and ability to carry out everyday tasks. For long 
term remission, the drug dosage should be cautiously lowered with regular 
monitoring until both the patient and clinician are satisfied that a lower and stable 
disease activity has been achieved. 
As detailed in section 1.0.5, comorbidities must be taken into account during 
treatment and monitoring of RA. Comorbidities are commonly associated with high 
disease activity. For example, a recent study found that RA patients with 
comorbidities such as osteoporosis and depression exhibited a higher DAS score than 
those without (Garip et al. 2016). Additionally, effective treatment may prevent 
comorbidities from developing (Westlake et al. 2010). NICE recommend regular 
monitoring of inflammatory markers including CRP and erythrocyte sedimentation 
rate (ESR), which can assist in assessing elevated risk of comorbidities (NICE 2009). If 
a comorbidity is detected, appropriate referrals must be made within the 
multidisciplinary team, and the treatment strategy may need to be revised 
depending on each case.  
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Other blood tests may be carried out during treatment to detect adverse effects of 
the medication. For example liver function tests (LFTs) and urea and electrolytes 
testing (U+E) check for liver and kidney damage. This is particularly important during 
cDMARD treatment, as some drugs have been linked specifically to organ damage 
(Dahl et al. 1971; Salliot and van der Heijde 2009). 
1.0.5 Comorbidities 
 
RA has been associated with a range of comorbidities which may contribute to 
increased risk of mortality (Wolfe et al. 1994; Gabriel and Michaud 2009). A recent 
study has established that depression is the most common comorbidity associated 
with RA (Dougados et al. 2014), with an average of 15% of RA patients affected, 
depending on geographical location. A separate study found that as many as 31% of 
RA patients suffer from major depressive episodes (MDE) (Cabrera-Marroquin et al. 
2014), and these patients had a poorer outcome compared to non-MDE patients. 
Similar to RA, depression is now considered an inflammatory condition (Berk et al. 
2013; Kiecolt-Glaser et al. 2015), however it is unclear in many cases whether 
depression manifests as a consequence of RA. 
Cardiovascular disease (CVD) is also strongly associated with RA. For example, a 
recent study found 6% of RA patients also suffer from ischaemic CVD (Dougados et 
al. 2014). Further studies suggest chronic inflammation such as RA can lead to the 
development or increased risk of CVD such as myocardial infarction and stroke 
(Solomon et al. 2010), and may subsequently reduce the lifespan of patients (Avina-
Zubieta et al. 2008). EULAR recommendations suggest clinicians should take a 
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multidisciplinary approach when treating such patients, for example involving 
cardiologists when making clinical decisions. (Peters et al. 2010). 
RA is associated with a high risk of infection (Doran et al. 2002), which could be a 
consequence of immunosuppressive drugs used to reduce symptoms. One example 
is periodontitis (PD), an inflammatory condition caused by a bacterial infection in the 
mouth. Many studies have associated RA with an increased prevalence of PD 
compared to controls (de Pablo et al. 2008; Dissick et al. 2010; Scher et al. 2012). It 
has also been found that infection in RA may contribute to poorer clinical outcome 
(Wolfe et al. 1994; Bjornadal et al. 2002; Perez-Sola et al. 2011). 
RA patients also have an increased prevalence of other conditions including diabetes. 
Approximately 12% of patients are more likely to be diabetic if they have RA 
compared to non-RA controls (Liao et al. 2009; Dubreuil et al. 2014). Additionally, 
ophthalmological manifestations such as Sjögren’s syndrome have been linked to RA 
in approximately 25% of patients (Antero et al. 2011; Artifoni et al. 2014). With all of 
the evidence presented to date, it seems that in the case of some patients, RA may 
be part of a multi-morbidity rather than just one condition. However, the 
pathogenesis behind this phenomenon is unclear, therefore clinicians must carefully 






1.1 Cellular pathology of RA and loss of tolerance 
 
 
The physical manifestations of RA are a result of cells involved in the adaptive and 
innate immune responses, which migrate into the synovial membrane (Figure 1.3). 
This leads to various changes within the joint, one of the earliest being the formation 
of a thin layer of tissue called pannus. Pannus can be considered an aberrant 
transformation of the synovial tissue toward a tumour-like, invasive and hyper-
proliferative state. Within pannus there is a high density of migrated immune cells 
including B cells, T cells, macrophages and neutrophils (Wright et al. 2014). As 
described in subsequent sections, these cells are responsible for the production of 
various cytokines and chemokines, which can lead to the development and activation 
of osteoclasts. Osteoclasts are responsible for irreversible bone destruction (Jung et 




Fibroblast-like synoviocytes (FLS) are specific cells within the synovium that also play 
a role in RA pathogenesis. Following activation from specific cytokines including IL-1 
and TNFα, FLS and chrondrocytes are responsible for cartilage degradation by 
mobilisation of matrix metalloproteinase enzymes (MMPs) (Miller et al. 2009; Sabeh 
et al. 2010). This increases risk of disability and long term damage in RA as the bone 




 1.1.1 Neutrophils 
 
Neutrophils are the most abundant leukocyte in peripheral blood and are one of the 
first cells recruited to inflammatory sites, such as the synovium in RA (Wright et al. 
2014). In RA, they become activated within the joint following interaction with 
vascular endothelial cells (Yang et al. 2005). Activation of these inflammatory 
neutrophils leads to production of cytokines and chemokines including IL1a, IL1b and 
IL-8, which subsequently triggers the activation of other inflammatory cells (Beaulieu 
and McColl 1994; Wright et al. 2013). For example, secretion of chemokine IL-8 
causes further neutrophils to migrate to the joint and continue the inflammatory 
process (Fujishima et al. 1993). Inflammatory neutrophils within the pannus also 
contribute to physical joint damage in RA through release of various cartilage-
degrading enzymes, including MMP-8 and MMP-9 (Murphy and Nagase 2008). 
 1.1.2 Monocytes and macrophages 
 
Monocytes are phagocytic cells that circulate in blood. They migrate into tissue in 
response to ongoing inflammation, before differentiating into mature macrophages. 
As discussed in further detail in chapter 3, monocytes and macrophages are highly 
significant in RA pathogenesis. Peripheral monocytes have been shown to be present 
at higher densities in RA circulating blood (Huang et al. 2007; Chara et al. 2015). 
Macrophages are also found in large numbers within the cartilage-pannus junction 
of RA patients. They display signs of activation such as the expression of the major 
histocompatibility complex class II (MHC-II), which enables them to function as 
antigen presenting cells (APCs), leading to T cell activation. Macrophages also 
produce cytokines, both pro-inflammatory and regulatory (Bresnihan 1999; Kinne et 
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al. 2000). TNFα, IL-6 and IL-1 are examples of pro-inflammatory cytokines produced 
by macrophages (Kinne et al. 2000). They lead to chondrocyte activation, which 
subsequently results in secretion of cartilage degrading enzymes, including MMPs 
(Bresnihan 1999).  
Macrophage activation correlates with progression of joint destruction, as evidenced 
by radiological examination (Mulherin et al. 1996). Previous studies have shown 
synovial macrophages can differentiate into distinct subpopulations, which can 
trigger the activation of T-cells and pro-inflammatory cytokines, leading to more 
damage and further progression of the disease (Klareskog et al. 1982; Miossec and 
van den Berg 1997). 
 1.1.3 Lymphocytes 
 
Lymphocytes are important cells in maintaining immune tolerance. They are exposed 
to two types of tolerance, recessive and dominant. Briefly, recessive or central 
tolerance involves exposure of self-antigens to early lymphocytes before they further 
mature. In cases where lymphocytes ‘self-react’, they can be subject to higher rates 
of apoptosis (Sakaguchi et al. 2008). Dominant or peripheral tolerance is mediated 
by Tregs following maturation. Tregs, discussed further in section 1.1.3.1 are 
suppressor cells that ensure over-reactive lymphocytes do not survive in the 
periphery. In autoimmune disease (AD) such as RA, tolerance is lost allowing self-
reactive cells to rapidly lose control and participate in tissue and organ damage. 
 1.1.3.1 T cells 
Although the exact aetiology of RA remains elusive, the pathogenesis is largely 
believed to be T cell driven. T cells play a primary role in cellular mediated immunity 
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through interaction with MHC molecules. This interaction leads to a variety of 
inflammatory responses including production of cytokines, recruitment and 
activation of other immune cells to the inflammatory site, and production of memory 
cells and cytotoxic killer T cells (Alberts and Johnson 2002). HLA-DRB1 is a specific 
human MHC involved in antigen presentation to T cells, and is widely studied in 
relation to RA due to its association with increased prevalence (Gregersen et al. 1987; 
Amos et al. 2007; Mohan et al. 2014). 
During inflammation in RA, CD4+ T helper (Th) and CD8+ cytotoxic T cells migrate into 
the synovial membrane following recruitment from other inflammatory cells (Smeets 
et al. 2001; Lundy et al. 2007; Wehrens et al. 2013). CD4+ cells are associated with RA 
initiation and autoantibody production (Kadowaki et al. 1994; Petrow et al. 1996; 
Wong et al. 2006; Alzabin and Williams 2011). Furthermore, CD4+ and CD8+ cells 
contribute to disease severity, initiated by IL-6 production which subsequently leads 
to bone resorption by osteoclasts (Wong et al. 2006). 
Specific Th cells including pro-inflammatory Th-1 and Th-17 are associated with RA 
pathogenesis and joint damage (Alzabin and Williams 2011). These cell subsets 
produce further inflammatory molecules including IL-17 (van den Berg and Miossec 
2009), which triggers the release of cytokines such as IL-6 and TNFα, chemokines such 
as C-X-C ligand 1 and 2, and MMPs leading to bone degradation (Chabaud et al. 2000; 
Onishi and Gaffen 2010). 
Further to Th-1 and Th-17, Tregs are also considered major players in RA 
pathogenesis (Mellado et al. 2015). The function of Tregs is widely researched in 
relation to AD because of their association with self-tolerance (Eakin et al. 2016). 
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They work to suppress the functions of effector T-cells (Teffs), thus keeping the 
immune response under control by limiting damage (Wu et al. 2009). However, their 
suppressive function is compromised during an autoimmune response, allowing loss 
of control of damage-causing Teffs, and in the case of RA this damage is targeted to 
the joints.  
The suppressor function of Tregs depends on cell-cell interactions between Tregs, 
Teffs and APCs. A number of studies report negative regulation of Tregs in RA (van 
Amelsfort et al. 2007; Bonelli et al. 2016), as well as other autoimmune conditions 
(Morita et al. 2016; Schloder et al. 2017). Consequently, Tregs are unable to suppress 
damage-causing Teffs. However, several studies report conflicting levels of active 
Tregs in autoimmune diseases, possibly due to contamination of non-regulatory T 
cells during immunophenotyping (Ehrenstein et al. 2004; van Amelsfort et al. 2004; 
Mottonen et al. 2005). 
Forkhead box P3 (Foxp3) is a Treg cell transcription factor which activates genes 
including TNF-related apoptosis-inducing ligand (TRAIL) and CTLA4 which are 
required for the suppressor function (Gavin et al. 2007). Previous studies have 
associated FoxP3 expression with impaired Treg activity (Kennedy et al. 2014; Cribbs 
et al. 2015). For example, one study analysed the Treg cell-specific demethylated 
region (TSDR), which is located in the FoxP3 locus and relates to regulation of its 
expression (Polansky et al. 2008).  
Additional to the uncertainty surrounding levels of active Tregs in RA, there are 
conflicting reports of FoxP3 expression levels. A recent study reported an increase in 
FoxP3 expression by circulating Tregs in RA (Walter et al. 2016), strongly suggesting 
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peripheral Tregs are in an active state before entering the joint. Additionally, FoxP3+ 
Treg levels are increased in synovial fluid compared to peripheral blood in matched 
RA samples (Shalini P. et al. 2015). However, a number of studies have reported no 
difference in the percentage of FoxP3+ T cells in peripheral blood of RA patients (Cao 
et al. 2003; Mottonen et al. 2005). Conversely, the percentage of FoxP3+ Tregs reduce 
in mouse models in association with increased autoimmunity (Sakaguchi et al. 2006). 
Furthermore, in other autoimmune conditions such as multiple sclerosis (MS), 
separate studies have reported circulating FoxP3+ Tregs both increase and decrease 
compared to healthy controls (Kumar et al. 2006; Venken et al. 2008). 
The reason for the discrepancies between studies is unclear. One suggestion is that 
results may be dependent on the treatment pathway of individual patients. For 
example, an increase in FoxP3 expression, thus Treg suppressive activity, was found 
in patients who were treated with MTX compared to cDMARD naïve patients (Cribbs 
et al. 2015). Additionally, RA patients exhibited an increase in FoxP3 expression after 
response to anti-TNFs, suggesting restoration of Treg function (Nie et al. 2013).  
Furthermore, the immunophenotypic classification of Treg cells differs between 
studies, with the potential of contaminating Teff cells contributing to the results 
(Appendix D). 
 1.1.3.2 B cells 
 
B cells are involved in the humoral response as part of the adaptive immune system. 
In healthy individuals, they differentiate into plasma cells which produce antibodies 
that bind to specific foreign antigens. In AD conditions such as RA, B cell central and 
peripheral tolerance is lost. Loss of tolerance at each checkpoint has been observed 
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by production of self-reactive autoantibodies from defective B cells in RA patients 
(Samuels et al. 2005). As previously mentioned, RF and ACPAs are the most 
commonly studied autoantibodies in RA, and are generally used in diagnosis of the 
disease (NICE 2009). 
B cells also influence other inflammatory cells during the immune response. For 
example, they can act as APCs in order to activate T cells. Previous studies have 
demonstrated this role of B cells in T cell stimulation within the synovial membrane 
in RA (Takemura et al. 2001). T cell activation subsequently leads to the release of 
pro-inflammatory cytokines, which in turn triggers the activation of other immune 
cells, thereby continuing this inflammatory process (Bugatti et al. 2014). Cytokines 
produced by B cells have been studied in RA, including IL-6 and IL-17 (Barr et al. 2012; 
Schlegel et al. 2013). In particular, IL-6 has been found to lead to further activation 
of pathogenic T cells (Barr et al. 2012). 
As B cells are considered central to RA pathogenesis, many studies have confirmed 
the benefits of targeting B cells using specific biological DMARD rituximab. (Caporali 
et al. 2009). 
 1.1.3.3 Glycosylation in immune cell function 
 
Immune cells contain sugar structures known as glycans on their surface (Alavi and 
Axford 2006). An increasing number of studies have analysed the role of glycans in 
health and disease because of their pivotal role in cell function (Alavi and Axford 
2008). For example, glycans are involved in maintaining protein structure, and 
importantly immunogenicity (Caramelo and Parodi 2007; Li et al. 2008). During 
disease, because of the vast changes in cell biology as discussed, glycan alterations 
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are also observed (Alavi and Axford 2008). Analysis of cellular glycosylation changes 
has enabled researchers to understand functions of the monocyte cell-surface 
marker CD14, including cell trafficking (Meng et al. 2008). Additionally, researchers 
have studied glycosylation changes of the B cell receptor in multiple myeloma, and 
further studies have shown a role of glycosylation in Teff cells in regulating cell death 
(Toscano et al. 2007; Ilic et al. 2008). The importance of glycosylation in relation to 
RA is discussed in further detail in section 1.2.2.  
 1.1.4 Siglecs as master regulators of immune response 
 
Lectins are a type of protein that will bind to glycans on the surface of a cell, which is 
an important process in regulating specific cell functions during the immune 
response (Toscano et al. 2007; Meng et al. 2008; Alavi and Axford 2008). Sialic acid-
binding immunoglobulin-like lectins (Siglecs) are a family of trans-membrane 
proteins that are present on a variety of immune cells and are involved in 
determining immune tolerance. There are many subtypes of siglec, differing in 
function and structure. The general function of siglecs is to modulate the immune 
response, participating in cell adhesion, signalling and endocytosis (Crocker 2002; 
Nitschke 2005; Varki and Angata 2006; Crocker et al. 2007).  
The structure of siglecs comprises of one ligand binding V-set domain, and a varying 
number of C2-set domains (Figure 1.4) (Crocker et al. 2007). The extracellular 
structure of siglecs can facilitate specific functions. For example siglec-1, also known 
as sialoadhesin or CD169, contains a large number of C2-set domains, which extend 
the V2-set binding domain away from the surface of the cell (Crocker et al. 1994). 
This elongation may overcome ‘masking’ of the binding site, caused by cis 
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interactions with alternative glycans (Razi and Varki 1999). CD22 (siglec-2) is also 
thought to overcome ‘masking’, due to the competitive binding of its sialylated 
glycans with same-cell cis ligands (Collins et al. 2006).  
 
Additionally, intracellular characteristics of the cytoplasmic tail contributes to the 
function of siglecs. For example CD22 and some CD33 (siglec-3) subtypes contain 
immunoreceptor tyrosine-based inhibitory motifs (ITIMs) within the cytoplasmic tail 
(Ravetch and Lanier 2000). These regions facilitate an inhibitory siglec function, 
suppressing activation signals to the cell. Conversely, siglec-14 and siglec-15 lack 
ITIMs and are associated with immunoreceptor tyrosine-based activation motifs 
(ITAMs). Siglec-14 in particular functions as both an inhibitor and activator of cellular 
signals (Angata et al. 2006; Hamerman and Lanier 2006). Siglec-1 and siglec-4, 
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however do not contain tyrosine-based motifs, which suggests their primary function 
is to enable cell-cell interactions (Hartnell et al. 2001; Pillai et al. 2012). 
Siglecs also possess specific binding affinities for sialylated glycans. Siglec-2 displays 
a binding preference for α2-6 glycosidic linkage (Powell et al. 1993; Kelm et al. 1994), 
whereas siglec-7 and siglec-11 bind in an α2-8 manner (Yamaji et al. 2002). Siglec-1 
preferentially binds α2-3 linked sialic acid and weakly binds α2-8 linked residues 
(Ohtsubo and Marth 2006; Crocker et al. 2007). This binding preference is important 
in facilitating the function of the siglec, and subsequently the immune cell to which 
it is bound. Siglec-1 is one of the most studied siglecs in relation to RA. The 
subsequent section will detail the involvement of siglec-1 in RA pathogenesis. 
 1.1.4.1 Siglec-1 
 
Siglec-1 is a cell surface protein present on monocytes, macrophages and dendritic 
cells. Its expression is associated with pro-inflammatory mechanisms in the immune 
response, displaying involvement in Teff cell induction as well as secretion of 
cytokines such as interferon-gamma (IFN-γ) (Jiang et al. 2006). Additional to a subset 
of CD8+ T cells, siglec-1 can bind to granulocytes, B-cells and erythrocytes (Hartnell 
et al. 2001).  
Siglec-1 has been shown to possess many roles, such as cell adhesion, 
accommodated by the elongation of the C2-set domains (Figure 1.4) (Munday et al. 
1999). Common highly conserved siglec-1 regions exist within mouse and man, 
especially in the extra-cellular region, which confirms its role in cell-cell interactions 
(Hartnell et al. 2001). Siglec-1 is regulated as a result of type I and type II IFN 
induction, which suggests a role in anti-viral and anti-bacterial activity (O'Neill et al. 
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2013). Furthermore, it has been suggested that it contributes to the internalization 
of sialic acid (Sia) carrying pathogens by acting as an endocytic receptor (Delputte et 
al. 2011).  
Siglec-1 has been described as a putative biomarker for RA due to its increased 
expression in patients with the disease, relative to patients with osteoarthritis (OA) 
or normal controls (Xiong et al. 2014). In RA patients, the increase in the relative 
number of siglec-1 positive cells, as measured by flow cytometry, positively 
correlates with clinical measures including DAS28, ESR, RF and CRP levels (Xiong et 
al. 2014). Furthermore, the average relative number of siglec-1 positive monocytes 
decrease after DMARD treatment response (Xiong et al. 2014). However, siglec-1 
expression is not specific to RA as it has also been associated with other inflammatory 
diseases, including systemic lupus erythematosus (SLE). A strong correlation has 
been observed between siglec-1 positive monocytes and clinical parameters for SLE 
patients (Biesen et al. 2008). 
The phosphorylation sites of siglec-1 responsible for intracellular signal transduction 
are poorly understood, however two potential sites that lack ITIMs have previously 
been investigated (Crocker et al. 1994). The cytoplasmic domain contains a Protein 
kinase C (PKC) motif and Casein kinase 2 (CK2) phosphorylation sites, which 
strengthens the suggestion that extracellular interactions potentiate intracellular 
signal transduction. The CK2 site is involved in signal transduction, transcriptional 
control, apoptosis and cell regulation (Malik and Clements 2004), therefore allowing 
for the normal functions of siglec-1. 
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It is thought that siglec-1 can bind ligands on the surface of Tregs, and that direct cell-
cell binding could contribute to their suppression (Wu et al. 2009). A recent study 
presented data showing the induction of siglec-1 ligand expression on both Tregs and 
a subset of Teffs after TCR (T-cell receptor) activation in a murine model of SLE, with 
the exposure of siglec-1 being linked to cell death (Kidder et al. 2013). Furthermore, 
there was an association found between siglec-1 ligand expression and increased 
sialylation. (Kidder et al. 2013). This further suggests siglec-1 could be acting in a pro-
inflammatory manner during the immune response. 
CD43 (Sialophorin) is a sialoglycoprotein expressed on, but not restricted to Tregs. It 
is a T cell ‘counter receptor’ of ligands presented by siglec-1 (van den Berg et al. 
2001), however a recent study suggested the induction of siglec-1 ligands can occur 
independent of CD43 (Kidder et al. 2013). In summary, although it is suggested that 
siglec-1 plays a role in Treg suppression, Teff activation, and therefore disease 
pathogenesis, the specific mechanisms behind these functions remain elusive. 
Furthermore, the nature and downstream effects of the siglec-1/CD43 balance is 
unclear. The interaction between siglec-1 (CD169) and CD43 is one of the key 







1.2 Systemic effects due to loss of immune system tolerance  
 
 
The acute phase response (APR) is a process by which plasma proteins synthesised 
by the liver change in concentration as a result of inflammation in the body. The 
release of cytokines from various immune cells triggers and modulates the APR 
(Heinrich et al. 1990; van Miert 1995; Heinrich et al. 1998). For example IFN-γ, 
interleukin-1β (IL-1 β) and TNFα are essential for induction of the APR, as well as 
further recruitment of inflammatory cytokines such as IL-6 and IL-8 (van Miert 1995; 
Gruys et al. 2005).  
Due to the inflammation present in the joint in RA, some studies have investigated 
APR proteins as a potential biomarker of disease (Ortea et al. 2012). Negative APR 
proteins which decrease during inflammation include transthyretin, retinol binding 
protein, transferrin and albumin (Kushner et al. 1981; Blackburn 1994; Ingenbleek 
and Young 1994). Positive APR proteins which increase in concentration during 
inflammation include CRP, serum amyloid A (SAA) and Haptoglobin (Hp) (Heinrich et 
al. 1990; Heinrich et al. 1998). The positive APR proteins are more commonly studied 
in relation to rheumatic disease, as discussed below. 
MRPs (myeloid related proteins) 8 and 14 are heterodimeric structures situated in 
the cytosol of leukocytes and monocytes (Hessian and Fisher 2001). Both MRP-8 and 
MRP-14 promote the pathogenesis of RA by triggering the activation of neutrophils 
and monocytes (Frosch et al. 2000). Additionally, they are markers of differentiation 
on tissue infiltrating macrophages (Chen et al. 2009), where their function is to 
recruit further macrophages to the inflamed tissue (Pouliot et al. 2008). 
33 
 
SAA is also a widely studied APR protein due to its increase in concentration during 
inflammation (O'Hara et al. 2000). It is secreted by the liver following production of 
cytokines including IL-1, IL-6 and TNFα. C-reactive protein is also increased during the 
APR and correlates strongly with SAA levels during inflammation in RA (Chambers et 
al. 1983). 
In summary, the complex proteomic environment in RA is potentially a promising 
target for biomarker discovery. These proteins have a direct impact on immune cells 
and vice versa, and therefore may be representative of disease activity. As discussed 
in chapter 5, the profiling of various proteins has the potential to improve 
understanding of RA pathogenesis and enables the analysis of differences between 
treatment responders and non-responders.  
 1.2.1 CRP and ESR 
 
CRP and ESR are blood-based measures of non-specific inflammation. The NICE 
guidelines encourage monitoring of both markers during RA treatment (NICE 2009). 
CRP is one of the positive APR proteins, secreted from the liver following induction 
of IL-6 during inflammation (Sokka and Pincus 2009; Doyle et al. 2013). CRP has been 
shown to increase years before the onset of symptoms, along with autoantibodies 
RF and ACPAs (Nielen et al. 2006). Previous literature provides conflicting evidence 
of CRP as a reliable marker of inflammation. For example, a recent study described 
CRP as a useful biomarker of flare-ups in SLE (Eudy et al. 2014). Furthermore, normal 
CRP levels have been associated with better clinical outcome in RA (Kojima et al. 
2013). However, other studies have found CRP is not representative of disease 
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activity in RA, with up to 45% of patients exhibiting normal levels (Sokka and Pincus 
2009). 
ESR is also a non-specific marker of inflammation, however it has previously shown 
no correlation with CRP levels in RA (Sbong and Feldman 2014). The increase of ESR 
is caused by the upregulation of the APR reactant fibrinogen. Therefore it is 
somewhat representative of the APR during inflammation (Gruys et al. 2005). A 
previous study suggested ESR is a sensitive measure of disease activity in RA, 
compared to CRP levels (Ward 2004). However, either marker may be used in the 
DAS28 equation during RA treatment. 
1.2.2 Glycosylation of APR proteins 
 
Glycosylation is an essential protein modification that is important to the structure 
and function of over 70% of proteins (Apweiler et al. 1999). Alteration of glycans is 
important because it can sterically disrupt interactions, for example between lectins 
and glycoproteins, which can in turn prevent normal receptor signalling (Collins et al. 
2013). Glycosyltransferase and glycosidase enzymes can lead to abnormal 
glycosylation (Ohtsubo and Marth 2006). Numerous studies have highlighted their 
potential role in the pathogenesis of rheumatic diseases (Raghav et al. 2006).  
Changes in glycosylation patterns of serum IgG have been associated with the 
progression of RA (Parkkinen 1989). Patients with RA express a higher concentration 
of agalactosylated IgG (IgG0), which correlates with disease severity in RA patients, 
suggesting a potential role in disease pathogenesis (Carson et al. 1987). Furthermore 
decreased galactosylation of IgG correlates with inflammatory markers IL-6 and CRP 
(Troelsen et al. 2012).  Previous studies have suggested the use of IgG0 as a marker 
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for severity and duration of RA. For example IgG0 levels were shown to return to 
normal in RA patients following treatment with anti-TNF (Pasek et al. 2006; Van 
Beneden et al. 2009). Furthermore, treatment with MTX and infliximab decreased 
levels of IgG0 in RA responder patients (Croce et al. 2007). 
The glycosylation patterns of several non-IgG proteins have also been widely studied 
in relation to RA inflammation. For example, increased numbers of bi-antennary and 
alpha 1, 3-fucosylated glycans were found at glycosylation sites of alpha-1 
glycoprotein (AGP) in patients with acute inflammation compared to healthy 
individuals (Higai et al. 2005). AGP is important in RA due to its increase in plasma 
during acute inflammation (Hrycaj et al. 1993). Additionally, fucosylation is 
abnormally elevated in the sera of RA patients (Mann et al. 1994). A recent study also 
reported a unique monosaccharide pattern of AGP and Hp in RA patients (Saroha et 
al. 2011), which is suggested to play a role in disease pathogenesis. 
1.2.2.1 Sialylation of APR proteins 
 
Several studies have highlighted the role of Sia and its residues in inflammation. IgG 
is a serum glycoprotein involved in inflammatory events by the binding of its Fc 
region. Glycosylation changes in IgG can lead to changes in antibody activity. 
Sialylation of the Fc region decreases the affinity of the antibody to its receptor, and 
increases inflammatory activity of IgG (Kaneko et al. 2006; Anthony et al. 2008; 
Chrostek et al. 2014). 
Sialylation of other APR glycoproteins have also been implicated in rheumatic disease 
pathogenesis (Chrostek et al. 2014), such as fibronectin, transferrin, Hp and AGP 
(Feelders et al. 1992; Przybysz et al. 2007; Saroha et al. 2011). Furthermore, these 
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changes in sialylation have been implicated as a potential biomarker for disease 
activity in RA (Cylwik et al. 2010). Previous studies have analysed levels of bound or 
unbound Sia to measure both APR activity and changes in sialylation of glycoproteins 
during disease (Paul and Rotzsch 1989; Alturfan et al. 2007). A recent study found 
increased levels of Sia in RA patients compared to healthy controls, which correlated 
with levels of positive APR proteins (Chrostek et al. 2014). Furthermore, levels of Sia 
in RA had a positive association with DAS28. Therefore, changes in Sia present in the 
sera of RA patients may be representative of sialylation patterns of APR 
glycoproteins, which could a play a role in disease pathogenesis. 
In summary, previous literature has stressed the importance of siglec-1 in relation to 
pivotal immune cells including Tregs and Teffs, and additionally has shown the 
association of siglec-1 with increased sialylation (Kidder et al. 2013). CD43, a known 
counter receptor of siglec-1 is not as well known in relation to RA, however some 
studies have demonstrated its downregulation in diseased subjects (Humbria et al. 
1994; Lopez et al. 1995).  This thesis postulates that CD43 may be responsible for 





In summary, evidence to date suggests there is need for a more robust measurement 
of disease activity in RA, with various studies demonstrating the potential of new 
biomarkers for the disease. The time between diagnosis and a successful treatment 
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program for RA patients is quite extensive. Additionally, 30-40% of RA patients are 
unresponsive to treatment, thus allowing the disease to rapidly worsen.  
On a cellular level there is strong evidence suggesting that siglec-1 could be a useful 
biomarker that is indicative of response or non-response to DMARD therapy. 
Research to date has also shown an association between siglec-1 positive monocytes 
and Tregs, where siglec-1 leads to Treg suppression. Specifically, siglec-1 interacts 
with CD43, however little is known about the nature or consequences of this 
interaction. It is also unclear whether this cellular interplay could be indicative of 
response or non-response to treatment of RA patients in relation to DAS28ESR. 
Further knowledge may assist in determining response at an earlier stage, thus 
improving the clinical outcome of patients, as non-responders could switch to a more 
effective treatment sooner than currently possible. 
APR proteins have been of significant interest in RA patients, with some being 
described as potential biomarkers for the disease due to their aberrant glycosylation 
patterns during RA inflammation. Specifically, the role of Sia, which is involved in the 
interaction between siglec-1 and CD43, has been implicated in RA pathogenesis. 
However, information is lacking in whether these protein patterns reflect on clinical 
measures of the disease. 
In summary, there is great need for sensitive biomarkers that are more 
representative of disease activity in RA than current clinical measures. This study 
aims to investigate the involvement of key immune cells and proteins present in 
peripheral blood in RA patients, their association with disease activity, and their 
potential in discriminating between responders and non-responders to treatment. 
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This could lead to the stratification of patients into clinically relevant groupings, 
subsequently assisting clinicians in providing an efficient treatment regimen. The 
knowledge gained from this study has the potential to prevent irreversible joint 




















The immunophenotype of circulating siglec-1 positive monocytes and CD43 positive 
Tregs, and the surrounding plasma proteome, act as sources of potential disease 

















1.5 Aims and objectives 
 
1.5.1 Aim 1 (Chapter 3): To determine the relationship between siglec-1 
(CD169) positive monocytes and CD43 positive Tregs in RA. 
 
Siglecs are of interest in RA due to their involvement in determining immune 
tolerance. Specifically, siglec-1 (CD169) has been widely studied due to its increased 
expression in RA in association with clinical measures of disease activity. Chapter 3 
aims to assess the ratio between CD169 positive monocytes and CD43 positive Tregs 
in circulating blood of RA patients who are DMARD naïve, DMARD responders and 
DMARD non-responders. This data will be compared to clinical measures of disease 
activity in order to assess their potential as circulating biomarkers. 
1.5.2 Aim 2 (Chapter 4): To assess the activation state of Tregs in RA. 
 
The intracellular activation of Tregs will initially be assessed in each patient group 
described in aim 1.5.1. This will be carried out by using FoxP3 as a surrogate measure 
of Treg activation. Additionally, co-culture experiments with CD169 positive 
monocytes will be carried out in order to assess their effects on specific Treg 
intracellular signalling pathways as well as activation state. 
1.5.3 Aim 3 (Chapter 5): To discover circulating protein biomarkers 
indicative of treatment response in RA. 
 
Plasma samples from each patient group will be analysed for various proteins 
associated with inflammatory and immune response pathways. This data will be 
compared to clinical measures of response, as well as cell data obtained from the 

























2.0 Participant recruitment and sampling 
 
 
2.0.1 Study Design 
 
Office for Research Ethics Committees Northern Ireland (ORECNI) approval 
(11/NI/0188), Ulster University Research Ethics Committee (UREC) approval 
(REC/14/0053) and Integrated Research Application System (IRAS) approval (88730) 
were obtained for the study. The research team at Ulster University (UU) 
collaborated with rheumatologists from the Western Health and Social Care Trust 
(WHSCT) and the Belfast Health and Social Care Trust (BHSCT) to design and conduct 
the study. All RA patients were recruited from either the WHSCT or the BHSCT. 
Healthy control subjects recruited to the study were staff or student members from 
either the WHSCT or UU. 
2.0.2 Sampling and participant demographics 
 
Venepuncture was used to extract peripheral blood from each participant. 
Vacutainer collection tubes (Aquilant Scientific) were used to obtain blood for either 
serum extraction (red topped tubes) or plasma and cell extraction (purple topped 
tubes). Sampling was carried out by a nurse during routine bloods were being taken, 
or by a trained member of the research team. 
Consent to participate was obtained from all patients and healthy controls. Diagnosis 
for all patients fulfilled the 2010 American college of rheumatology (ACR) criteria. 
Patients were classed as cDMARD ‘responders’ or ‘non-responders’ according to 
ACR/EULAR guidelines. Non-responders were due to commence biological DMARD 
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treatment on the day of sampling. Clinical data from the day of sampling was 
retrieved from patient notes retrospectively (Table 2.1). Healthy controls were also 
recruited to the study, excluding individuals with any chronic inflammatory or 
autoimmune disorder.  
The cDMARD non-responder patient numbers needed were estimated initially using 
previously determined potential genetic biomarkers of DMARD response. Flow 
cytometry analysis of this patient cohort was used to determine a suitable sample 
number needed based on relative numbers of FOXP3+ Tregs in healthy controls 
(mean = 45.86, n=24) compared to RA patients (mean = 29.74, n=24). The PWR 
package in R [http://cran.r-project.org/] was used to calculate a power of 0.81 with 
a sample number of n=24 in each group. This calculation assumes a significance level 

















2.1 Blood processing 
 
2.1.1 Density gradient separation for isolation of peripheral blood 
mononuclear cells (PBMCs) 
 
Density gradient separation is a well-established technique that allows for separation 
of whole blood into distinct layers. Figure 2.1 shows the isolation of peripheral blood 
mononuclear cells (PBMCs). 
 
Peripheral whole blood used for PBMC isolation was collected in an ethylene diamine 
tetra acetic acid (EDTA) coated tube (Aquilant Scientific) using a venepuncture 
technique. Blood tubes were stored at 18 ˚C until processing. Histopaque-1077 
(Sigma-Aldrich, UK) was used to isolate PBMCs. Prior to separation, whole blood was 
diluted 1:1 in BD Cell wash (Becton Dickinson). Then, 8 mL of diluted blood was 
carefully layered onto 5 mL Histopaque-1077 in a 15 mL Falcon. Ratios remained the 
same when the volume of blood was scaled up or down. The 15 mL falcon tube was 
centrifuged at 400 rcf for 30 minutes at 18 ˚C. This speed is sufficient for pelleting 
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cells with minimal damage. After centrifugation, the majority of the upper plasma 
layer was discarded, leaving approximately 0.5 mL above the PBMC layer. The PBMC 
layer was dispensed into a clean 15 mL falcon tube along with the remaining plasma 
layer and approximately half of the Histopaque layer. Extraction of all of the 
Histopaque layer would decrease the final cell yield because the density of this buffer 
is higher than standard wash buffer. BD Cell wash (Becton Dickinson), a sterile PBS 
buffer, was added to the crude extracted PBMCs up to the 15 mL mark. The tube was 
inverted 3-4 times to ensure sufficient mixing. The tube was centrifuged at 300 rcf 
for 10 minutes at 18 ˚C. After centrifugation, the supernatant was discarded and the 
cell pellet was resuspended in 10 mL BD Cell wash (Becton Dickinson). The tube was 
centrifuged again at 300 rcf for 10 minutes at 18 ˚C. After centrifugation, the 
supernatant was discarded and the cell pellet was resuspended in 5 mL BD Cell wash 
(Becton Dickinson). The tube was centrifuged again at 300 rcf for 10 minutes at 18 
˚C, followed by final resuspension in 0.5-3.0 mL BD Cell wash (Becton Dickinson). 
2.1.2 Buffy coat and plasma extraction from whole blood 
 
The extraction of the ‘buffy coat’ layer from whole blood allows for isolation of 
leukocytes and platelets (Mathay et al. 2012). It is commonly used prior to DNA 
extraction and analysis (Ip et al. 2015).  
Peripheral whole blood used for buffy coat extraction was collected in an EDTA 
coated tube (Aquilant Scientific) using a venepuncture technique. Blood tubes were 
stored at 4 ˚C until processing. The blood tube was centrifuged at 300 rcf for 10 
minutes at 18 ˚C. The centrifugation allows for the separation of layers, as shown in 




The majority of the plasma layer was removed leaving approximately 0.5 mL above 
the buffy coat. If required by the study protocol, the plasma layer was aliquoted and 
stored at -80 ˚C for later analysis. The remaining plasma along with the buffy coat 
and up to 1 mL of the RBC layer was removed and placed into a clean 1.5 mL 
Eppendorf tube. The remaining red blood cells in the blood tube were stored at -80 
˚C if required for future DNA analysis. The crude buffy coat sample was mixed gently 
using a pipette and divided appropriately for RNA and protein analysis. Then, 250 µL 
of Mammalian Protein Extraction Reagent (mPER) (Ambion) was added to tubes 
destined for protein analysis, and 500 µL of RNALater (Thermo Scientific) was added 
to those needed for RNA analysis. Samples were labelled and stored at -80 ˚C until 
future analysis.  
2.1.3 Serum extraction from whole blood 
 
Peripheral whole blood used for serum extraction was collected in a serum clot 
activator tube (Aquilant Scientific) using a venepuncture technique. The blood tube 
was kept upright at 18 ˚C for 30 minutes to allow clotting to occur, then stored at 4 
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˚C until processing. The tube was then centrifuged at 3500 rcf for 10 minutes at 18 
˚C. After centrifugation, the top serum layer was aliquoted (up to 5 x 500 µl) into 1.5-
2 mL screw-top vials and stored at -80 ˚C until further analysis.   
 
2.2 Magnetic-activated cell sorting (MACS) 
 
2.2.1 Pan Monocyte Isolation 
 
PBMCs were separated from whole blood as described in section 2.1.1. Then, 10 µl 
of the cell suspension was diluted with 90 µl autoMACS buffer (section 2.2.1.1) to 
make a 1 in 10 dilution. After pipetting up and down to ensure sufficient mixing, 20 
µl was added to a haemocytometer for counting. The cell number was determined 
and the original cell suspension was centrifuged at 300 rcf for 10 minutes at 4˚C. The 
supernatant was aspirated and the cell pellet was resuspended in 30 µl autoMACS 
buffer per 107 cells. The Pan Monocyte Isolation kit (Miltenyi Biotec) was used on the 
autoMACS Pro separator for all monocyte cell separations. Then, 10 µl of Fragment 
crystallisable region (FcR) blocking reagent was added per 107 total cells followed by 
10 µl biotin-antibody cocktail per 107 total cells. The cell suspension was vortexed 
gently and incubated for 5 minutes at 2-8˚C. Then, 30 µl of autoMACS buffer was 
added per 107 cells followed by 20 µl anti-biotin microbeads per 107 cells. The cell 
suspension was mixed well and incubated for an additional 10 minutes at 2-8˚C. If 
required for analysis, staining antibodies were then added at the optimized 
concentration (Appendix D). The cell suspension was gently vortexed followed by a 
final incubation at 2-8˚C for 15-30 minutes with protection from light. Cells were 
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washed by addition of 1-2 mL autoMACS buffer followed by centrifugation at 300 rcf 
for 10 minutes at 4˚C. After removing the supernatant, the wash step was repeated 
followed by final resuspension of the cell pellet in 500 µl autoMACS buffer per 108 
cells.  
The autoMACS Pro separator used to deplete the monocyte cell population. This 
automated instrument contains a magnetic column. When a magnetic field is applied 
to the column, it enables it to pull out the ferrite-containing anti-biotin microbeads. 
As these beads have now bound with the antibody-antigen complex, it enables 
specific cells to also be pulled out. This is a ‘negative selection’, which means the 
monocyte cells are not pulled out, so are depleted and eluted in the first flow-
through. The cell sample was placed in row A of the tube rack and empty tubes were 
placed in rows B and C. The tube rack was placed on the instrument stand and the 
‘Deplete’ program was selected. The monocyte cells were collected in row B. 
2.2.1.1 Preparation of autoMACS buffer (PBS + 2 mM EDTA + 0.5% BSA) 
 
Ten PBS tablets (Thermo Scientific) were dissolved in 1L dH2O and autoclaved to 
sterilise. Then, 5g BSA (Sigma-Aldrich) and 0.74 g EDTA (Sigma-Aldrich) were 
dissolved in the PBS. This solution was stored for no longer than 2 weeks at 2-8˚C. 
 
2.3 Fluorescence-activated cell sorting (FACS) 
 
FACS is a technique that utilizes lasers to detect specific cell phenotypes via an 
antibody-fluorophore conjugate. It is coupled with highly specialized software that 
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allows for simultaneous analysis and isolation of cells of interest. Once cells have 
been isolated, they can be stored until downstream analysis. 
2.3.1 Sample preparation and extracellular antibody-fluorophore labelling 
 
PBMCs were separated from whole blood as described in section 2.1.1. Then, 10 µl 
of the resulting cell suspension was diluted with 90 µl autoMACS buffer (section 
2.2.1.1) to make a 1 in 10 dilution. After pipette mixing, 20 µl was added to a 
haemocytometer for counting. The cell number was determined and the original cell 
suspension was centrifuged at 300 rcf for 10 minutes at 4˚C. The supernatant was 
discarded and the remaining cell pellet was resuspended in 100 µl BD Stain Buffer 
per 1x106 cells. Each required antibody-fluorophore conjugate was added according 
to the optimised concentration per 1x106 cells (Appendix D). The cell suspension was 
gently passed up and down through a pipette to ensure sufficient mixing. The sample 
was then incubated at 4 ˚C with protection from light for 15-30 minutes. After 
incubation, the cell suspension was made up to 4 mL with BD Stain buffer. This was 
centrifuged at 400 rcf for 10 minutes at 18 ˚C. The supernatant was discarded and 
the pellet was resuspended in 4 mL autoMACS buffer (section 2.2.1.1). The cell 
suspension was centrifuged again at 400 rcf for 10 minutes at 18 ˚C. The supernatant 
was discarded and the cell pellet was resuspended in 0.5-2.0 mL autoMACS buffer. 
The sample was then analysed using the FACS Aria III within 4 hours of processing.  
When analysing each sample using FACS, dot plots were drawn depending on the 
panel of antibodies used. A negative control was used (section 2.3.3) to determine a 
suitable gating strategy for the labelled sample. Once the gating strategy was 
established, the labelled sample was loaded onto the Aria III, and up to 100,000 
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events were recorded. If cells were to be sorted, a sort layout was prepared 
depending on the cell population of interest. Cells were either sorted into cold PBS 
or 20% human serum from AB donors (AB serum) (Sigma Aldrich) in PBS, depending 
on downstream analysis. The latter would be used in cases of downstream cell 
culture experiments, as detailed in section 2.4. 
When analysing cell populations for results chapter 3, the first part of the sample was 
used for monocyte analysis and was labelled with antibodies targeting CD14, CD16, 
CD32, CD64 and CD169 (Becton Dickinson) following use of the Pan Monocyte 
isolation kit (Miltenyi Biotec) for magnetic-activated cell sorting (MACS), as detailed 
in section 2.2.1 (Figure 2.3) (Appendix D). The autoMACS Pro Separator was used for 
this monocyte enrichment step (Miltenyi Biotec). Immunophenotyping and counts of 




The second part of the sample was used for Treg analysis and labelled with antibodies 
targeting CD3, CD4, CD45, CD45Ra, CD127, CD25 and CD43 (Figure 2.4) (Appendix D). 
The Treg phenotype was selected based on markers used in recent literature (Appel 
et al. 2011; Walter et al. 2016).  
 
2.3.2 Intracellular antibody-fluorophore labelling 
 
After cells were labelled extracellularly (section 2.3.1) for 15-30 minutes, the cell 
suspension was made up to 4 mL with BD stain buffer. This was centrifuged at 400 
rcf for 10 minutes at 18 ˚C. The supernatant was discarded and the cell pellet was 
resuspended in 500 µl 1X BD Permeabilizing Solution 2 (Becton Dickinson), a buffer 
containing <15% formaldehyde and <50% diethylene glycol. The cell suspension was 
incubated at 18 ˚C for 10 minutes. Following incubation, the cell suspension was 
made up to 4 mL with autoMACS buffer. The tube was inverted slowly a few times to 
ensure sufficient mixing. The cell suspension was then centrifuged at 400 rcf for 10 
minutes at 18 ˚C. The supernatant was discarded and the cell pellet was resuspended 
in 100 µl BD Stain Buffer per 1x106 cells. Each required antibody-fluorophore 
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conjugate was added according to the optimised concentration per 1x106 cells. The 
cell suspension was gently passed up and down through a pipette to ensure sufficient 
mixing. The sample was incubated at 18 ˚C with protection from light for 15-30 
minutes. Following incubation, the sample volume was made up to 4 mL with BD 
Stain Buffer and the tube was inverted a few times to ensure sufficient mixing. The 
cell suspension was centrifuged at 400 rcf for 10 minutes at 18 ˚C. After discarding 
the supernatant, the cell pellet was resuspended in 500 µl of 1X BD CellFix (Becton 
Dickinson). The sample was kept at 4 ˚C and analysed using the FACS Aria III within 4 
hours of processing. 
When analysing cell populations for chapter 4, extracellular antibody labelling was 
initially carried out according to section 2.3.1. The antibody panel used for 
extracellular staining included CD45-BV421, CD4-FITC, CD3-BV510, CD45RA-
APCR700, CD127-PE-Cy7, CD25-PE and CD43-BV605 (Becton Dickinson). Following 
extracellular staining, intracellular staining of FoxP3-APC and NFκB-PerCP-eFluor710 
(Thermo Fisher) was carried out. 
2.3.3 Preparation of negative controls 
 
Negative controls were used each time a sample was analysed on the FACS Aria III in 
order to determine the gating strategy that differentiates a positive and negative 
population.  
 2.3.3.1 Unstained PBMC negative controls 
 
Unstained PBMCs were prepared according to section 2.3.1, however autoMACS 
buffer was added in substitution for antibody-fluorophore conjugates. This sample 
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was carried through the same process as the labelled samples in order to ensure it is 
a fair negative control. These controls were run with every sample to rule out 
differences in auto-fluorescence between runs. 
2.3.3.2 Isotype negative controls 
 
Isotype control samples were prepared according to section 2.3.1, however isotype 
matched antibody-fluorophore conjugates were added in substitution for the specific 
panel antibody-fluorophore conjugates. Note: Isotype controls are antibody-
fluorophore conjugates of the same class of antibody, however the antibody has not 
been raised against the specific cell marker of interest. Isotype controls were also 
carried through the same process as the labelled samples in order to ensure it is a 
fair negative control. These controls were run every 6 months to ensure the gating 
strategy did not deter from batch to batch of antibody-fluorophore conjugates. 
2.3.4 Data analysis and statistical methods 
 
BD FACSDiva software was used to run and analyse all samples. Following recording 
of cell events and sorting, data was extracted from Diva software and stored on an 
encrypted hard drive. The positivity of a specific cell surface marker in labelled 
samples compared to the negative control was analysed as a percentage of the 
parent population, as detailed further in subsequent results chapters. The median 
fluorescence intensity (MFI), which gives an indication of cell surface density of a 
specific marker, was also noted for various cell populations. 
The mean percentage of positive cells and standard deviation (SD) or standard error 
of the mean (SEM) were recorded for healthy controls and RA patients, with 95% 
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confidence interval (CI). Unpaired T tests or non-parametric Mann Whitney tests 
were used to assess significant differences between sample groups, depending on 
normality of distribution. The normality of distribution was tested using IBM SPSS 
statistics software using the ‘explore’ command. Two-tailed P values and R squared 
values were recorded. The mean and standard deviation was noted for all data in the 
format mean ± standard deviation, however when a Mann Whitney test was used, 
graphs depict the median value with error bars representing the interquartile range. 
Linear regression analysis was used to assess any correlation within the RA patient 
group, as well as association with clinical data using 95% CI. R squared and P values 
were also recorded. 
 
2.4 Cell culture 
 
All cells were sorted as detailed in sections 2.2 and 2.3, depending on the specific cell 
population of interest. Cell were cultured in TexsMACSTM medium (Miltenyi Biotec), 
supplemented with 5% AB serum (Sigma Aldrich), 1% Penicillin-Streptomycin (Gibco) 
and human IL-2 (Miltenyi Biotec). During culture, cells were stored in a temperature 
controlled incubator (Galaxy 170 S, New Brunswick) at 37 ˚C with 5% CO2. Counting 
and viability tests were carried at specific time points throughout culture. Images of 
cells were also taken during culture using an inverted microscope (Zeiss Primovert). 
This was to observe any physical differences of the cells. 
PBMCs were obtained from anonymous healthy participants for the purpose of cell 
culture. As detailed in section 2.1.1, PBMCs were separated using Ficoll density 
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gradient buffer and labelled with extracellular antibodies depending on the cell 
populations of interest. Tregs used in results chapter 4 were labelled using antibodies 
CD4, CD25 and CD127. Tregs were then sorted into PBS containing 20% AB serum 
(Sigma Aldrich) using the phenotype CD4+CD25+CD127-, and were expanded as 
detailed in section 2.4.2. 
 Monocytes used for co-culture experiments were obtained from healthy 
participants. Following isolation of PBMCs using Ficoll, cells were extracellularly 
labelled with antibodies CD14-APCCy7, CD16-PECy7 and CD169-PE. Monocytes were 
initially enriched using the Miltenyi Biotec Pan monocyte isolation kit, as detailed in 
section 2.2.1. The enriched monocytes were then analysed by FACS and sorted into 
20% AB serum according to the phenotype CD14+CD169+.  
Following cell sorting of Tregs or monocytes into 20% AB serum, cells were washed 
twice in TexsMACSTM medium (Miltenyi Biotec), supplemented with 5% AB serum 
(Sigma Aldrich), 1% Penicillin-Streptomycin (Gibco) and human IL-2 (Miltenyi Biotec).  
 
2.4.1 Cell viability 
 
The cell viability test was carried out using Trypan Blue solution (Sigma). Trypan blue 
allows for the differentiation between live and dead cells as it will penetrate the cell 
membrane of non-viable cells, causing them to stain blue. The cell suspension was 
added at an equal volume to Trypan blue, for example 25 µL cells + 25 µL Trypan blue. 
The solution was pipetted up and down gently to ensure sufficient mixing, then 
incubated for 5 minutes at 18 ˚C. Following incubation, the live and dead cells were 
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counted on a standard haemocytometer. The percentage of viable cells was 
calculated using the following equation: 
  No. Live cells / (No. Live cells + No. Dead cells) * 100 
 2.4.2 Human Treg expansion 
 
Following Treg cell sorting and wash steps, cell were resuspended in 1 mL of media 
per 1x106 cells. 100 µL (1x105 cells) was added to each well of a round-bottom 96-
well plate (Sarstedt). The Miltenyi Biotec human Treg expansion kit was used to 
induce Treg proliferation in order to expand the cell population for sufficient cell 
numbers prior to stimulation experiments. CD3/CD28 particles were resuspended 
thoroughly before taking 100 µL into a fresh tube. Then 500 µL of fresh media was 
added, and the particles were centrifuged at 300 rcf for 5 minutes at 18˚C. The 
supernatant was discarded and the particles were resuspended in 100 µL fresh 
media. Then 20 µL of the particle suspension was added per well containing 1x105 
cells. Then 100 µL of media was added to each well on Day 1 of expansion. On Day 3-
5, depending on cell counts and viability, cells were either split between wells to 
allow further expansion, or media was exchanged in each well. These checks were 
carried out carefully every other day until Day 14. On Day 14, if further expansion 
was needed, the particles were removed using a DynaMAGTM spin magnet 
(Invitrogen). In order to successfully remove particles, cells were placed in a 1.5 mL 
eppendorf and held on the magnet for 1-2 minutes. The supernatant was carefully 
placed in a fresh tube, and replaced on the magnet for a further 1-2 minutes. The 
cells in the supernatant could then be re-stimulated with fresh CD3/CD28 particles 
as before, if necessary. 
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Sorted Tregs were expanded for a no longer than 14 days. Cell stimulation 
experiments were carried out in a 24-well plate at a density of 3-5x105 cells per well. 
At each time point, counting and viability testing was carried out as described in 
section 2.4.1. Additionally, at relevant time points during stimulation, cells were 
centrifuged at 1600 rcf for 5 minutes at 18 ˚C and the supernatant was stored at -80 
˚C if required for ELISA analysis of secreted cytokines. The cells were resuspended in 
1 mL of sterile PBS and centrifuged at 400 rcf for 10 minutes at 18 ̊ C. The supernatant 
was discarded, and cells were either resuspended in 1 mL Trizol if required for RNA 
extraction and qPCR (storage at -80 ˚C until RNA extraction), or staining buffer if 
required for flow cytometry (processed immediately at 18 ˚C). 
2.4.3 Phorbol 12-myristate 13-acetate/Ionomycin (PMA/IO) and 
Lipopolysaccharide (LPS) optimisation  
 
LPS was reconstituted in media to make a stock solution of 1 µg/ml (Sigma Aldrich). 
The stock solution was diluted as required using media. PMA (Abcam) was 
reconstituted in 99.8% ethanol (Sigma Aldrich) to make a stock solution of 1 mg/ml. 
The stock solution was diluted as required using media. PMA was used in 
combination with IO (Invitrogen). IO was reconstituted in dH2O to make a stock 
solution of 1 mg/ml. The stock solution was further diluted to 500 ng/ml using media. 
The expanded Tregs were initially exposed to a range of each stimulant, based on 
quantities reported in previous literature papers (Yu et al. 2012). In preliminary 
experiments aimed at optimising the concentration of each stimulant, cells were 
stored for subsequent RNA extraction and qPCR at time points 0, 24hrs and 48hrs 
after exposure to the appropriate stimulant. On repeating the experiment with 
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optimal conditions subsequent to these preliminary experiments, cell supernatants 
were analysed for cytokine secretion by ELISA. 
 2.4.4 Sialic acid (Sia) stimulation of Tregs 
 
Expanded Tregs (3-5x105 cells per well of 24-well plate) were stimulated with 10 
ng/ml PMA and 500 ng/ml IO as these conditions were found to be optimal primarily 
in increasing TNFα and IL-10 cytokine secretion (Chapter 4). Tregs were also 
stimulated with 10 mM Sia either with or without PMA/IO. Monomeric Sia was 
reconstituted in dH2O to make a stock solution of 50 mg/ml (Sigma Aldrich). Then 10 
mM of Sia was added directly to each well as required from the stock solution. The 
effects of adding Sia after 1 day of PMA/IO stimulation were assessed. A vehicle 
control was also included in the experiment to ensure the dH2O in which Sia was 
resuspended did not have any effect on the Treg cells. At time points Day 0, Day 1 
and Day 2, cells were removed from culture and labelled for FACS analysis with 
extracellular staining antibodies CD4, CD25, CD127 and CD43, as well as intracellular 
staining antibodies NFκB and FoxP3. The cell culture supernatants were also analysed 
for secreted cytokine levels as before. 
 2.4.5 Monocyte/Treg co-culture  
 
Sorted monocytes were used in culture on the same day of sampling. The ratio of 
monocytes to Tregs in co-culture was approximately 1:2 i.e. 1.5-2.5x105 monocytes: 
3-5x105 Tregs per well of a 24-well plate. Blocking antibodies were used in co-culture 
experiments of Tregs and monocytes. CD169 blocking antibody was reconstituted in 
PBS and used at a concentration of 4 µg/ml (AF5197, R&D systems). CD43 blocking 
antibody was reconstituted in PBS and used at a concentration of 1 µg/ml (AF2038, 
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R&D systems). CD169 was incubated with monocytes in TexsMACSTM medium 
(Miltenyi Biotec), supplemented with 5% AB serum (Sigma Aldrich), 1% Penicillin-
Streptomycin (Gibco) and human IL-2 (Miltenyi Biotec) at 37 ˚C for 30 minutes prior 
to addition of Tregs. Similarly, CD43 was incubated with Tregs in the supplemented 
TexsMACSTM medium at 37 ˚C for 30 minutes prior to addition of monocytes. 
Following co-culture, cells were gently scraped with a sterile scraper (Thermo Fisher) 
into suspension before placing into a 1.5 mL eppendorf tube prior to antibody 
labelling for FACS analysis 
 
2.5 Molecular methods 
 
 
2.5.1 RNA extraction 
Total RNA was extracted from human cells using TRIzol® (Invitrogen). Cells were 
resuspended in 1 mL TRIzol® in a 1.5 mL eppendorf and mixed vigorously up and 
down using a pipette. Cell samples were then frozen at -80 ˚C prior to continuing the 
extraction. The homogenized cell samples were thawed to room temperature then 
vortexed thoroughly. Then 200 µL chloroform (Sigma Aldrich) was added to each 
sample in a fume hood. The Eppendorfs were capped and shaken well for 15-20 
seconds. The mixture was allowed to settle at room temperature for 2-3 minutes to 
allow layers to separate, then each sample was centrifuged at 12,000 rcf for 15 
minutes at 4 ˚C. Following centrifugation, the mixture separates into 3 layers; an 
upper aqueous layer where RNA is contained, a cloudy interphase and a lower phenol 
layer. RNA was pipetted from the upper layer and into a clean 1.5 mL Eppendorf, 
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being careful not to disturb the interphase. 5 µg of Glycogen (Invitrogen) was added 
to the wall of each Eppendorf. Glycogen is a carrier protein that is co-precipitated 
with the RNA. The aim of adding a carrier is to improve yield of RNA. 500 µL of 100% 
propan-2-ol (Sigma Aldrich) was added to each sample, ensuring to flood the small 
quantity of Glycogen to the bottom of the Eppendorf. The sample was mixed gently 
up and down using a pipette, then incubated at room temperature for ten minutes. 
Following incubation, the samples were centrifuged at 12,000 rcf for 10 minutes at 4 
˚C. During centrifugation, the hinge of the Eppendorf was pointed upwards to ensure 
the RNA pellet would fall on the same side of the Eppendorf. The supernatant was 
carefully removed as the pellet is often not visible. The pellet was resuspended in 1 
mL 75% ethanol (Sigma Aldrich) and pipetted up and down gently to ensure sufficient 
mixing. The suspension was then centrifuged at 7500 rcf for 5 minutes at 4 ˚C. After 
discarding the supernatant, the pellet was again resuspended in 75% ethanol. At this 
point, the suspension was placed at -80 ˚C for 1 hour to overnight. The centrifugation 
step was repeated and the supernatant was discarded, ensuring not to leave any 
liquid behind. The lid of the Eppendorf was left open and the pellet was allowed to 
air-dry for 10 minutes, ensuring not to completely dry the pellet as it would cause 
difficulty when resuspending. RNase-free water (20 µl – 50 µl) (Roche) was added to 
the pellet followed by gently pipetting up and down to ensure sufficient mixing. The 
sample was placed on a heat block at 55 ˚C for 10-15 minutes then cooled on ice for 




 2.5.1.1 RNA Quantification 
RNA was quantified using a NanoDrop 1000 spectrophotometer (Thermo Scientific). 
The NanoDrop was blanked using 2 µL of RNase-free water (Roche). Following 
instrument blanking, 2 µL of sample was added for quantification. The NanoDrop 
software provides RNA quantities in ng/µl as well as absorbance ratios A260/A280 and 
A260/A230 for an estimation of purity. 
2.5.2 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
Reverse transcription is a process where RNA is used as a template to produce 
complementary DNA (cDNA), a reaction that is enabled by a reverse transcriptase 




All RT-PCR reactions were facilitated by the Transcriptor First Strand cDNA Synthesis 
kit (Roche Diagnostics). Following RNA quantification (section 2.5.1.1), the 
concentration of RNA to be used for RT-PCR was calculated. The volume of RNA to 
satisfy this concentration could not exceed 11 µl, and if required, PCR grade water 
(as supplied in kit) was added to the RNA to make up the volume. Throughout 
preparation of RNA/water, samples were kept on ice to prevent degradation of the 
RNA. Then 2 µl of random hexamer primers (as supplied in kit) was added to each 
sample. The tube was then capped and briefly spun in a microcentrifuge in order to 
ensure all of the sample was at the bottom of the tube. Each sample was then placed 
in a thermocycler (Techno) at 65 ˚C for 10 minutes to allow the primers to bind to the 
RNA. During this incubation, a master mix was prepared as detailed in Table 2.2. It is 
important to compensate for pipetting losses when calculating master mix volumes. 
Generally, a 10% increase is recommended, for example if there were 20 samples, 




Once all the relevant kit components were added, the master mix was vortexed 
gently and briefly spun in a microcentrifuge to pull the entire volume to the bottom 
of the tube. The samples were removed from the Thermocycler and 7 µl of master 
mix was added to each sample. The samples were mixed by gently flicking the capped 
tube, and briefly spun to pull all of the liquid to the bottom of the tube. They were 
then placed back in the thermocycler at 25 ˚C for 10 minutes, 50 ˚C for 60 minutes, 
85 ˚C for 5 minutes and finally 4 ˚C for up to 2 hours. The samples could be stored at 
-20 ˚C until PCR, or if using immediately they were kept on ice. 
 2.5.2.1 Negative controls in RT-PCR 
Negative controls are introduced into RT-PCR to ensure reliability of results. The first 
negative control used for every PCR experiment is called ‘no RT’. This is when PCR 
grade water is used as a substitute of RT enzyme during master mix preparation. 
Usually the sample with the highest amount of RNA is prepared twice, only with no 
RT added for the duplicate tube. This will give confidence to PCR results following 
amplification of cDNA because it eliminates the possibility that DNA has been 
introduced accidently into the reaction. 
The second negative control introduced at this stage of PCR is called ‘no RNA’. This is 
simply an extra tube that has been carried through RT-PCR, however at the start of 
the reaction 11 µl of water is added with no RNA. This type of control also gives 




2.5.3 Quantitative Polymerase Chain Reaction (qPCR) 
Quantitative PCR (qPCR) is a molecular technique used to amplify and obtain a 
relative quantity of DNA. This amplification is measured in real-time, which is why 
this method is often referred to as real-time qPCR (RT-qPCR). All qPCR reactions were 
carried out using sequence-specific probe sets (Roche, RealTime ready) that are 
compatible with the LightCycler 480 Probes Master kit (Roche Diagnostics). The kit 
comprises of a ready to use master mix which utilizes Taq DNA polymerase, the 
enzyme that drives the reaction. 
Following RT-PCR, samples were thawed and tubes were placed in a microcentrifuge 
briefly to allow all contents to be recovered. All qPCR reagents were kept on ice 
throughout to avoid degradation. The qPCR master mix was prepared on ice using 
quantities described in Table 2.3, where the final volume depended on the number 
of wells needed. Pipetting losses were compensated for by increasing the required 




The final master mix was pipetted up and down gently to ensure sufficient mixing. 
The master mix preparation was repeated for each probe set required. Note: Each 
sample was also run with a β-actin probe as the housekeeping gene. Then 2 µL of 
each sample was pipetted into the relevant well, followed by 8 µL of final master mix. 
The plate was covered with plastic film and centrifuged for 2 minutes at 1500 rcf, 4 
˚C to ensure all contents are pulled to the bottom of the well. A LightCycler 480 PCR 
machine (Roche) was used to read the plate. The plate was read under the Roche 
template programme ‘Monocolour Hydrolysis Probes’, with an annealing 
temperature of 60 ˚C.  
Results displayed in chapter 4 use probe sets obtained from Roche including TNF, IL-
6 and IL-10. βactin was used as the housekeeping gene to calculate ΔCt values for 
each probe as it was found exhibit stable Ct values when tested with unstimulated 
and stimulated expanded Tregs (Appendix P). 
 
 2.5.3.1 Negative controls in qPCR 
Negative controls are introduced into qPCR to ensure reliability of results. The first 
negative control used for every qPCR experiment is called a ‘no probe control’. This 
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is when PCR grade water is substituted for the probe during master mix preparation. 
Usually, the sample with the highest amount of RNA is prepared with double the 
quantity at the RT-PCR stage. This is to ensure there is enough leftover sample for 
the ‘no probe’ control. Inclusion of the ‘no probe’ control gives confidence that any 
signal produced when a probe is present is true signal.  
The second negative control used in qPCR is called a ‘no cDNA control’. This is simply 
when the sample is substituted for PCR grade water supplied in the kit. The ‘no cDNA 
control’ alongside the ‘no RNA control’ from the RT-PCR reaction gives confidence 
that no contaminating DNA has been introduced into the process. If one of the 
negative controls gives a signal at the PCR stage, the presence of both helps to 
determine the reagent in which the contaminant was introduced. However, any 
probes used were exon spanning in order to reduce measurement of genomic DNA. 
2.5.4 Data analysis 
Following RT-PCR and qPCR, plates were run on the LightCycler 480 using LightCycler 
480 Software (release 1.5.0 SP4). The cycler threshold (Ct), which is the number of 
amplification cycles it has taken for the fluorescent signal to be detected, was 
recorded for each well. The ΔCt value was calculated by subtracting the Ct value of 
the housekeeping gene β-actin from that of the gene of interest. This value was then 





2.6 Proteomic Methods 
 
2.6.1 Proseek multiplex 
Plasma from each patient, extracted as described in section 2.1.2, was thawed and a 
small volume of ~40 µl was sent to OLINK (Analysis service Uppsala, Sweden). Each 
sample was analysed across OLINK’s CVD II, CVD III, immune response and 
inflammatory panels (Appendix F). Each high throughput multiplex immunoassay 
consists of 92 proteins. The technology used is known as ‘Proximity Extension Assay’ 
(PEA), where matched antibody pairs containing unique DNA sequences are 
incubated with the sample. Sequences that are exactly matched will hybridize and 
are extended using DNA polymerase. The elongated DNA can then be amplified and 
a qPCR readout using Fluidigm® BioMARKTM is used to determine the results of each 
protein target. The assay includes internal controls at each stage of the reaction, 
negative controls to determine background values, and inter-plate controls to 
account for variability between plates. ΔCt values are log normalised to what is called 
‘normalised protein expression’ values or NPX. 
2.6.1.1 PEA analysis: Statistical methods 
 
Perseus software (version 1.6.0.7) was used to analyse the vast range of NPX values 
across patient groups (Tyanova et al. 2016). A Z-score was performed across the 
entire data set in order to standardise the NPX values. The order in which each 
analysis was carried out is summarised in Figure 2.6. To visualise significant changes 
in protein expression between groups, initially a volcano plot was drawn using a two 
sided t-test. In order to filter data based on significance of differentially expressed 
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proteins across all patient groups, an analysis of variance (ANOVA) test was carried 
out. These proteins were expressed in a heat map with unsupervised clustering. The 
ANOVA test was carried out either with or without permutation-based false 
discovery rate (FDR) depending on the analysis required, as detailed in section 
2.6.1.2. Following this statistical analysis, bioinformatic analysis was carried out using 
online pathway programmes including STRING (Szklarczyk et al. 2017), Enrichr 
(Kuleshov et al. 2016), and Reactome (Fabregat et al. 2017). These programmes were 




2.6.1.2 Comparisons of OLINK data to clinical and cellular data 
 
The patient subgroup comparisons made with PEA data are broken into 4 sections as 
detailed below. On analysing A and B, the more stringent ANOVA test with 
permutation based FDR was used. However, on analysing sections C and D, the less 
stringent ANOVA test without FDR was used due to the low patient number present 
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in the group (C) or in due to the lack of significance observed using the more stringent 
test (D). 
A) cDMARD response: (Section 5.1.1) Initially, the aim was to determine whether a 
subset of circulating proteins distinguish cDMARD treatment response in RA. Patients 
were grouped according to EULAR response criteria, and data was analysed as 
detailed in section 2.6.1.1. 
B) Disease activity: (Section 5.1.2) The above analysis was repeated when patients 
were grouped by DAS28-ESR score according to EULAR disease activity criteria, 
recorded on the day of sampling. A score of ≥5.1 was classified as ‘high’ disease 
activity, >3.2 and ≤5.1 was ‘moderate’, >2.6 and ≤3.2 was ‘low’, and <2.6 was 
classified as ‘remission’. The aim was to determine whether the circulating proteome 
is associated with disease activity in RA, thus discovering which proteins may be 
involved in disease pathogenesis and subsequently treatment response. 
C) Biologic DMARD Response: (Section 5.1.3) The last comparison involved patients 
treated with biological DMARDs who were sampled before treatment and after 6 
months. These patients were grouped according to response to treatment. The aim 
of this analysis was to determine whether circulating proteins correlate with 
biological DMARD treatment response, and if so whether these proteins are the same 
as those representative of cDMARD treatment response. 
D) Immunophenotype: (Section 5.1.4) Additionally, a comparison was made 
between the OLINK data and previous immunophenotype and flow cytometry data 
(chapter 3 and 4). The aim of this analysis was to determine associations between 
pathologically relevant cells in circulating blood and changes in circulating proteins. 
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2.6.2 Enzyme-linked immunosorbent assay (ELISA) 
 
2.6.2.1 DuoSet ELISAs 
 
Following cell culture experiments (section 2.4), cell supernatants were analysed by 
DuoSet ELISA for quantification of human TNFα, human IL-10 and human IFN-γ (R&D 
systems). Before beginning, the kit contents were brought to room temperature. The 
capture antibody was prepared according to the instructions for each specific kit 
(Table 2.5). The wells of a 96-well plate were then coated with 100 µL of the diluted 
antibody. The plate was sealed and incubated overnight at 18 ˚C with gentle shaking 
of 300 rpm. 
 
Following overnight incubation, the contents of each well was discarded and washed 
3 times with 1x wash buffer. After the last wash, any remaining wash buffer was 
removed by inverting the plate and blotting against dry paper towels. Each well was 
then blocked with 300 µL block buffer and incubated for 1 hour at 18 ˚C on a shaker 
at 300 rpm. Following blocking, the wash step was repeated and the plate was 
blotted dry on tissue paper as before. Standards were prepared as detailed in Table 
2.6, and samples were diluted 1:1 with reagent diluent. Then 100 µL of each standard 
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or sample was added to wells in replicates of 2, and the plate was covered and 
incubated for 2 hours at 18 ˚C on a shaker at 300 rpm. 
 
Following incubation of standards and samples, the wash step was repeated. The 
plate was blotted dry as before and 100 µL of detection antibody was added to each 
well (Table 2.7). The plate was incubated with detection antibody for 2 hours at 18 




The plate was then washed and blotted dry as before. Then 100 µL of streptavidin-
horseradish peroxidase (HRP) was added to each well and the plate was covered with 
foil to protect from light. The plate was incubated for 20 minutes at 18 ˚C on a shaker 
at 300 rpm. The wash step was repeated as before and the plate was blotted dry. 
Then 100 µL of substrate solution was added to each well and the plate was covered 
in foil to protect it from light. The plate was then incubated for 20 minutes at 18 ˚C 
on a shaker at 300 rpm. Then 50 µL of stop solution was added to each well and the 
plate was gently tapped to ensure sufficient mixing. The optical density (OD) was 
determined using an EPOCH plate reader (Biotek) with Gen5TM software. The plate 
was read at a wavelength of 450 nm and 540 nm. The OD values at 540 nm were 
subtracted from those at 450 nm in order to account for wavelength correction. A 
standard curve was plotted using the ODs and known concentrations from the 
standards. Using the y=mx+c equation produced by the standard curve, the 
concentrations of the unknown samples were then calculated. 
2.6.2.2 Proximity extension assay validation by ELISA 
In order to validate the changes in protein expression observed from the OLINK data 
set, two of the proteins of interest were selected to be quantified by ELISA.  
  2.6.2.2.1 Caspase-3 
 
The first protein quantified by ELISA was Caspase-3 (CASP-3), using the Human 
CASP3/Caspase 3 ELISA kit (sandwich ELISA) sourced from LifeSpan BioSciences, Inc. 
The kit was brought to room temperature (18 ˚C) before preparation of the standard. 
The CASP-3 standard was reconstituted in 1 mL of sample diluent to make a stock 
concentration of 20 ng/ml. Then 500 µL of the stock solution was pipetted into an 
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Eppendorf as the highest concentration standard. Then 250 µL of the highest 
standard was pipetted into a fresh Eppendorf and diluted 1:1 with sample diluent in 
order to make the next standard. This was repeated until there was a total of 7 
standards, with the lowest concentration of 0.313 ng/mL. A blank of only sample 
diluent was included as the lowest standard. The plasma samples were thawed on 
ice and diluted 1:1 with sample diluent. Then 100 µL of standard or sample was 
pipetted in duplicate into corresponding wells of the provided 96-well plate. The 
plate was covered with a provided sealer and incubated for 90 minutes at 37 ˚C on a 
shaker at 150 rpm. Following incubation, the liquid of each well was removed and 
discarded using a multi-channel pipette. Then 100 µL of biotinylated detection 
antibody was added to each well and the plate was recovered with a fresh plate 
sealer. The plate was incubated for 1 hour at 37 ˚C on a shaker at 200 rpm. Following 
incubation, the liquid was aspirated and the wells were flooded with wash buffer 
using a squirt bottle. The plate was allowed to sit for 1-2 minutes before aspirating 
the liquid and repeating this wash step 3 times. Following the last wash, the liquid 
was aspirated and the plate was inverted and gently blotted on paper towels to 
remove any excess liquid. Then 100 µL of HRP conjugate working solution was added 
to each well and the plate was covered with a sealer. The plate was incubated for 30 
minutes at 37 ˚C on a shaker at 150 rpm. Following incubation, the liquid was 
discarded and the wells were washed a total of 4 times as before. The plate was 
blotted onto paper towels to dry and 90 µL tetramethylbenzidine (TMB) substrate 
solution was added to each well. A plate sealer was added and the plate was 
incubated for 15 minutes at 37 ̊ C on a shaker at 150 rpm. During this incubation step, 
the plate was covered with aluminium foil to protect from light. Then 50 µL stop 
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solution was added to each well following development and the ODs for each well 
were determined using an EPOCH plate reader (Biotek) with Gen5TM software. The 
plate was read at a wavelength of 450 nm and 540 nm. The OD values at 540 nm 
were subtracted from those at 450 nm in order to account for wavelength correction. 
A standard curve was plotted using the ODs and known concentrations from the 
standards. Using the y=mx+c equation produced by the standard curve, the 
concentrations of the unknown samples were then calculated. 
2.6.2.2.2 CD40 Ligand 
 
CD40 Ligand (CD40-L) was also quantified by ELISA, using the Human CD40 
Ligand/TNFSF5 Quantikine®ELISA kit (R&D systems). The kit was brought to room 
temperature (18 ˚C) prior to use. 100 µL of assay diluent as supplied in the kit was 
added to each well. CD40-L standard was reconstituted in 1 mL of ddH2O to make a 
stock concentration of 40,000 pg/mL. Then 100 µL of standard was added to 900 µL 
calibrator diluent to make the highest standard at a concentration of 4000 pg/mL. 
Then 500 µL was taken out of the top standard into a fresh tube and diluted 1:1 with 
diluent. This was repeated until there were a total of 7 standards. A blank containing 
only calibrator diluent was also included as the lowest standard. Plasma samples 
were thawed on ice and diluted 1:1 with calibrator diluent. Then 100 µL of standard 
or sample was added in duplicate to corresponding wells. The plate was covered with 
a sealer and incubated for 2 hours at 18 ˚C on a shaker at 450 rpm. Following 
incubation, the liquid of each well was discarded and the wells were flooded using a 
squirt bottle containing 1x wash buffer. This was repeated 3 times and the plate was 
blotted onto tissue paper to remove excess liquid. Then 200 µL of Human CD40 
77 
 
Ligand Conjugate, as supplied in the kit, was added to each well. A new plate sealer 
was added and the plate was incubated at 18 ˚C for 2 hours on a shaker at 450 rpm. 
Following incubation, the liquid was discarded from each well and the wash step was 
repeated 4 times as before. The plate was blotted dry on paper towels and 200 µL of 
substrate solution was added to each well. The plate was incubated for 30 minutes 
at 18 ˚C and covered with aluminium foil to protect from light. Then 50 µL stop 
solution was added to each well to stop the development. ODs for each well were 
determined using an EPOCH plate reader (Biotek) with Gen5TM software. The plate 
was read at a wavelength of 450 nm and 540 nm. The OD values at 540 nm were 
subtracted from those at 450 nm in order to account for wavelength correction. A 
standard curve was plotted using the ODs and known concentrations from the 
standards. Using the y=mx+c equation produced by the standard curve, the 





















Monocytes and Tregs, the key 












Rheumatologists commonly use the disease activity score across 28 joints (DAS28) to 
determine whether a patient has responded to treatment. The DAS28 is assessed 
before and during DMARD therapy, however response is frequently not determined 
until 3-6 months after commencing treatment. Many studies have highlighted 
weaknesses with DAS28, especially due to the use of CRP or ESR in the composite 
score. Additional to being non-specific markers of inflammation, environmental and 
lifestyle factors may play a role in the elevation of CRP and ESR (Kushner et al. 2006; 
Kushner et al. 2010). Several studies indicate that ESR and CRP can be poor markers 
of inflammation, namely due to their lack of correlation with disease activity, and 
therefore their elevation can be misleading (Sheehan et al. 1986; Ruof and Stucki 
1999; Baum et al. 2008). Thus there is a strong clinical need for more specific 
biomarkers that are directly associated with disease activity in RA. Such markers 
would ideally enable treatment response to be determined at an early stage, 
enabling non-responders to switch to an alternative DMARD medication sooner than 
currently possible. Furthermore, identifying those with highly active or potentially 
subclinical disease would be extremely useful for clinicians to direct DMARD 
treatment. Finding the correct treatment for individual patients soon after diagnosis 
could potentially improve clinical outcome. This chapter investigates how the 
immunophenotype of pathologically relevant circulating cells relates to clinical 




3.0.1 Monocyte subsets 
 
As mentioned in section 1.1.2, monocytes and macrophages are key mediators of the 
inflammatory response, and have been widely studied in RA patients due to their 
increase during active disease (Huang et al. 2007; Chara et al. 2015). Furthermore, 
an increasing number of studies have emerged that subdivide CD14 positive 
monocytes into resident or inflammatory subsets, depending on the presence or 
absence of CD16, respectively (Passlick et al. 1989; Auffray et al. 2009). Inflammatory 
CD14++CD16- monocytes are also termed classical M1 type monocytes, whereas 
resident M2 type monocytes can be further subdivided into CD14++CD16+ 
intermediate and CD14+CD16++ non-classical.  
Previous studies have highlighted the differences between these subsets in relation 
to RA. Resident CD16+ monocytes have been shown to increase during active RA 
(Kawanaka et al. 2002; Cairns et al. 2002), whereas CD16- classical monocytes are 
reduced in RA peripheral blood compared to healthy controls (Lacerte et al. 2016). 
However, classical and intermediate dominate over non-classical macrophages in RA 
synovial fluid (Lacerte et al. 2016). Additionally, a previous study demonstrated an 
increase in intermediate, but not classical or non-classical monocytes and 
macrophages in RA peripheral blood and synovial fluid compared to healthy controls 
(Yoon et al. 2014). This increased expression of CD16 on synovial macrophages was 
shown to be induced by inflammatory cytokine transforming growth factor-beta 
(TGF-β) (Yoon et al. 2014). Furthermore, although the main function of classical 
monocytes has previously been believed to be phagocytic (Ziegler-Heitbrock 2000), 
a recent study demonstrated their ability to produce pro-inflammatory cytokines 
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including IL-6 and TNFα following in vitro stimulation with TLR2 and TLR9 agonists 
(Lacerte et al. 2016). 
The number of circulating monocyte subsets has been linked to treatment response 
in RA patients. A previous prospective study by Chara et al. demonstrated the role of 
the absolute count of monocytes, as well as each monocyte subset in predicting anti-
TNF treatment response (Chara et al. 2012). More recently, the group analysed 
monocyte differences in RA responders and non-responders to MTX both before and 
during treatment. They found that the numbers of each subset were increased in 
non-responders compared to responders and healthy controls. Furthermore, the 
number of classical and intermediate monocytes had predictive value in determining 
response to MTX before starting the drug (Chara et al. 2015). 
3.0.2 The monocyte-Treg interplay in RA 
 
Evidence to date implies monocytes play a role in RA pathogenesis and may be 
clinically useful in determining treatment response. However, additional studies have 
highlighted the need to consider the interplay between monocytes and T cells. 
Localisation of macrophages and T cell clusters have been identified within the 
inflamed synovium, suggesting they may interact at the inflamed site (Fonseca et al. 
2002). In vitro studies have demonstrated the ability of synovial macrophages to 
promote Th1 and Th17 responses in CD4+ T cells (Yoon et al. 2014), for example the 
induction of pro-inflammatory cytokines which in turn releases damage-causing 
enzymes. 
Additional studies have found an association between RA monocytes and Tregs, and 
the potential effects monocytes exhibit on Treg activation. An increase in IL-6 and IL-
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23 secretion was observed from monocyte derived dendritic cells, which was 
associated with the induction of Th17 cells and Tregs in RA (Estrada-Capetillo et al. 
2013). Similarly, activated monocytes were shown to increase the percentage of 
Tregs possessing intracellular inflammatory cytokines IL-17, IFN-γ, TNFα and IL-10 
(Walter et al. 2013). Interestingly, the increase in Treg cells was induced by monocyte 
derived cytokines, including IL-6 and TNFα (Walter et al. 2013). 
3.0.3 CD169 (Siglec-1) interacts with CD43 
 
CD169 (Siglec-1) is a cell surface protein present on monocytes and macrophages. 
CD169 expression is associated with pro-inflammatory mechanisms in the immune 
response, displaying involvement in effector T cell induction as well as secretion of 
cytokines such as IFN-γ from activated T cells (Jiang et al. 2006). As detailed in section 
1.1.4.1, previous studies have shown an association between increased levels of 
CD169+ monocytes and RA (Hartnell et al. 2001; Xiong et al. 2014). Furthermore, a 
number of studies have highlighted the direct involvement of CD169 expression with 
disease pathogenesis in RA among other autoimmune conditions (York et al. 2007; 
Xiong et al. 2014). Circulating relative numbers of CD169+ monocytes also show 
correlation with clinical measures of disease activity in RA, and significantly reduce 
as a result of treatment response (Xiong et al. 2014).  
It is thought that CD169 can bind to ligands on the surface of Tregs, and that direct 
cell-cell binding could contribute to Treg suppression (Wu et al. 2009), which further 
suggests the function of CD169 to be pro-inflammatory. Previous studies have 
uncovered CD169 ligands on the surface of Tregs that may play a role in Treg activity, 
including CD43 (van den Berg et al. 2001). CD43 is a sialoglycoprotein expressed on 
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nucleated cells. It has been associated with T cell activation, where proliferation is 
observed following CD43 stimulation in vitro (Higashi et al. 2001). Importantly, CD43 
was previously shown to partake in the activation of monocytes and Tregs (Axelsson 
et al. 1988; Nong et al. 1989; Piller et al. 1989; Park et al. 1991). Furthermore, a more 
recent finding demonstrated direct binding between CD169 and CD43 using 
immunostaining, suggesting CD169 and CD43 are involved in the interaction of 
monocytes and T cells (Ohnishi et al. 2013). 
CD43 expression is increased during inflammation on synovial cells including 
lymphocytes and neutrophils in an adjuvant induced arthritis model (Volin et al. 
1999). However, conflicting results show CD43 is downregulated in synovial 
neutrophils of RA patients (Humbria et al. 1994; Lopez et al. 1995). Other intriguing 
studies have demonstrated a role for CD43 in relation to HIV. CD43-directed 
autoantibodies have been observed in HIV infected patients (Ardman et al. 1990), 
which on further investigation are related to differential patterns of CD43 
glycosylation (Lefebvre et al. 1994). Additional studies have linked CD43 to Wiskott-
Aldrich syndrome, which further suggests it plays role in autoimmunity (Remold-
O'Donnell et al. 1984). 
In summary, the interaction between monocytes and Tregs plays an important role 
in RA pathogenesis. This thesis postulates that CD169 is involved in Treg suppression 
via CD43 interaction, however the balance between these two cell types is unclear. 
This study focuses on establishing the relationship between disease activity in RA and 
the balance of CD169+ monocytes and CD43+ Tregs in peripheral blood. This chapter 
specifically addresses the objective to identify circulating biomarkers of RA disease 
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3.1.1 Decreased absolute numbers of circulating monocytes in DMARD 
responders compared to non-responders 
 
As part of routine blood testing, full blood counts (FBCs) were carried out on the 
same day as sampling. The absolute number of monocytes present in each sample 
was obtained retrospectively from the online electronic care record of the sampling 
date. Healthy control samples were anonymously analysed for FBC in Altnagelvin 
Hospital (WHSCT), and results were obtained on the same day. The absolute number 
of circulating monocytes in DMARD responders (0.527x109/l ± 0.097, n=23) and non-
responders (0.670 x109/l ± 0.229, n=30) were significantly increased compared to 
healthy controls (0.452 x109/l ± 0.097, n=19, p=0.019 and 0.0003 respectively) 
(Figure 3.1). There was no statistically significant difference between healthy 
controls and DMARD naïve patients (0.552 x109/l ± 0.223, n=6, p=0.407). 
Additionally, the absolute number of monocytes in responders was significantly 
lower than non-responders (p=0.041). 
3.1.2 Relative number of CD16+ monocytes increase and CD16- monocytes 
decrease in RA compared to health 
 
FACS analysis was used to assess the relative numbers of circulating CD14+ 
monocytes in RA patients and healthy controls. In order to isolate monocytes, 
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samples were initially enriched using the pan monocyte isolation kit (Miltenyi Biotec) 
and the autoMACS Pro separator, as detailed in section 2.2. The relative number of 
CD14++CD16- classical monocytes was significantly decreased in RA responders 
(21.37% ± 9.68, n=24) and non-responders (22.09% ± 15.03, n=32) to DMARD 
treatment, compared to healthy controls (45.03% ± 20.33, n=19, p<0.001) (Figure 
3.1). However, the relative number of CD14+CD16++ non-classical monocytes was 
increased in RA patients compared to healthy controls (7.595% ± 2.606, n=19), 
reaching statistical significance in DMARD responders (10.93% ± 4.978, n=24, 
p=0.017). Furthermore, the relative number of CD14++CD16+ intermediate 
monocytes was significantly increased in both responders (66.37% ± 10.31, n=24, 
p=0.004) and non-responders (66.90% ± 13.90, n=32, p=0.001) compared to healthy 
controls (45.83% ± 21.31, n=19). However, no statistically significant difference was 
observed between responders and non-responders across any of the monocyte 
subsets. 
3.1.3 Increased CD169+ monocytes in RA patients compared to healthy 
controls 
 
The percentage of CD169 was analysed in classical, non-classical and intermediate 
monocytes by FACS. Overall, CD169 percentage was increased in RA patients 
compared to healthy controls when considering each patient subgroup (Figure 3.2). 
RA patients who are DMARD naïve (21.83% ± 22.80, n=6, p=0.039) and DMARD 
responders (21.89% ± 26.31, n=24, p=0.014) have a significantly increased relative 
number of CD169+ classical monocytes compared to healthy controls (9.426% ± 
5.890, n=19), however the difference was not statistically significant in DMARD non-
responders (19.83% ± 26.40, n=32, p=0.185) compared to healthy controls. A similar 
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observation was made in non-classical monocytes, where CD169 percentage was 
increased in DMARD naïve (30.10% ± 18.41, 0.014), DMARD responder (30.95% ± 
16.73, p<0.001) and DMARD non-responder (30.68% ± 15.05, p<0.001) RA patients 
compared to healthy controls (12.15% ± 8.392). Additionally, CD169 percentage was 
increased in intermediate monocytes for each patient group compared to healthy 
controls (13.87% ± 9.778), however only with statistical significance in DMARD naïve 
patients (30.02% ± 23.00, p=0.011). Furthermore, the MFI of CD169 on the surface 
of classical and intermediate monocytes was increased in DMARD non-responders 
compared to other patient groups and healthy controls, however without reaching 



















3.1.4 Decreased CD43+ Tregs in RA compared to health 
 
CD43 positivity was analysed as a percentage of CD4+CD25+CD127- Tregs using FACS. 
The relative number of CD43+ Tregs was reduced in each patient group compared to 
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healthy controls (96.94% ± 2.434, n=19), however only with statistical significance in 
DMARD responders (94.37% ± 2.698, n=24, p=0.001) (Figure 3.3). Furthermore, the 
relative number of CD43+ Tregs was significantly reduced in DMARD responders 
compared to DMARD naïve (96.37% ± 2.524, n=6, p=0.049) and non-responder 
patients (95.41% ± 4.647, n=32, p=0.024). Additionally, the MFI of CD43 on the 
surface of Tregs was reduced in each RA patient group compared to healthy controls 
(23.44MFI ± 27.96), however significance was only observed in non-responders 





3.1.5 The balance between CD169 and CD43 may be related to disease 
activity 
 
The DAS28-ESR score was assessed on the day of sampling and recorded. A significant 
positive association was observed between DAS28-ESR and the percentage of CD169 
on classical (p=0.022, r=0.424, n=29), non-classical (p=0.012, r=0.459, n=29) and 
intermediate (p=0.017, r=0.440, n=29) monocytes (Figure 3.4). However, the relative 
number of CD169+ non-classical monocytes showed the most significance. The 
relative number of CD43+ Tregs had no significant association with DAS28-ESR 
(p=0.868, r=0.032, n=29). 
Additionally, the CD169 MFI of monocytes was compared to DAS28-ESR (Figure 3.5). 
A weak positive association was observed between DAS28-ESR and the CD169 MFI of 
classical monocytes (p=0.156, r=0.271, n=29), however without statistical 
significance. No significant association was observed between DAS28-ESR and the 
CD169 MFI of non-classical monocytes (p=0.920, r=0.019, n=29). However, a 
significant positive association was observed between DAS28-ESR and the CD169 MFI 















Before a comparison was made of the combination of CD169 and CD43 to clinical 
data, the ratio between relative numbers of CD169+ monocytes and CD43+ Tregs was 
assessed in healthy controls and each patient group (Figure 3.6). Initially, the ratio of 
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the percentage of CD169 to CD43 was analysed when considering each of the three 
monocyte subsets. The %CD169/%CD43 ratio was significantly increased in DMARD 
naïve (0.232±0.252, n=6, p=0.039) and DMARD responders (0.232±0.280, n=24, 
p=0.009) compared to healthy controls (0.098±0.062, n=19) when considering 
classical monocytes. The same observation was made when analysing non-classical 
monocytes, where DMARD naïve (0.313±0.194, p=0.017) and DMARD responders 
(0.328±0.177, p<0.001) exhibited a significantly increased %CD169/%CD43 ratio 
compared to healthy controls (0.125±0.086). Similarly, in intermediate monocytes 
the ratio was significantly increased in DMARD naïve (0.317±0.256, p=0.010) and 
DMARD responders (0.273±0.267, p=0.044) compared to healthy controls 
(0.144±0.104). However, in the case of non-classical monocytes, DMARD non-
responders also had a significantly increased ratio (0.321±0.155) compared to 
healthy controls.  
The ratio between CD169 MFI on monocytes and CD43 MFI on Tregs was also 
analysed and compared between healthy controls and RA patient groups. The 
CD169/CD43 MFI ratio was significantly increased in DMARD non-responders 
compared to healthy controls when considering classical (0.571±0.430 vs 
0.295±0.187, p=0.005), non-classical (0.463±0.316 vs 0.261±0.163, p=0.012) and 
intermediate monocytes (0.572±0.378 vs 0.281±0.177, p=0.003). Additionally, the 
CD169/CD43 MFI ratio when considering intermediate monocytes was significantly 





The ratio of CD169 to CD43 was also compared to DAS28-ESR (Figure 3.7). Initially 
the comparison was made using the ratio between the relative numbers of CD169 
and CD43 positive cells. A significant positive correlation was observed between 
DAS28-ESR and the %CD169/%CD43 ratio when considering classical (p=0.025, 
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r=0.415, n=29), non-classical (p=0.01, r=0.464), n=29) and intermediate monocytes 
(p=0.020, r=0.429, n=29). Additionally, DAS28-ESR was compared to the ratio 
between CD169 MFI and CD43 MFI. The results show no significant association 
between DAS28-ESR and CD169/CD43 MFI ratio when considering classical (p=0.398, 
r=0.166, n=28), non-classical (p=0.818, r=0.046, n=28) and intermediate monocytes 




Due to the finding that the percentage ratio between CD169+ non-classical 
monocytes and CD43+ Tregs had the strongest positive association with DAS28-ESR, 
these values were also compared to SJC (Figure 3.8). A weak positive association was 
observed when comparing ESR to SJC (p=0.409, r=0.163) and when comparing the 
ratio of %CD169(non-classical)/%CD43 to SJC (p=0.377, r=0.174, n=28), however with 
a lower p value for the latter, and without reaching statistical significance in either 
comparison. 
 
3.1.6 Potential role of CD169 in determining biological DMARD treatment 
response 
 
A number of patients who had failed cDMARD treatment were sampled before 
commencing biological DMARDs and 6 months after (Table 2.1b). Treatment 
response was determined by EULAR criteria. Changes in cellular levels of CD169 and 
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CD43 were assessed at baseline and 6 months, and the difference between the two 
time points was calculated (Figure 3.9). A previous study highlighted the potential 
predictive role of circulating monocytes in determining Adalimumab treatment 
response (Chara et al. 2012). In order to test this finding, only patients treated with 
Adalimumab were included in the analysis. If patients experienced an adverse event 
to the drug, this was not classified as non-response, and therefore these samples 
were excluded. Overall, of the 16 patients sampled at baseline and 6 months 
following biologic treatment, 7 were classed as responders and 3 were non-
responders. Although patient numbers were low in the current study, CD169 MFI was 
shown to decrease in 6 out of the 7 responders to Adalimumab at 6 months 
compared to baseline (Figure 3.9). Furthermore, CD169 MFI increased in non-
responders at 6 months compared to baseline. However, no clear pattern was 









The objective of this chapter was to investigate the relationship between disease 
activity in RA and the balance between circulating relative numbers of CD169+ 
monocytes and CD43+ Tregs. The data presented in relation to circulating monocytes 
and their subsets is in agreement with previous findings. Increased absolute 
monocyte numbers were observed from FBC results of RA patients compared to 
healthy controls, which confirms that inflammatory recruitment of monocytes can 
be detected even in peripheral blood. Similar to Chara et al., the absolute number of 
monocytes were significantly reduced in DMARD responders compared to non-
responders (Chara et al. 2012). This is in agreement with a more recent study by 
Chara et al., which describes how monocytes were found to increase in number 
during active disease (Chara et al. 2015). This explains why in the current study 
monocytes are found in higher numbers in non-responders to treatment who are 
inclined to have a greater disease activity. 
In agreement with previous studies, the relative number of CD16+ monocytes was 
observed to be increased in RA (Kawanaka et al. 2002; Cairns et al. 2002), whereas 
CD16- classical monocytes were reduced (Lacerte et al. 2016). A previous study also 
found an increase in CD16+ intermediate monocytes in patients with longer disease 
duration compared to those with less than 2 years duration (Radwan et al. 2015), 
however this observation was not made when the group analysed CD16+ non-
classical monocytes. Possibly due to the low number of early RA DMARD naïve 
patients, this observation was not confirmed in the current study. However, a similar 
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pattern was observed where DMARD responders and non-responders had higher 
intermediate monocytes compared to healthy controls. Additionally, intermediate 
monocytes, which seem to represent a middle state between classical and non-
classical, adopted a similar pattern to non-classical monocytes with increased 
percentage noted in RA compared to healthy controls. This indicates that CD16+ 
monocytes may have more impact on RA pathogenesis than previously considered. 
CD16+ monocytes are more likely to differentiate into dendritic cells (Ancuta et al. 
2003), which are believed to play a pivotal role in RA progression and have been 
suggested as a potential target for therapy (Khan et al. 2009). However, despite the 
recent finding that classical and intermediate monocytes had predictive value in 
determining treatment response (Chara et al. 2015), the data presented in the 
current study demonstrates no significant difference between responders and non-
responders for any of the monocyte subsets. This may be due to modest patient 
numbers in the current study. 
Despite the differences observed in the relative number of each monocyte subset, 
the relative number of CD169 positive classical, non-classical and intermediate 
monocytes was increased in RA compared to healthy controls. This is similar to 
findings by Xiong et al. (Xiong et al. 2014), however the relative number of CD169+ 
non-classical monocytes in the current study were found at significantly increased 
levels in RA compared to health. To our knowledge this observation has not been 
previously made and therefore represents a novel finding. This result further 
suggests CD16+ monocytes perhaps have a more important role in RA pathogenesis 
compared to CD16- monocytes, due to the previous suggestions of CD169 playing a 
pivotal role in progression of the disease (York et al. 2007; Xiong et al. 2014). 
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Additionally, no significant difference was observed between healthy controls or any 
of the RA groups and the MFI of CD169 across the monocyte subsets. This suggests 
that although CD169 positivity as a percentage of monocytes is increased in RA, the 
number of CD169 cell surface markers remains constant. 
The cell surface density of CD43 (MFI) on circulating Tregs, as well as the relative 
number of CD43+ Tregs, was found to be reduced in RA compared to health. There is 
limited knowledge of CD43 as a Treg transmembrane sialoglycoprotein, however 
previous studies have demonstrated its involvement in T cell activation and 
proliferation (Sperling et al. 1995; Cruz-Munoz et al. 2003). Therefore, the reduction 
in CD43 density and percentage observed in this study may be related to the reduced 
activation observed in Tregs (Bonelli et al. 2016). However, in disagreement with this 
theory, DMARD responders have a significantly lower relative number of CD43+ Tregs 
compared to non-responders. Conversely, although no significance is observed, the 
MFI of CD43 is increased in responders compared to non-responders. This means 
that although there may be lower CD43 as a percentage of Tregs in responders 
compared to non-responders, there is perhaps increased CD43 cell surface density 
per CD43+ Treg cell in responders. Therefore the increase in CD43 per cell in 
responders may be related to increased T cell activation, as previously suggested 
(Sperling et al. 1995; Cruz-Munoz et al. 2003), however further investigation is 
needed to confirm this. Although the CD43 profile may be difficult to interpret in this 
preliminary study, the difference in percentage between responders and non-




In addition to analysing CD169 and CD43 as individual cell surface markers, a possible 
association between the combined markers and disease activity was also assessed. 
The relative number of CD169+ monocytes when considering each subset had a 
significant association with DAS28-ESR. Interestingly, CD169+ non-classical 
monocytes had a stronger association with DAS28-ESR, whereas CD169+ classical 
monocytes had the weakest of the three subsets. This implies CD16+ monocytes are 
more closely associated with disease activity than CD16- monocytes. Additionally, in 
comparing CD169 MFI to DAS28-ESR, significance was only observed in CD16+ 
intermediate monocytes. Therefore, contrary to previous findings of the current 
study where CD169 MFI was not significantly differentially expressed between 
patient groups, it appears to be associated with disease activity in a subset of 
monocytes.  
When analysing the ratio of the relative numbers of CD169+ classical monocytes to 
CD43+ Tregs, an increase was found in RA compared to healthy controls. However, 
no significant difference was observed between responders and non-responders. 
Additionally, the ratio of the percentage of CD169 to CD43 had a significant positive 
association with DAS28-ESR when each monocyte subset was considered. Similar to 
before, the strongest association was observed when only non-classical monocytes 
were considered in the CD169 to CD43 ratio. Despite the lack of association between 
the relative number of CD43+ Tregs and DAS28-ESR, a slightly stronger positive 
association was observed when accounting for the relationship between the ratio of 
the relative number of CD43+ Tregs to CD169+ non-classical monocytes and DAS28-
ESR. This implies that the ratio of %CD169/%CD43 may be a useful surrogate measure 
of disease activity. The lack of difference in these markers between responders and 
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non-responders may be due to various factors. For example, comorbidities may 
account for a change in DAS28-ESR, or perhaps a flare of disease in a responder would 
emulate the cell profile of a non-responder at the time of sampling. One way of taking 
these factors into consideration would be to increase the patient cohort and 
subdivide depending on confounding factors. 
As the strongest positive association between DAS28-ESR and the ratio of CD169 to 
CD43 positive cells was observed when accounting for non-classical monocytes only, 
this data was also compared to SJC. Swollen joints is one of the main symptoms of 
RA, therefore this comparison was made to determine whether the balance of these 
key cells contribute to this physical manifestation of the disease. A weak positive 
association was observed between SJC and the ratio of %CD169/%CD43, as well as 
ESR. Due to the lack of statistical significance in each association it is difficult to say 
whether the cellular ratio or ESR has any influence on SJC. The association with 
%CD169/%CD43 ratio was slightly stronger, indicated by a lower p value, however 
further investigation with increased patient numbers would be useful in verifying 
these findings. Overall, the potential involvement of changes in the ratio of 
%CD169/%CD43 with disease activity appears to be mainly driven by CD169. This 
suggestion is made based on the evidence of the relative number of CD169+ 
monocytes as being more strongly associated with DAS28-ESR.   
The MFI of CD169 on monocytes and CD43 on Tregs was also assessed in RA patients 
before and after 6 months of Adalimumab therapy.  In order to robustly compare 
responders to genuine non-responders, any patients who experienced an adverse 
event were excluded from the analysis. Six out of the seven patients who responded 
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at 6 months had a reduction in CD169 MFI compared to baseline. Conversely, non-
responders did not have a reduction in CD169 MFI, but rather a modest increase. 
These preliminary results further suggest CD169 MFI could be a potential marker of 
response in individual patients. However, patient numbers are small and this analysis 
would need to be repeated on a larger cohort, and perhaps compared across 
different drug types. 
In summary, these results strongly suggest that relative numbers of CD169+ 
monocytes and CD43+ Tregs mirror disease activity in RA, and can be measured in 
peripheral blood, coincident with synovial inflammation. Although inconclusive in 
the current study, it can be postulated that with further investigation, these markers 
have the potential to determine treatment response in RA. Future work could 
demonstrate treatment response may be determined at an earlier time point than 
currently possible, thus improving overall patient outcome. For example, introducing 
early sampling time points and analysing these cellular levels before the clinical 3-6 
month assessment could verify this. 
 
3.3 Conclusion  
 
The key findings of this study highlight the need to consider CD16+ as well as classical 
CD16- monocytes. Although the increased relative number of CD169+ classical 
monocytes with RA disease activity has been previously highlighted in other studies, 
it is demonstrated here that CD169+ non-classical monocytes may have a more 
pronounced role. This is mainly shown by the increased association of CD169+ non-
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classical monocytes with DAS28-ESR compared to CD169+ classical monocytes. 
Furthermore, these results provide preliminary evidence of an association between 
the balance of CD169+ monocytes and CD43+ Tregs in peripheral blood, and disease 
activity in RA. Although CD169 plays a role in the negative regulation of Tregs (Wu et 
al. 2009), further investigation is required to determine whether CD169 and CD43 
positive cells interact, and if this interaction directly contributes to this function. The 
results of this study allows postulation that the balance of these cells is key in the 
immune response and could be a surrogate measure of disease activity, and 
subsequently treatment response in RA. With further investigation, these markers 






































4.0.1 Tregs in RA  
 
As discussed in section 1.1.3.1, Tregs are associated with self-tolerance and therefore 
are believed to play a pivotal role in AD. In health, Tregs function by suppressing over-
reactive Teff cells, which maintains balance in the immune response by preventing 
unnecessary inflammation that can precipitate tissue damage (Wu et al. 2009). 
However, in autoimmune conditions such as RA, this function is inhibited. Previous 
studies report conflicting Treg numbers and activation state in RA, likely due to lack 
of clarity of patient characteristics, such as disease activity, disease duration and 
treatment pathway at the point of sampling. For example, one study reported 
reduced suppressive capabilities of CD4+CD25+ Tregs from RA patients when co-
cultured in vitro with autologous monocytes (van Amelsfort et al. 2007). However, a 
recent study reported that although there were increased relative numbers of 
CD4+CD25+FoxP3+ Tregs in RA patients following abatacept treatment, they had 
reduced activity as measured by activation markers CD69 and CD71 (Bonelli et al. 
2016). The latter study did not specify whether patients were responding to the 
treatment, and furthermore used an alternative phenotype to assess Tregs and their 
activation state. A separate study did however classify patients by response to anti-
TNF therapy, and found increased relative numbers of CD4+CD25+ Tregs in peripheral 
blood of responder RA patients (Ehrenstein et al. 2004). Importantly, this observation 
was shown to be associated with a reduction in CRP levels, suggesting circulating Treg 
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numbers may be a useful surrogate measure of, and may play a role in, RA disease 
activity. 
Further studies have compared the relative number of Tregs in RA synovial fluid to 
circulating peripheral blood. RA patients have been shown to exhibit an increased 
relative number of CD4+CD25+ Tregs in synovial fluid compared to peripheral blood, 
and increased Tregs in peripheral blood compared to that of healthy controls (van 
Amelsfort et al. 2004; Mottonen et al. 2005). Additionally, synovial fluid Tregs were 
in an active state as measured by activation markers including FoxP3 and CTLA-4 (van 
Amelsfort et al. 2004; Mottonen et al. 2005). For such studies, it is difficult to obtain 
synovial fluid from healthy controls due to the invasive sampling procedure. 
Therefore, the ‘normal’ range and activation state of synovial Tregs in health is 
unclear.  
4.0.2 Forkhead box P3 (FoxP3) 
 
FoxP3 is an intracellular transcription factor of Tregs. As described in section 1.1.3.1, 
it can be used as a marker of Treg activation as it has been shown to regulate the 
suppressor function (Gavin et al. 2007). Furthermore, increased FoxP3 expression 
leads to decreased activity of Teff cells, and subsequent reduction of pro-
inflammatory cytokines including IL-2 and IFN-γ (Bettelli et al. 2005). Some 
researchers have suggested that FoxP3 is a phenotypic marker of Tregs because of 
this association with suppressive activity (Hori et al. 2003; Fontenot et al. 2005). The 
involvement of FoxP3 in relation to AD has been widely studied, where reduced 
FoxP3 expression is related to increased autoimmune susceptibility (Ulmanen et al. 
109 
 
2005). This may be due to the association of FoxP3 with impaired Treg activity in 
autoimmune conditions such as RA (Kennedy et al. 2014; Cribbs et al. 2014).  
The development of FoxP3+ Tregs in the thymus is dependent on c-REL, which is a 
transcription factor of the NFκB family (Isomura et al. 2009). Additionally, NFκB 
activity is increased in FoxP3 KO mice, adding further weight to the concept of a 
relationship between the two transcription factors (Bettelli et al. 2005; Le Bras and 
Geha 2006). NFκB is associated with an increased inflammatory response in RA. This 
has previously been observed primarily with CD45RA- memory Tregs (Nagar et al. 
2010). Furthermore, a reduced inflammatory response as measured by osteoclast 
activity is associated with NFκB inhibition (Aya et al. 2005).  
NFκB activation is controlled by the enzyme complex IκB kinase (IKK). IKK 
phosphorylates IκBα, subsequently releasing NFκB (Figure 4.1) (Li and Verma 2002). 
The NFκB essential modulator (NEMO) plays a pivotal role in NFκB activation as it can 
inhibit the actions of the IKK complex. Various studies have investigated the potential 
therapeutic effects of targeting NFκB responses via the NEMO pathway in 
inflammatory arthritis (May et al. 2000; Dai et al. 2004; Min et al. 2013). Specifically, 
NEMO-binding domain peptide (NBD) therapy can prevent NFκB activity, thus 
reducing the severity of inflammation via reduced osteoclastogenesis and bone 
erosion (May et al. 2000; Dai et al. 2004). More recently, NBD therapy was shown to 
prevent IκBα phosphorylation thus reducing NFκB activity in inflammatory arthritis 
(Min et al. 2013). Furthermore, this observation was associated with an increase in 
relative numbers of FoxP3+ Tregs as well as restored Treg suppressor function. Anti-
TNF treatment is also believed to combat the inflammatory role of NFκB in RA. On 
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binding to its receptor, TNF can activate the NFκB pathway, a response that is 
inhibited with anti-TNF treatment (Baud and Karin 2001; Nagar et al. 2010). 
 
 
4.0.3 The influence of monocytes on Tregs 
 
As discussed in section 3.0.2, previous studies have uncovered the association of 
monocytes with Treg activity (Estrada-Capetillo et al. 2013; Walter et al. 2013). For 
example, CD169 binds to various ligands on the surface of Tregs, including CD43 (van 
den Berg et al. 2001). It has been found that through binding these ligands, 
monocyte-CD169 can suppress Treg activity (Wu et al. 2009). As explored in chapter 
3, the balance between CD169+ monocytes and CD43+ Tregs may be associated with 
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disease activity in RA, as determined by the DAS28-ESR score. However, the impact 
of CD169+ monocytes on CD43+ Treg activity remains elusive. Furthermore, although 
a previous study has demonstrated direct binding of these two cell surface markers 
via immunocytochemistry, the function of this interaction is unclear (Ohnishi et al. 
2013). 
4.0.4 In vitro stimulation of Tregs 
 
One of the aims of the experiments within this chapter is to assess the effect of 
peripheral CD169+ monocytes and their sialic acid (Sia) motifs on Tregs in an in vitro 
inflammatory model of RA. The effects of C169+ monocyte co-culture and Sia 
incubation upon Tregs will be quantified by measuring intracellular Treg percentages 
of NFκB and FoxP3, as well as secreted cytokines from both cell types. In order to 
create a state of inflammation in cultured Tregs, they must first be exposed to a 
suitable stimulant that will induce an inflammatory response similar to that present 
in RA patients. 
Previous studies have investigated the ability of lipopolysaccharides (LPS) to induce 
an inflammatory response in human immune cells, such as CD4+ cells (McAleer and 
Vella 2008). LPS is a component of the membrane of Gram-negative bacteria, mainly 
functioning to maintain structural support of the bacteria (Ramachandran 2014). It 
binds to Toll-like receptor-4 (TLR4) assisted by CD14, a cell surface receptor present 
on monocytes and dendritic cells (Figure 4.2) (Kawai and Akira 2006; Kagan and 
Medzhitov 2006; McAleer and Vella 2008). TLR4 contains an intracellular 
Toll/interleukin-1 receptor (TIR) which initiates the signalling cascade. This includes 
recruitment of myeloid differentiation primary response 88 (MYD88) by the TLR 
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adaptor TIRAP. The MyD88 pathway involves phosphorylation of IL-1 receptor-
associated kinase -1 and -4 (IRAK-1/4), which subsequently activates TNF receptor-
associated factor 6 (TRAF6) and transforming growth factor-β-activated protein 
kinase 1 (TAK1). TAK1 activates the IKK complex (Figure 4.1), ultimately leading to 
the release of NFκB and thus upregulation of inflammatory cytokines including TNF 
and IL-6. Additional to the MyD88 pathway, LPS also induces TIR domain-containing 
adaptor inducing IFN-β (TRIF) through the TRIF-related adaptor molecule (TRAM). 
The induction of TRIF leads to activation of receptor interacting protein 1 (RIP1) as 
well as TRAF6, which both contribute to the release of NFκB (Kagan and Medzhitov 




Previous studies have also demonstrated the activation of Tregs by LPS stimulation. 
For example, LPS has been shown to increase the suppressive function of CD4+CD25+ 
Tregs in mice (Caramalho et al. 2003). Additionally, this suppressive function was 
previously suggested to be IL-10 dependent (Lewkowicz et al. 2006). More recently, 
Lewkowicz et al. demonstrated the role of LPS-stimulated Tregs in IL-10 production 
by neutrophils, which was not observed when Tregs were unstimulated (Lewkowicz 
et al. 2016). IL-10 plays an important anti-inflammatory role as it promotes Treg 
production as well as reduces the pathogenic effects of Th17 cells (Heo et al. 2010). 
Furthermore, a previous study showed an upregulation of FoxP3+ Tregs upon LPS and 
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IL-2 stimulation (Milkova et al. 2010). This effect was not observed following NFκB 
pathway inhibition, suggesting FoxP3 expression is dependent on NFκB. 
Other studies have demonstrated a role of phorbol 12-myristate 13-acetate (PMA) in 
combination with ionomycin (IO) in inducing cytokine production from T cells (Wang 
et al. 2013). PMA, along with TCR/CD28 co-stimulation, increases T cell activation 
pathways including protein kinase-C (PKC), mitogen-activated protein kinases 
(MAPK) and IKK (Figure 4.3) (Macian et al. 2002). IO is often used in combination with 
PMA as it is required for the calcium ion dependent nuclear factor of activated cells 
(NFAT) signalling pathway (Schwartz 1996). The upregulation of these signalling 
pathways from PMA/IO stimulation ultimately leads to increased transcription 
factors NFAT, AP-1 and NFκB, which subsequently upregulates inflammatory 
cytokines including IFNγ and TNF (Macian et al. 2002; Ai et al. 2013). In a similar 
mechanism, anti-CD3/CD28 antibodies are often used to induce proliferation of T 




In summary, this chapter initially aims to define the activation state of Tregs in 
peripheral blood of RA patients, by analysing relative numbers of FoxP3+ Tregs. 
Specifically, this chapter focusses on relative numbers of FoxP3 positive CD45RA+/- 
Tregs, where CD45RA is used as a marker of naïve Tregs. Furthermore, this chapter 
will assess both intracellular and extracellular consequences of Sia or CD169 binding 
to Tregs, and whether CD43 is necessary for this interaction. Induction of NFκB and 
FoxP3 will be the core readouts used to define effects caused by the interaction 





 4.1.1 Relative numbers of circulating Tregs in RA 
 
Tregs from PBMCs of healthy control participants and RA patients were analysed by 
flow cytometry using the phenotype CD4+CD25+CD127-. Relative Treg numbers were 
expressed as a percentage of CD3+CD45+ T cells (Figure 4.4). Circulating relative Treg 
numbers were significantly increased in DMARD naïve and DMARD responder RA 
patients compared to healthy controls. Furthermore, RA patients who have not 
responded to DMARD treatment had a significantly lower percentage of circulating 







4.1.2 Treg activation state in RA (FoxP3 and CD45Ra) 
 
The relative numbers of CD45RA+ and activated FoxP3+ Tregs were analysed in 
healthy controls and RA patients (Figure 4.5 (A, B)). Furthermore, CD45RA and FoxP3 
were analysed specifically in CD43+ Tregs (Figure 4.5 (C, D)). The results for Tregs and 
CD43+ Tregs showed similar patterns between patient groups (Figure 4.6). The 
relative number of CD45RA+FoxP3- Tregs was significantly higher in DMARD non-
responders, compared to healthy controls, DMARD naïve and DMARD responder 
patients. The same result was shown in CD43+ Tregs. Alternatively, the relative 
number of CD45RA+FoxP3+ Tregs was significantly reduced in DMARD non-
responders compared to healthy controls, however the same observation was made 
of DMARD responders. This result was also shown in CD43+ Tregs. The relative 
number of CD45RA-FoxP3+ Tregs was significantly elevated in DMARD naïve, DMARD 
responder and DMARD non-responder patients, in comparison to healthy controls. 
However, DMARD non-responders exhibited a significantly lower relative number of 
CD45RA-FoxP3+ Tregs compared to DMARD naïve and DMARD responder patients. A 
















 4.1.3 Effect of PMA and LPS on in vitro Tregs 
 
Sorted CD4+CD25+CD127- Tregs were expanded in culture with CD3/CD28 
microbeads as described in section 2.4.2, and incubated with varying concentrations 
of PMA/IO or LPS.  At this preliminary stage, qPCR reactions were carried out as 
output measures of pro-inflammatory cytokines TNFα, IL-6 and IL-10. βactin was 
used as the housekeeping gene as it was shown to be stable using unstimulated and 
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stimulated expanded Tregs (Appendix P). The cell supernatants were not kept at this 
stage as the purpose of this experiment was to determine the optimal concentration 
of each stimulant in increasing cytokine production. 
The cells increased in number on Day 1 and Day 2 when stimulated with LPS 
compared to control cells with no stimulant. However, the viability of the cells 
remained fairly stable throughout the experiment for both LPS stimulated and 
control cells (Figure 4.7). Cell counts of the PMA/IO stimulated cells were fairly 
similar to control cells, however the viability was slightly compromised on Day 1 




At each time point, the cells were removed from wells and resuspended in Trizol for 
RNA extraction, followed by transcriptomic analysis by qPCR. The relative gene 
expression of TNF and IL-6 was obtained using β-actin as the reference housekeeping 
gene. Transcript levels of TNF were increased in Tregs that were stimulated for 2 days 
with PMA/IO, however no significant increase was observed when stimulated with 
LPS (Figure 4.8). Similarly, IL-6 gene expression was increased in Tregs that were 
stimulated for 2 days with 20 ng/ml PMA. 50 ng/ml of LPS was observed to increase 
IL-6 gene expression after stimulation for 1 day. 
The experiment was subsequently repeated using just one concentration of each 
stimulant, i.e. 200 ng/ml LPS and 10 ng/ml PMA. At the transcript level, the results 
showed no detectable effect of LPS on expression of any of the genes tested (Figure 
4.9). However, PMA stimulation decreased TNF expression after 2 days, and 
increased IL-10 expression. Similarly, the ELISA results showed no statistically 
significant difference in levels of any of the secreted cytokines levels after stimulation 
with LPS. However, an increase in TNFα and IL-10 cytokine levels was observed after 
cells were treated with PMA for 2 days. Conversely, PMA stimulation caused a 
reduction in levels of secreted IFNγ. Due to the detectable impact of PMA on cytokine 
production, and the success of its use in previous literature to stimulate an in vitro 
inflammatory model (Macian et al. 2002; Wang et al. 2013), going forward PMA was 



















4.1.4 Effect of sialic acid on in vitro PMA stimulated Tregs 
 
Upon stimulation with PMA, a reduction in CD4 cell-surface expression was observed 
(Figure 4.11). Additionally, percentage levels of CD43 was significantly lower across 
all Tregs following in vitro expansion, compared to that observed from fresh PBMCs 
analysed on the same day of sampling (chapter 3.0). NFκB and FoxP3 percentage 
positivity was assessed in CD43+ and CD43- Tregs (Figure 4.10). Stimulation with PMA 
increased intracellular percentages of NFκB and FoxP3 in both CD43+ and CD43- Tregs 
at each time point. After 1 day in culture, Sia reduced the relative numbers of NFκB+ 
and FoxP3+ Tregs, where the latter displays a statistically significant reduction over 
time. The same effect was observed after 2 days in CD43-FoxP3+ Tregs but not in 
CD43+FoxP3+ Tregs. Furthermore, after 2 days, the addition of Sia had no significant 


























Additionally, the cell culture supernatants from the same experiment were analysed 
as before for levels of cytokines including TNFα, IL-10 and IFNγ (Figure 4.12). As 
shown previously, PMA increased levels of TNFα and IL-10 on both Day 1 and Day 2. 
IFNγ levels were also increased upon stimulation with PMA on Day 1, however 
contradictory to previous results, IFNγ levels remained similar in PMA stimulated and 
unstimulated cells. At each time point, addition of Sia caused a significant reduction 
in each of the cytokines tested. The experiment was repeated using Tregs expanded 
from a different source. On this occasion, only time points Day 0 and Day 1 were 



















4.1.5 Monocyte and Treg co-culture 
 
Similar to the previous experiments, expanded Tregs were stimulated with PMA and 
exposed to a range of conditions. The Tregs were co-cultured for 1 day with CD169+ 
monocytes that were sorted on Day 0 of the experiment. CD169 and CD43 blocking 
antibodies were also added in separate conditions in order to assess the downstream 
effects of preventing any interaction between these markers. As a control, Tregs not 
co-cultured with monocytes were also subjected to CD169 and CD43 blocking 
antibodies in order to test the effect of the antibodies alone on the Tregs. The 
experiment was carried out using expanded Tregs from two healthy individuals. As 
before, relative numbers of NFκB+ and FoxP3+ Tregs were assessed by flow 
cytometry. Additionally, the media in which the cells were incubated was kept for 
cytokine analysis. For each biological replicate, an increase in relative number of 
FoxP3+ Tregs was observed after CD43 blocking for Tregs with and without 
monocytes, however this was not statistically significant (Figure 4.13). A similar 
effect was observed in NFκB+ Tregs, however statistical significance was only 
observed in Tregs that were co-cultured with monocytes, and only in one of the two 
biological replicates. Additionally, NFκB+ Tregs were increased in PMA stimulated 
Tregs that were co-cultured with monocytes compared to those that were not, 
however significance was observed only with one of the two replicates. 
The ELISA results show a significant increase in levels of TNFα when monocytes are 
co-cultured with Tregs compared to Tregs alone (Figure 4.14). Additionally, a 
decrease was observed when the co-cultured Tregs and monocytes were incubated 
with CD169 blocking antibody, however statistical significance was only observed in 
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one replicate. Similarly, a decrease in secreted TNFα was also observed when CD43 
blocking antibody was added to Tregs both with and without monocyte co-culture. 
However, this was only significant for one replicate. IL-10 levels were significantly 
decreased when Tregs were incubated with CD43 antibody for one of the two 
replicates, however this observation was not made when monocytes were co-
cultured with the Tregs. Furthermore, blocking with CD169 antibody increased IL-10 
levels in Treg-monocyte co-culture, which was statistically significant in one of the 
biological replicates. Finally, IFNγ levels were increased when monocytes were co-
cultured with Tregs compared to Tregs alone, with statistical significance observed in 























This chapter is focused on an investigation of the activation state of circulating Tregs 
in RA patients as well as an in vitro model of RA. Furthermore, it investigates the role 
of Sia in potentiating Treg intracellular signalling pathways that are involved in 
cytokine production during an in vitro inflammatory response. 
The initial studies defined the relative number of circulating Tregs in RA patients who 
were cDMARD naïve, responders and non-responders, with healthy participant 
samples as controls. cDMARD naïve and responder patients have an increased 
relative number of Tregs compared to healthy controls, however cDMARD non-
responders exhibit reduced Tregs compared to responders. This is in agreement with 
previous data, where patients who responded to anti-TNF treatment had increased 
relative numbers of circulating Tregs compared to their own baseline samples, 
suggesting the downregulation of Tregs in RA may be reversed as a consequence of 
treatment response. (Ehrenstein et al. 2004). This is one explanation for the 
significant reduction in Tregs of cDMARD non-responders compared to responders 
in the current study. However, the current study did not find a significant difference 
in relative Treg numbers between cDMARD naïve patients and cDMARD responders, 
perhaps because of its cross-sectional rather than longitudinal nature. Also, there 
was a relatively small number of cDMARD naïve patients (n=6) sampled for the study 
compared to responders (n=24).  
Intracellular levels of FoxP3 were determined in each patient subgroup as a surrogate 
measure of Treg activation, as summarised in Figure 4.15. CD45RA+ Tregs were also 
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analysed, representing a naïve subset of Tregs that have not previously been exposed 
to activation by antigen encounter. Within the CD45RA+ Tregs, the percentage of 
FoxP3- cells were increased in cDMARD non-responders compared to healthy 
controls, cDMARD naïve and cDMARD responder patients. Furthermore, the relative 
number of FoxP3+ cells was decreased in cDMARD responders and non-responders 
compared to healthy controls. This suggests the activation state of naïve Tregs is 
reduced in circulating blood of RA patients, which concurs with previous findings, 
where FoxP3+ Tregs from peripheral blood were reduced in RA patients compared to 
healthy controls (Matsuki et al. 2013). Interestingly, the relative number of CD45RA-
FoxP3+ Tregs was increased in RA patients compared to healthy controls, in 
agreement with a recent study (Walter et al. 2016). This data suggests there is an 
increase in activation of CD45RA- memory Tregs in RA peripheral blood compared to 
health. However, a significant decrease is observed in the relative number of 
CD45RA-FoxP3+ Tregs in cDMARD non-responders compared to cDMARD naïve and 
cDMARD responder patients. In summary, these findings suggest cDMARD non-
responder RA patients exhibit reduced activity in both naïve and memory Tregs. 
Similar findings were observed in CD43+ Tregs, suggesting there is no significant 
difference in the activity state of overall Tregs compared to the CD43+ subset. 
However, as reported in chapter 3, the percentage of CD43 positive Tregs is >80% in 




An in vitro model of inflammation was created in order to assess specific intracellular 
signalling pathways of Tregs and the subsequent cytokines produced. The aim of the 
inflammatory model was to induce an activation state in Tregs mimicking their 
phenotype in RA, as measured by production of pro-inflammatory cytokines 
including TNFα and IL-6. As described in section 4.0.4, LPS and PMA/IO are common 
stimulants used to activate Tregs. Transcript levels of TNFα and IL-6 were measured 
in preliminary experiments in order to firstly decide which stimulant was optimal, 
and secondly which concentration of the stimulant had the greatest effect on 
cytokine production. LPS stimulation had no effect on TNFα or IL-6 transcript levels, 
or on TNFα, IL-10 and IFNγ cytokine production. One possible explanation for this is 
that perhaps 48-hour stimulation was insufficient to observe a significant increase in 
TNFα or IL-6. Although 10 ng/ml PMA/IO increased TNFα transcript levels after 2 days 
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of stimulation, this was not reproducible when the experiment was repeated. A 
similar effect was observed in IL-6 transcript levels. However, PMA/IO reproducibly 
increased TNFα cytokine production of Tregs. An increase in TNFα transcript may be 
detected at an earlier time point than Day 1, and perhaps for this experiment this 
effect could have been missed. This would explain why secreted TNFα levels are 
higher in surrounding media when stimulated with PMA/IO, but transcript levels are 
not. Previous studies have used short incubation times of usually 5 hours during 
PMA/IO stimulation of Tregs (Duhen et al. 2012; Guo et al. 2016). Interestingly, 
PMA/IO stimulation increased IL-10 transcript levels as well as cytokine production. 
This effect was not observed with LPS stimulation. Conversely, PMA/IO reduced IFNγ 
cytokine levels after 2 days of stimulation, however later experiments demonstrate 
the opposite effect with a reduced stimulation time of just 1 day. This suggests there 
is an initial increase in IFNγ within 1 day of PMA/IO stimulation, however it is unclear 
why this is not detected between Day 1 and Day 2 of stimulation. It may be possible 
that IFNγ eventually binds to its receptors on the surface of Tregs and therefore is 
not detected by ELISA, however further experiments are needed to confirm this 
finding. Furthermore, it may reflect the fact that IFNɣ is unstable and has a relatively 
short half-life (Lortat-Jacob et al. 1996). 
Sia was added to the activated Tregs in order to imitate the effect of CD169, which 
can bind to and present this residue. CD169 binds to Sia in order to carry out its 
functions, including binding to ligands on the surface of Tregs. A previous study 
showed Tregs contain many Sia ligands on their cell surface (Wu et al. 2009). 
Although the purpose of the experiment was to determine cytokine and intracellular 
pathway responses, it cannot be definitively stated that CD169 has the same effect. 
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This experiment concluded that the addition of Sia significantly reduced the 
activation state of Tregs, as measured by decreased levels of secreted cytokines 
TNFα, IL-10 and IFNγ, as well as decreased relative numbers of NFκB+ and FoxP3+ 
Tregs (Figure 4.16). This agrees with previous findings, where Sia has been shown to 
reduce Treg activation as measured by a reduction of Treg suppressive function as 
well as activation markers including CD25 (Wu et al. 2009; Naito-Matsui et al. 2014). 
However, the impact on cytokine and transcription factors utilised in the current 
study has not previously been reported.   This effect was observed in NFκB+ Tregs 
only when they were activated with PMA/IO for just 1 day. A similar effect was 
observed for NFκB+CD43+ and NFκB+CD43- Tregs. However, after 2 days of stimulation 
Sia significantly reduced FoxP3+CD43- Tregs, an effect which was not observed in 
FoxP3+CD43+ Tregs. However, although CD43 is present in on average >80% of Tregs 
in healthy individuals and RA patients (Chapter 3.0), Tregs that have been in culture 
exhibit a large reduction in CD43 levels. For this reason, CD43+ and CD43- Tregs were 
analysed, primarily because CD43- cells were greater in number than CD43+, and thus 
data analysis was more reliable.  
Introducing Sia into Treg culture significantly reduced TNFα, IL-10 and IFNγ cytokine 
secretion, an effect that was observed on both Day 1 and Day 2 of culture (Figure 
4.16). Perhaps the discrepancy between the relative number of NFκB+ and FoxP3+ 
Tregs, and cytokine levels on Day 2 of culture is a result of an initial cytokine response 





In order to assess the direct impact of CD169+ monocytes on activated Tregs, and the 
CD169-CD43 interaction, the two cell types were co-cultured for one day and 
cytokine secretion as well as intracellular signalling pathways were analysed. The 
relative number of FoxP3+ Tregs were increased following CD43 blocking, an effect 
observed both when cells were co-cultured with monocytes and without co-culture. 
Similarly, NFκB+ Tregs were also increased with CD43 blocking. Although further 
experiments are needed to confirm this effect, these results suggest blocking CD43 
increases the activation state of Tregs as measured by FoxP3 and NFκB. This 
contradicts previous findings that suggest CD43 activation leads to increased 
proliferation of T cells (Higashi et al. 2001). Furthermore, NFκB positivity was 
increased in PMA stimulated Tregs that were co-cultured with monocytes compared 
to those that were not. Overall, significant differences in these intracellular levels 
were not consistent across each biological replicate, therefore perhaps with further 
replicates the results would be more conclusive. However, despite the lack of 
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statistical significance, similarities are observed between relative numbers of FoxP3+ 
and NFκB+ Tregs which is in agreement with previous studies. 
TNFα cytokine levels in surrounding media are significantly increased when 
monocytes are co-cultured with Tregs compared to Tregs alone (Figure 4.14). 
Furthermore, TNFα was reduced when the co-cultured Tregs and monocytes were 
incubated with CD169 blocking antibody. This result suggests CD169 has a direct 
effect on TNFα secretion, however further replicate experiments would need to be 
carried out to strengthen this. Furthermore, it cannot be determined which cell type 
is producing the increased TNFα levels. However, as CD169 does not contain a 
cytoplasmic tail and is believed to partake primarily in cell-cell interactions, this 
suggests the blocking of CD169 is likely to have a direct effect on Tregs. Similarly, 
TNFα expression decreased when CD43 blocking antibody was added to Tregs both 
with and without monocyte co-culture. The similarity in results between CD169 
blocking and CD43 blocking suggests their interaction may have a direct effect on 
TNFα, however again further replicates are needed to strengthen this result. IL-10 
levels were decreased when Tregs were incubated with CD43 antibody, however this 
observation was not made when monocytes were co-cultured with the Tregs.  
Additionally, IFNγ levels were increased when monocytes were co-cultured with 
Tregs compared to Tregs alone. Previous studies have detected TNFα secretion from 
peripheral monocytes following LPS stimulation (Schildberger et al. 2013), however 
although macrophages have been shown to produce IFNγ in vitro, less is known about 
whether monocytes have the same capability (Darwich et al. 2009). Therefore it is 
not clear whether the increase in TNFα or IFNγ is a product of Tregs after monocyte 





In summary, despite the increase of circulating Tregs in peripheral blood of RA 
patients compared to healthy controls, their activation state is reduced as observed 
in the naïve CD45RA+FoxP3+ Treg population. Furthermore, although RA patients who 
have responded to cDMARD treatment have an increased relative number of 
memory CD45RA-FoxP3+ Tregs compared to healthy subjects, cDMARD non-
responders have a significantly lower relative number of overall FoxP3+ Tregs, 
suggesting these patients contain peripheral Tregs with a lower activation state. 
Furthermore, this suggests memory Tregs are upregulated in activation state during 
cDMARD response thus enabling Tregs to carry out their regulatory function in 
suppressing Teff cells, therefore suppressing disease activity. However, cDMARD 
non-responders do not regain an activation state in memory Tregs, therefore the 
disease cannot be suppressed.  Additionally, this data confirms the activity of Tregs 
can be measured in the peripheral blood of RA patients before they migrate into the 
synovium. Therefore, it may be possible to use activated Tregs as a surrogate 
measure of disease activity and treatment response. 
Additionally, Sia has a negative effect on Treg activation as measured by a reduction 
in FoxP3 and NFκB intracellular levels, as well as TNFα, IL-10 and IFNγ cytokine 
secretion. However, in the present study it is inconclusive whether monocytes have 
an effect on Treg activity, as further replicates would be needed to provide evidence 
of this. Furthermore, although similarities are observed in TNFα secretion when 
CD169 and CD43 blocking antibodies are added to monocyte-Treg co-culture, further 
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evidence is needed to definitively decide whether the CD169-CD43 interaction has 
an effect on Treg activation. It is clear however that siglec-Sia mediated signalling is 
an important control mechanism governing Treg activation and response to 
inflammation. In the context of RA, the siglec-Sia axis could therefore have significant 













































Many studies have highlighted the need for robust biomarkers in RA in order to assist 
with diagnosis, prognosis and determining treatment response. The human plasma 
proteome is of interest as it contains proteins secreted or shed by circulating cells 
and tissue (Wilkins et al. 1996). When the body is under stress, for example during 
chronic inflammation, the plasma proteome changes as part of the immune response 
(Lee et al. 2015). This chapter focusses on identifying and analysing levels of 
circulating plasma proteins, as it not only holds potential for discovering treatment 
response biomarkers, but can also improve our understanding of disease 
pathogenesis. 
5.0.1 Current clinical assessment 
 
Currently, clinicians consider CRP as a protein biomarker, which when combined with 
clinical observations into a composite score (ie. DAS28-CRP), can assist in the 
determination of treatment response in RA. Although NICE guidelines recommend 
CRP levels are regularly monitored throughout treatment (NICE 2009), some studies 
suggest it can be used as a substitute of ESR in the DAS28 composite score (Wells et 
al. 2009).  The increase in circulating CRP levels is caused in part by the secretion of 
IL-6 from T cells and macrophages during inflammation. However, as discussed in 
section 1.2.1, the literature presents conflicting evidence of CRP as a reliable marker 
of joint inflammation or disease activity. (Sokka and Pincus 2009; Eudy et al. 2014). 
Furthermore, the lack of specificity of CRP to RA pathology may be one of the reasons 
for contradictory evidence (Sokka and Pincus 2009).  
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Numerous studies have analysed a vast range of proteins in order to more accurately 
reflect the multifactorial nature of RA pathology, and broaden knowledge of 
proteomic changes during drug responses in RA. Such studies have successfully 
identified protein signatures that may increase the reliability of disease activity 
measures and detection of treatment response in RA.  
5.0.2 Proteomic studies in RA 
 
The wide variety of proteomic techniques available has enabled research groups to 
robustly analyse a number of biological sample types. The most obvious proximal 
sample to study disease activity in RA patients is synovial fluid. For example, one 
study used chemical labelling of isobaric tags that react with peptides in order to 
analyse differentially expressed proteins in synovial fluid between RA and OA 
patients (Balakrishnan et al. 2014). Over 500 proteins were successfully identified as 
being differentially expressed between the two disease types. Therefore, there is 
potential with analysing the synovial proteome to better distinguish RA and OA, and 
thus improve clinical decisions and patient outcome. Cytosolic proteins can be 
isolated from synovial tissue by 2-dimensional gel electrophoresis. A study using this 
method found protein expression patterns which differentiate RA from 
spondyloarthropathy (Tilleman et al. 2005), therefore enabling earlier diagnosis. 
Similar studies have used the same method to analyse proteins from fibroblast-like 
synoviocyte (FLS) cells and have also identified potential novel diagnostic proteins for 
RA (Dasuri et al. 2004; Li et al. 2013). The analysis of proteins from synovial fluid or 
tissue may be useful in understanding disease pathogenesis, as this is the target of 
the autoimmune response in RA. However, this sampling method is rather invasive, 
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and it is impractical to sample comparator healthy control groups. Although the study 
of proteins from tissue-specific cells is advantageous in understanding the cell 
biology of RA, the lengthy laboratory procedures are somewhat impractical for 
regular determination of treatment response. 
Other studies adopt a less invasive approach, by analysing alternative biological 
samples including urine, plasma and serum. A recent study used liquid 
chromatography – tandem mass spectrometry (LC-MS/MS) in order to quantify 
proteins in urine (Kang et al. 2014). The study resulted in identification of 134 
differentially expressed proteins between RA and OA patients. Furthermore, they 
identified soluble CD14 as a potential biomarker of disease activity in RA, as it was 
shown to correlate to ESR, CRP and DAS28. These results are similar to a previous 
study which used the same method to analyse synovial fluid protein expression 
profiles in RA, which were found to be associated with serum CRP levels (Liao et al. 
2004). However, urine proteome analysis demonstrates that less invasive sampling 
may prove useful in identifying RA biomarker candidates (Kang et al. 2014) 
An increasing number of studies are analysing proteins in circulating blood. One 
study compared circulating serum and plasma proteins in RA patients treated with 
anti-TNFs, in order to identify the mechanism of action of an anti-TNF biologic 
(Sekigawa et al. 2008). They used LC-MS/MS in order to deplete abundant proteins 
and analyse low level protein peptides in each sample. Initial findings reported 
differences in protein expression between serum and plasma samples, for example 
S100 calcium-binding protein A9 could be detected in plasma but not serum. 
Additionally, they identified an increase in proteins related to NFκB activation 
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following anti-TNF treatment, suggested to be released as a result of the death of 
TNFα producing cells following treatment.  
In summary, previous proteomic studies have demonstrated how global analyses has 
the potential to improve our knowledge on the association of the circulating 
proteome with RA pathogenesis. However, a compromise must be made when 
deciding on which biological sample type to use. The analysis of synovial fluid is ideal 
in increasing understanding of the disease, however the invasiveness of the 
procedure may be impractical for biomarker discovery that may eventually inform 
clinical decisions. Additionally, previous chapters have discussed the involvement of 
pathologically relevant cells in response and non-response to treatment in RA. Thus, 
it is important to consider the impact the balance and interactions these circulating 
cells may have on surrounding plasma. Thus, this chapter focuses on the plasma 
proteome in RA patients, as it is a potentially rich source of biomarker candidates to 
more accurately define disease activity and treatment response. Furthermore, it 
contributes to our knowledge of the circulating changes in secreted and shed cellular 











 5.1.1 cDMARD response  
 
NPX values from all four OLINK panels across each patient group were analysed using 
Perseus software. Initially, a volcano plot was drawn to observe significant 
differences between the protein expressions of responders and non-responders 
(Figure 5.1A). Several proteins are upregulated in DMARD non-responders compared 
to responders. Such proteins include caspase-3 (CASP-3), P-selectin (SELP), junctional 
adhesion molecule-A (JAM-A), melusin (ITGB1BP2), dickkopf-related protein 1 (Dkk-
1), angiopoietin-1 (ANG-1) and CD40 ligand (CD40-L) among others. Furthermore, 
peroxiredoxin-1 (PRDX1) is significantly reduced in DMARD non-responders 
compared to responders.  
Statistically significant differences in detected levels of plasma proteins were 
calculated between each patient group using an ANOVA test with permutation based 
FDR, where FDR = 0.05 (with the number of randomizations set at 250). A heat map 
was then drawn showing only the proteins that were significantly different between 
groups, having an FDR q value of <0.05 (Figure 5.1B and 5.1C). 
Of the 42 proteins calculated as significantly different between patient groups, the 
majority were upregulated in DMARD non-responders, compared to responders and 
DMARD naïve patients. The unsupervised clustering of the heat map shows a split 
between a) DMARD non-responders and b) DMARD naïve and responders, where just 
one DMARD non-responder is clustered among the responders. Furthermore, one 
DMARD non-responder shows a reduced protein expression for the majority of the 
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42 proteins graphed, compared to all other patient samples. The reason for this 
outlier is unclear from available clinical data. 
Volcano plots were also drawn to observe any significant differences in protein 
expression between DMARD naïve patients and other patient groups. No statistically 
significant differences between DMARD naïve and responder RA patients were 
observed. However, 5 proteins were found to be significantly increased in DMARD 
non-responders compared to DMARD naïve patients, including CASP-3, SELP, JAM-A, 
PDGF subunit A and ITGB1BP2 (Figure 5.2). Furthermore, PRDX1 was significantly 






























As detailed in Figure 2.6 (section 2.6.1.1), in order to obtain information on the 
potential impact which these protein expression profiles may have within immune 
pathways, various online protein pathway programmes were used. Initially STRING 
was used to map any interaction between the 42 proteins of interest, and key 
pathways in which they are involved (Figure 5.3). The majority of proteins mapped 
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play a role in signal transduction. Additionally, a number of proteins are involved in 
MAPK and protein kinase activity, for example ANGPT1/ANG-1 and PDGF. 
Furthermore, a few of the proteins listed are associated with LPS induction through 
the TLR4 receptor, such as CASP-3, which has an unspecified reaction with 
serine/threonine-protein kinase 4 (STK4). Dkk-1 inhibits the plasminogen 
activator/inhibitor-1 (PAI/serpine1), which has a downstream effect on PDGFA and 
PDGFB. PDGFB is involved in ANG-1 activation, which subsequently regulates the 
transcription of proheparin-binding EGF-like growth factor (HBEGF). 
Enrichr was also used to obtain further pathway information of the 42 significant 
proteins. Initially, the relevance of each protein to disease type was assessed. This 
data was plotted as a bar chart, where increasing length indicates a lower p value 
and therefore more significance in terms of evidence from current literature (Figure 
5.4). The full table of associated diseases can be found in Appendix H. Among the 42 
proteins analysed, the most statistically significant associated disease group was 
arthritis, involving proteins SELP, CASP-3, CXCL1 and Dkk-1.  
The Enrichr programme was secondly used to obtain details about the pathways 
these proteins are involved in. One result, originating from Reactome, displayed 
several of these pathways (Figure 5.5). The full list of pathways obtained from the 
Reactome search can be found in Appendix I. The most significant resulting pathway 
in terms of evidence in literature from the Reactome search was regulation of 
phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) signalling (Appendix J), which 
involves PDGF and interleukin-1 receptor-associated kinase-4 (IRAK4) proteins. 
Additionally, several proteins were found to be involved in various immune system 
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pathways, for example IL-10 downregulates CXCL1 among others (Appendix K). 
Furthermore, NEMO was found to be involved in interleukin-17 receptor A (IL17RA) 
signalling via the NFκB pathway (Appendix L). 
In agreement with findings from STRING (Figure 5.3), the Reactome search also 
demonstrated an interaction between CASP-3 and STK4 (Appendix M). As part of the 
Hippo signalling pathway which regulates cell proliferation and apoptosis, CASP-3 is 

















 5.1.2 Disease activity  
 
DAS28-ESR scores from clinical data recorded on the same day as sampling were 
classified according to EULAR criteria (NICE 2009; Smolen et al. 2014b). A DAS28-ESR 
score of ≥5.1 was classified as ‘high’ disease activity, >3.2 and ≤5.1 was ‘moderate’, 
>2.6 and ≤3.2 was ‘low’, and <2.6 was classified as ‘remission’. As before, volcano 
plots were drawn to show the significant difference between patients grouped 
according to class of disease activity at the time of sampling.  
No significant difference was observed in protein expression between RA patients 
with high or low disease activity, likely due to the low number of patients with low 
disease activity (n=2). However, numerous proteins were significantly different 
between patients with high disease activity and those in remission (Figure 5.6). These 
proteins include Dkk-1, CD40-L and CASP-3, which are upregulated in patients with 
high disease activity compared to remission. Furthermore, HSP-27 and MB are 
downregulated in patients with high disease activity compared to those in remission. 
As before, each group was analysed by ANOVA with permutation based FDR. A heat 
map was then drawn with unsupervised clustering showing only the proteins that 
were significantly different between groups (Figure 5.6C). Of the four protein panels 
analysed, only ten were statistically significantly different in normalised levels 
between patient groups. Each of the ten proteins were also significantly different 










 5.1.3 Biologic DMARD response 
 
A number of the cDMARD non-responders commenced biological DMARD treatment 
on the day of sampling. Thirteen of these patients were sampled again at their 6-
month follow-up appointment, and their response was recorded according to clinical 
notes. The change in protein expression between these two time points was assessed 
in responders and non-responders to treatment by calculating the difference 
between the NPX value at baseline and 6 months. A volcano plot was drawn to 
observe the significant changes in expression between responders and non-
responders (Figure 5.7A and 5.7B).  
According to the volcano plot threshold, no significant difference was observed 
between each patient group when looking at the change in protein expression over 
time. However, several proteins highlighted in red display the highest change in 
expression between responders and non-responders. These include NEMO, CD40-L 
and mitochondrial 2,4-dienoyl-CoA reductase (DECR1), all of which were observed to 
be significantly different between cDMARD responders and non-responders.  
An ANOVA test was carried out across all proteins using a p value threshold of 0.05. 
FDR was not included in the ANOVA test in order to reduce the stringency of the test 
parameters due to the low patient numbers. The results were plotted in a heat map 
using unsupervised clustering (Figure 5.7C). Of the 4 protein panels tested, 22 
proteins were shown as statistically significantly different between responders and 
non-responders to biologics when considering the change in protein expression after 
6 months of therapy. Although in this case patient numbers are small, similarities are 
observed with the differentially expressed proteins between cDMARD responders 
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and non-responders. For example, CD40-L and ANG-1 are upregulated in cDMARD 
non-responders compared to responders, and also in biologic DMARD non-
responders compared to responders. However, patient numbers would need to be 
increased in the biologic DMARD cohort to confirm these findings. 
Due to the low number of patient samples available and the use of the less stringent 
ANOVA test to carry out statistical analysis, protein mapping programmes were not 










5.1.4 Comparison of cellular data 
 
Cellular data from previous chapters obtained from FACS analysis was compared to 
proteomic data obtained from the OLINK analysis. The expression of each protein 
across all patients was initially compared to the relative of CD169+ classical 
monocytes. The average was calculated and patients were grouped as having either 
‘above’ or ‘below’ average relative numbers of CD169+ monocytes. A volcano plot 
was then used to visually assess significant changes in protein expression between 
‘above’ and ‘below’ patient groups (Figure 5.8). 
Although no proteins were observed to be significantly differentially expressed 
between patient groups, those with the highest fold change between groups as well 
as the highest –Log p value are highlighted in red. For example, IL-5 is increased in 
patients with above average CD169+ monocytes compared to those with below 
average. Furthermore, TNFRSF10C was found to be decreased in patients with above 
average CD169+ monocytes compared to below average. 
ANOVA tests were carried out across all proteins using a p value threshold of 0.05. 
When including FDR in the analysis, none of the proteins analysed were found to be 
significantly differentially expressed between patients with ‘above’ or ‘below’ 
relative numbers of CD169+ monocytes. Therefore, the less stringent ANOVA was 
used without FDR to assess significance. The results were plotted as a heat map using 







The same analysis was carried out when considering above and below average 
relative number of CD43+ Tregs (Figure 5.9). Similar to the CD169 observation, none 
of the proteins were significantly different between patients who had above or below 
average CD43+ Tregs. However, MCP-1 had the greatest fold difference between 
patients with above and below average CD43+ Tregs, and the highest –Log p value. 
This protein was upregulated in patients with below average CD43+ Tregs, compared 




















The relative numbers of FoxP3+ Tregs were also grouped into ‘above’ or ‘below’ 
average categories. As before differential protein expression was analysed across 
patient groups and observed as a volcano plot (Figure 5.10). Two of the proteins 
tested were shown to be significantly different in expression between patients with 
above and below average relative numbers of FoxP3+ Tregs when the more stringent 
ANOVA test was used including FDR in the analysis. These proteins were CASP-3 and 
dynactin subunit-1 (DCTN1), which were observed to be increased in patients with 
below average FoxP3+ Tregs, compared to those with above average levels. 
Furthermore, the less stringent ANOVA test was carried out in order to observe 
further significant differences between proteins. In this case SELP, JAM-A and 
ITGB1BP2 were among proteins that increased in patients with below average FoxP3+ 
Tregs compared to those with above average levels. It is worth noting, these proteins 
were also among those that are significantly increased in cDMARD non-responders 
compared to cDMARD responders. Additionally, PRDX1 was shown to have the 
highest fold increase in patients with above average FoxP3+ Tregs compared to those 
with below average. Similarly, this protein was previously observed to be significantly 













 5.1.5 Quantification by ELISA 
 
CASP-3 and CD40-L were quantified from the same plasma samples analysed by PEA, 
from DMARD naïve, DMARD responder and DMARD non-responder RA patients 
(Figure 5.11 and 5.12). The results from PEA show that CASP-3 is significantly 
increased in DMARD non-responders (11.91NPX±1.096, n=17) compared to DMARD 
naïve (9.104NPX±0.5961, n=6, p<0.001) and DMARD responder patients 
(8.964NPX±0.6093, n=17, p<0.001) (Figure 5.11). However, no significant differences 
were observed between patient groups when the same samples were analysed by 
ELISA. When plotting a receiver operating characteristic (ROC) curve on PEA CASP-3 
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results, a threshold can be set at 10.06 NPX to distinguish DMARD responders from 
non-responders, with 94.12% sensitivity and 94.12% specificity (p<0.001). 
Furthermore, the area under the curve is 0.955 which represents a strong classifier. 
However, a threshold cannot be set on the ELISA quantification of CASP-3 to 
significantly distinguish between patient groups (p=0.142), where the area under the 
curve is fair (AUC = 0.706). Although, a significant positive association was observed 
between PEA (NPX) and ELISA (ng/mL) results when all patient groups were included 
in the analysis (p=0.049, r=0.314, n=40). 
CD40-L was found to be significantly increased in DMARD non-responders 
(9.637NPX±1.717, n=17) compared to DMARD naïve (6.713NPX±0.3653, n=6, 
p<0.001) and DMARD responder patients (6.971NPX±0.3778, n=17, p<0.001) when 
analysed by PEA (Figure 5.12). Furthermore, CD40-L was found to be significantly 
increased in DMARD non-responders (6.006ng/mL±3.077, n=17) compared to 
DMARD responders (4.044ng/mL±1.539, n=17, p=0.025) when analysed by ELISA. 
However, no significant difference was observed between DMARD naïve patients and 
DMARD responders. When plotting a ROC curve on PEA CD40-L results, a threshold 
can be set at 7.448 NPX to distinguish DMARD responders from non-responders, with 
100% sensitivity and 94.12% specificity (p<0.001). This provides an excellent area 
under curve score of 1.000. Furthermore, if a threshold is set on ELISA CD40-L 
quantification results at 5.729 pg/mL, a 58.82% sensitivity and 88.24% specificity is 
achieved, p=0.05. However, the area under curve score is poor (AUC = 0.696). 
Additionally, a weak positive association was found between ELISA and PEA values 
when all patient groups were included in the analysis (p=0.069, r=0.291, n=40), 









CASP-3 and CD40-L NPX values were compared to ESR and CRP values recorded from 
the same patient on the day of sampling (Figure 5.13). However, no statistical 
significant association was observed between NPX values of either protein when 









One of the key aims of experiments described in this chapter was to discover 
circulating protein biomarkers that may aid in differentiating clinical response to 
DMARD treatment in RA. Of the 4 protein panels tested from OLINK (total number = 
384), 42 proteins were significantly differentially expressed between DMARD naïve, 
DMARD responder and DMARD non-responder RA patients. When classifying 
patients based on disease activity as determined by EULAR criteria, 10 proteins were 
shown to be differentially expressed between patient groups. Interestingly, these 10 
proteins were also included in the 42 proteins previously shown to be differentially 
expressed when patients were classified by response (Figure 5.14). This suggests that 
these 10 proteins have the potential of distinguishing both disease activity and 




From the Reactome pathway table, cytokine signalling is one of the key pathways 
common to many of the significant proteins. For example, CASP-3, one of the 10 
proteins of interest, is a regulator of cell apoptosis and has previously been 
associated with cleavage of pro-inflammatory cytokine IL-16 (Zhang et al. 1998). The 
findings from the current study are in agreement with previous literature. For 
example a recent study associated CASP-3 gene expression with DAS28 in DMARD 
naïve patients (Tchetina et al. 2017). Furthermore, CASP-3 was suggested to have 
potential in predicting DMARD response. 
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Additional proteins shown by Reactome to be associated with cytokine signalling 
include IRAK-1 and -4, which are linked to pro-inflammatory cytokine IL-1. 
Furthermore, IRAK-4 along with PDGFA and PDGFB is associated with PI3K/AKT 
signalling, an essential pathway involved in regulation of the cell cycle. The PI3K/AKT 
pathway has previously been suggested to be involved with progression of RA, and 
furthermore may be a potential therapeutic target (Malemud 2015). 
SELP was also shown be associated with both disease activity and cDMARD treatment 
response. Along with other selectins, it plays a role in cell adhesion between 
leukocytes and endothelial cells, an important process in early inflammatory stages 
(de Bruijne-Admiraal et al. 1992). From the Reactome pathway list, SELP is associated 
with platelet activation in addition to PDGFA and PDGFB. Previous studies have 
shown an increase in serum SELP in RA patients compared to systemic sclerosis and 
healthy controls (Ertenli et al. 1998; Ates et al. 2004), suggesting it may be a useful 
marker in diagnosis. However, from current literature SELP is not known to 
distinguish response and non-response in RA. 
The transport of antigen-bound MHCII molecules to the cell surface involves DCTN1 
(Appendix N). This is an important process in T cell activation as part of the adaptive 
immune response. The data presented in this chapter shows that DCTN1 is 
significantly increased in DMARD non-responders compared to responders, however 
it is not associated with disease activity in RA. A previous study demonstrated an 
increase in DCTN1 gene expression in RA patients compared to control patients with 
OA (Li et al. 2014). However, it has not been previously associated in the literature 
with cDMARD treatment response. Interestingly, in the current study both CASP-3 
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and DCTN1 plasma concentrations are significantly decreased in patients with higher 
FoxP3+ Tregs, however increased in non-responder patients with higher disease 
activity. This is in agreement with previous findings presented in chapter 4, where 
DMARD non-responders exhibit lower levels of FoxP3 compared to responders.  
Dkk-1 is also among the 10 significantly differentially expressed proteins between 
patients sub-grouped based on disease activity. Dkk-1 has previously been of interest 
in relation to RA due its association with bone formation. For example, a recent study 
demonstrated an increase in serum Dkk-1 levels in RA patients with increased 
radiographic disease progression (Seror et al. 2016). The observation made in the 
current study of increased Dkk-1 in DMARD non-responders may be linked to 
increased bone damage due to lack of treatment efficacy, however this suggestion 
would need to be confirmed with radiographic assessment. 
ITGB1BP2 and CD40-L proteins appear to be associated with disease activity and 
response in cDMARD treated patients, and also response in patients treated with 
biological DMARDs. However, increased numbers of patients treated with biologic 
DMARDs are required confirm the latter observation. ITGB1BP2, a protein expressed 
by heart muscles, is not known to be associated with response in arthritis. However, 
reduced levels have been previously linked to cardiac impairment (Brancaccio et al. 
1999). CD40-L is a marker of platelet activation and is present on certain T cell subsets 
(Datta and Kalled 1997; Otterdal et al. 2004). It has an inflammatory role in the 
immune response because via CD40 binding, it is associated with non-canonical NFκB 
signalling (Appendix O). CD40-L has been shown to play a role in autoimmune 
diseases including SLE and RA (Koshy et al. 1996; Wang and Liu 2003). Circulating 
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CD40-L secreted from activated T cells and platelets has been linked to disease 
activity in SLE (Kato et al. 1999). An increase in membrane bound CD40-L has been 
linked to increased RA disease activity (Berner et al. 2000), and furthermore soluble 
CD40-L was shown to be increased in the periphery of RA patients compared to 
healthy controls (Tamura et al. 2001). In summary, the current study’s findings are 
completely novel, where ITGB1BP2 and CD40-L were found to be associated with RA 
disease activity in patients treated with cDMARDs and biological DMARDs. 
PRDX1 was also a protein of interest because of its downregulation in cDMARD non-
responders compared to responders and DMARD naïve patients. Furthermore, it is 
the most significantly increased protein detected in patients with above average 
FOXP3+ Tregs, compared to those with below average levels. PRDX1 is essential in 
regulating reduction and oxidation within the cell, and its release from the cell has 
previously been associated with the induction of pro-inflammatory cytokines IL-6 and 
TNFα (Shichita et al. 2012; Liu et al. 2014). Thus, it is regarded as a promotor of 
inflammatory processes, and its reduction in DMARD non-responders is perhaps a 
curious result, as inflammatory pathways are generally upregulated in non-
responders. Further investigation is needed to confirm and understand this finding. 
Links between the previously obtained CD169 and CD43 cellular data (chapter 3) and 
proteomic data were also investigated in the current study. IL-5 and IgG Fc receptor-
IIb were among those that were increased in patients with an above average relative 
number of CD169+ monocytes, compared to those with below average levels. IL-5 
showed the highest significant difference between patient groups, however this was 
only determined using a p value of 0.05 without accounting for FDR. IL-5 is an anti-
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inflammatory cytokine produced by T helper and mast cells. It can be speculated 
whether monocytes play a role in IL-5 production as they act as antigen-presenting 
cells to T cells, subsequently activating T helper cells. However, whether CD169 has 
a specific role in IL-5 production would need to be verified. It is possible that the lack 
of association between specific cellular findings, and the circulating proteome to 
which the same cells contribute, is due to masking from the abundance and variety 
of circulating secreted proteins. 
ELISA analysis was used to quantify a select number of proteins found to have 
significantly different NPX values between patient groups. The purpose of the ELISA 
was also to verify findings from the PEA analysis and show whether or not the more 
accessible ELISA method could be used to distinguish disease activity and treatment 
response in RA. CASP-3 and CD40-L were selected for ELISA quantification because 
both proteins were found to be significantly differentially expressed between 
cDMARD responders and non-responders, as well as between patients with high 
disease activity and in remission. Furthermore, as discussed CASP-3 and CD40-L have 
previously been associated with disease activity in RA (Berner et al. 2000; Tchetina 
et al. 2017), however to current knowledge this association with CASP-3 has only 
been made by gene expression analysis and not proteomic studies. The data from 
the current study shows a threshold can be set to reliably distinguish cDMARD 
responders from non-responders when PEA analysis is used. The sensitivity and 
specificity percentages with both CASP-3 and CD40-L are promising when analysed 
by PEA, where both values are above 90%. However, this cannot be said with regard 
to ELISA quantification results. This may be due to the difference in mechanism of 
each method used, for example PEA technology relies on a PCR readout following 
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extension and amplification steps after hybridisation of unique DNA sequences. ELISA 
on the other hand relies on an absorbance readout after TMB is oxidised in the 
presence of HRP, which is conjugated to a specific antibody targeting the protein of 
interest. Additionally, neither technology distinguishes between membrane bound 
and soluble proteins, however centrifugation steps can be introduced prior to ELISA 
in order to detect only the soluble form of the protein. However, the results of this 
study show a positive association between PEA and ELISA results, and with 
significance when analysing CASP-3. Therefore, perhaps with further method 
development of the ELISA, it may be possible to improve this association between 
the two assays. Additionally, as PEA data was shown to be associated with cDMARD 
treatment response when considering CD40-L and CASP-3 among others, this data 
was compared with ESR and CRP clinical data recorded on the same day of sampling. 
However, ESR or CRP values showed no significant association with CD40-L or CASP-
3 PEA data, suggesting these blood-based inflammatory markers are unreliable in 




These results show the potential of using the circulating proteome to distinguish 
between response and non-response to cDMARDs and biological DMARDs, as well as 
disease activity classification before and during treatment in RA. For example, CASP-
3 and SELP are among the most differentially expressed proteins between DMARD 
naïve, responder and non-responder RA patients, thus having the most potential in 
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distinguishing response in peripheral blood. However, a more accessible analysis 
method such as ELISA would need to be carried out to firstly quantify protein levels, 
and secondly to confirm that these findings can be transferred to this more 
commonly used platform.  
This study demonstrates a lack of concordance between CD169 and CD43 cellular 
measures, and circulating proteomic findings. An in vitro model may be used in order 
to further understand the impact of this cellular interaction on the circulating 
proteome. However, it may be possible that in circulating blood any proteomic 
impact is masked by the vast numbers of circulating proteins from various sources. 
Although higher patient numbers are required to confirm this, there was an 
association found between the change in CD40-L and ITGB1BP2 in individual 
biological DMARD-treated patients, and treatment response. Interestingly, both 
proteins are also significantly differentially expressed between cDMARD naïve, 
responder and non-responder patients, as well as those classed as having high, 
moderate or low disease activity. This suggests treatment response may be 
determined over time for individual patients. Thus, there may be opportunity to 
determine treatment response at an earlier time point than current measures, 
therefore allowing for greater treatment efficacy as treatment regimens can be 
adjusted in early disease.  
Additionally, CASP-3 protein expression can reliably distinguish between DMARD 
responders and non-responders with sensitivity and specificity >94% when analysed 
by PEA. Furthermore, these PEA results had a significant positive association with 
ELISA quantification results of the same samples. Thus, CASP-3 could be a potential 
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biomarker of treatment response in RA, and with further optimisation, ELISA could 
be used as a more accessible and cost effective method of detection. However, if a 
protein based assay or test were developed to distinguish treatment response in 
order to aid clinical decisions, due to the vast range of proteomic data available it 
would likely be a multiplex measurement with an algorithm which discerns the 











































6.0 General Discussion 
 
6.0.1 CD169+ monocytes and CD43+ Tregs 
 
The aim of chapter 3 was to determine the relationship between CD169+ monocytes 
and CD43+ Tregs in RA patients who were DMARD naïve, responders and non-
responders as classified by EULAR criteria (Smolen et al. 2014b). One of the key 
findings of this chapter was the need to consider CD16+ non-classical and 
intermediate monocytes, as well as CD16- classical monocytes. CD16+ monocytes 
have been implicated as dendritic cell precursors (Ancuta et al. 2003), and 
furthermore are induced by inflammatory cytokine TGFβ (Yoon et al. 2014). In 
agreement with previous literature (Kawanaka et al. 2002; Cairns et al. 2002), CD16+ 
monocytes are increased in peripheral blood of RA patients compared to healthy 
controls, whereas CD16- monocytes are decreased. This finding emphasised the need 
to consider both CD16- and CD16+ monocyte subsets when analysing the relative 
number of CD169+ monocytes. Previous studies have shown an increase in the 
relative number of CD169+ classical monocytes in RA compared to health (Xiong et 
al. 2014), however have failed to report relative numbers of CD169+ non-classical or 
intermediate monocytes. This chapter presents the novel finding of a statistically 
significant increase in CD169+ non-classical monocytes in RA compared to health. 
Interestingly, DAS28-ESR had a strong association with the relative number of CD169+ 
non-classical monocytes, which was more statistically significant than when 
compared to CD169+ classical or intermediate monocytes.  
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The relative number of CD43+ Tregs was reduced in RA compared to healthy controls. 
Furthermore, the ratio of CD169+ monocytes and CD43+ Tregs was found to be 
positively associated with DAS28-ESR. However, neither cell-surface marker could 
definitively discriminate between responders and non-responders to cDMARD 
treatment. This finding suggests CD169 and CD43 in combination are representative 
of disease activity in RA, however cannot distinguish long term response or non-
response. It has previously been reported that CD169+ monocytes and CD43+ Tregs 
directly bind via these cell-surface markers (Ohnishi et al. 2013), and that the 
interaction between the two cell types may contribute to the decreased activation 
state of Tregs in RA (Wu et al. 2009). Although siglecs play an important role as 
inhibitory regulators of Treg activation and function, the findings of this chapter do 
not confirm a direct suppression of Tregs by CD169+ monocytes via the CD169-CD43 
interaction. Therefore, in order to address this question and understand the Treg 
activation state in RA, an in vitro model of inflammatory Tregs was used in the 
following chapter. 
6.0.2 Treg activity in RA 
 
The aim of chapter 4 was to investigate the activation state of Tregs in RA compared 
to health. Initial finding showed an increase in circulating Tregs in DMARD naïve and 
responder patients compared to health, in agreement with previous literature 
(Ehrenstein et al. 2004). However, a decrease in circulating Tregs was observed in 
DMARD non-responders compared to responders. Furthermore, not only were Tregs 
found to be reduced in number in DMARD non-responders, but also in activation 
state as measured by FoxP3. Specifically, this chapter reports differential relative 
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numbers of FoxP3+ Tregs in CD45RA+ naïve vs CD45RA- memory subsets. FoxP3+ naïve 
Tregs were decreased in DMARD responders and non-responders compared to 
healthy controls. Furthermore, FoxP3+ memory Tregs were increased in DMARD 
responders and non-responders compared to healthy controls, however DMARD 
non-responders exhibited significantly lower levels compared to responders. This 
suggests overall Treg activity may be restored with treatment response, and that Treg 
activity may be defective in non-responders. 
In order to emulate an inflammatory Treg environment, such as that presented in RA, 
Tregs were stimulated with PMA in vitro, which increased relative numbers of NFκB+ 
and FoxP3+ Tregs, as well as TNFα, IL-10 and IFNɣ cytokine secretion. The key novel 
finding of this chapter was the role of Sia in reducing this cytokine secretion from 
Tregs as well as reducing intracellular percentages of NFκB and FoxP3. The purpose 
of the experiment was to mimic the effect monocyte-CD169 might have on the 
activation state of Tregs, because CD169 binds to Sia before binding its ligand. 
Previous studies have also highlighted a role of Sia in inflammation, and importantly 
Sia has been shown to increase in RA compared to healthy controls (Chrostek et al. 
2014). It is clear that siglec-Sia mediated signalling plays a pivotal role in Treg 
activation and could therefore have significant influence on tolerance and 
suppression within the immune system. Monocyte-Treg co-culture was used in order 
to try to identify if Sia has the same effect on Tregs as monocytes. Additionally, CD169 
and CD43 blocking antibodies were used to confirm or deny whether any effect 
observed is directly due to the binding of these two markers. However, due to the 
lack of concordance between biological replicates, the results of the co-culture were 
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inconclusive and thus further optimisation is needed in order to verify a relationship 
between CD169 and CD43. 
Chapters 3 and 4 address the potential involvement of specific peripheral blood cells 
in disease activity and treatment response in RA. However, it is important to consider 
the protein environment in which they are bathed, as addressed in chapter 5. 
6.0.3 Circulating protein biomarkers of response in RA 
 
The aim of chapter 5 was initially to determine levels of a vast range of circulating 
proteins in cDMARD naïve, responder and non-responder RA patients in order to 
discover specific proteins that could act as a biomarker of treatment response. 
ITGB1BP2, Dkk-1, CD40-L and DECR1 were found to be significantly increased in i) 
cDMARD non-responders compared to responders, ii) RA patients with high disease 
activity compared to those in remission and iii) biological DMARDs non-responders 
compared to responders, where the change in protein levels between baseline and 
6 months of therapy was assessed. However, due to low patient numbers the latter 
would need to be confirmed. The findings of this chapter demonstrated a lack of 
concordance between previous CD169 and CD43 cellular findings, and protein 
expression in autologous plasma samples. However, this may be due to masking by 
more abundant plasma proteins. An in vitro cell model is one option of investigating 
the contribution CD169+ monocytes and CD43+ Tregs may have to the circulating 
plasma proteome. 
The key findings of this analysis demonstrated the role of a subset of proteins in 
distinguishing not only treatment response, but also disease activity in RA. One such 
protein is CASP-3, a regulator of cell apoptosis which has not previously been 
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reported to distinguish treatment response in RA. Although CASP-3 levels analysed 
by ELISA did not confirm PEA results of increased expression in DMARD non-
responders compared to responders, the results between the 2 assays had a 
significant positive association. With further optimisation of the more accessible 
ELISA method, it may be possible to use CASP-3 among a panel of other proteins as 
markers of treatment response in RA. 
6.0.4 Conclusions 
 
The hypothesis of this thesis was that the interaction between circulating CD169+ 
monocytes and CD43+ Tregs, and the proteomic environment in which these cells are 
bathed, could act as potential biomarkers of disease activity in RA, and therefore 
could assist in determining treatment response. Firstly, this thesis suggests there is 
an interaction between CD169 and CD43 that contributes to disease activity in RA 
due to the finding of the ratio of CD169+ monocytes to CD43+ Tregs having a 
significant correlation with DAS28-ESR. However, whether there is a direct CD169-
CD43 interaction that contributes to this result is inconclusive in the current study.  
Furthermore, this thesis presents evidence of the ability to detect Treg activity in 
peripheral blood via measurement of intracellular FoxP3. DMARD non-responders 
exhibit reduced Treg activity compared to responders, suggesting defective Treg 
activity may contribute to or be a consequence of treatment non-response. 
Importantly, this data suggests Treg activity could be used as a surrogate measure of 
treatment response in RA. 
Additionally, the association of monocytes with reduced Treg activity was addressed. 
It was found that Sia suppresses Tregs in an in vitro model of inflammation, as 
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measured by a reduction in inflammatory cytokines as well as a reduction in relative 
numbers of NFκB+ and FoxP3+ Tregs. This may mimic the action of CD169 on Tregs, 
however this could not be confirmed in the current study. Furthermore, the 
investigation of an association of the CD169-CD43 interaction with reduced Treg 
activity was inconclusive, and in need of further work to determine the role of this 
interaction. 
This thesis demonstrates that specific circulating proteins in RA are representative of 
disease activity and cDMARD treatment response, therefore accepting the 
hypothesis, albeit further validation studies are required. In summary, this thesis 
presents findings that easily accessible circulating blood can be used to determine 
treatment response in RA. Furthermore, with this novel evidence there may be 
opportunity to determine treatment response at an earlier time point than current 
measures, therefore allowing for greater treatment efficacy as treatment regimens 




Due to patient recruitment primarily being based in a location geographically distant 
from where samples were analysed, this part of the study was quite time consuming. 
Furthermore, DMARD naïve patients were difficult to recruit in large numbers as they 
needed to be sampled on the day of diagnosis prior to commencing their drug. 
Furthermore, patients treated with biological DMARDs were difficult to re-sample at 
their 6-month time point. This was due to a number of reasons including last minute 
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changes of appointment days, therefore there were low patient numbers with 
baseline and 6 month matched samples. 
Often clinical data was not recorded by hospital staff on the day of sampling, which 
meant when comparing cellular or proteomic data to DAS28-ESR or other clinical 
measures, some samples had to be excluded from the analysis. Furthermore, 
although full blood counts could be recovered from clinical notes and used in the 
analysis of absolute monocytes, the same could not be done for T cell or Tregs. One 
option to improve this would be to use an automated cell counter to determine 
absolute numbers of Tregs, however this facility was not available for the study. 
 Overall, patient recruitment was extremely time consuming, unfortunately leaving 
less time for later cell culture experiments. Therefore, although rigorous cell culture 
experiments were carried out, further work is essential to confirm findings. 
 
6.2 Future Work 
 
Although this thesis suggests an interaction between CD169+ monocytes and CD43+ 
Tregs is representative of RA disease activity, further experiments are needed to 
confirm this finding. The cell culture experiments presented were inconclusive in 
determining i) whether CD169 and CD43 directly bind when cells are in an 
inflammatory state and ii) whether an interaction between CD169 and CD43 directly 
contributes to reduced Treg activity. One suggestion is repeating this experiment 
with increased biological replicates in order to increase reliability of results and 
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conclusively determine whether CD169 and CD43 contribute to Treg activity. 
Furthermore, immunocytochemistry could be useful in confirming that CD169 and 
CD43 physically bind during inflammation. 
Furthermore, in addition to the ratio between CD169+ monocytes and CD43+ Tregs 
being representative of disease activity, FoxP3+ Tregs were found to be associated 
with treatment response. It would be interesting to confirm these finding in a 
longitudinal study, where patients are sampled throughout treatment, and changes 
in these cellular markers are recorded. 
This thesis also identified a range of circulating protein that were found to be 
representative of both disease activity and treatment response when tested using 
PEA analysis. Preliminary experiments showed a correlation PEA and ELISA analysis 
in the detection of CASP-3. However, further optimisation of the ELISA method is 
required to confirm that PEA findings can be translated to a more accessible and cost 
effective method. Additionally, only 2 of the proteins found to be significantly 
differentially expressed between patient groups were tested. It would be interesting 
to confirm PEA results with ELISA for each of the proteins of interest. This would 
enable a ‘cut-off’ quantification value to be set that would distinguish disease activity 
and response. Furthermore, in order to confirm these findings an independent 
cohort of patients could be sampled.  
One of the key clinical issues in RA is the excessive time of 3-6 months after 
commencing treatment to determine whether a patient has responded or not. The 
value of the cellular and proteomic markers presented in this thesis in determining 
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disease activity and treatment response suggests it may be possible to classify 
patients as responders or non-responders at an earlier time point than currently 
possible. This suggestion would need to be confirmed primarily by introducing 
sampling points soon after treatment and up until the 3-month time point. The ability 
to determine treatment response by analysing these key cell types and/or specific 
protein signatures at an early stage would aid clinical decisions as well as improve 
overall patient outcome, as patients could be commenced on a more suitable 
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Siglec-1 and -2 as potential biomarkers in autoimmune 
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Autoimmune diseases (ADs) are currently treated with anti-inflammatory and 
immunosup- pressive drugs, aimed at reducing symptoms of disease in order to 
improve quality of life for patients. However, for a significant number of patients these 
therapies are ineffective, leading to an increased risk of irreversible damage and 
eventual disability in certain cases. Growing evidence has implicated glycosylated 
proteins and their cognate receptors in modulation of the autoimmune response. This 
review will summarize these findings with particular focus on sialic acid-binding 
immunoglobulin-like lectin (Siglec)-1 and Siglec-2 involvement in AD. Fluctuations in 
these glycosylation-dependent pathways could act as sentinels of disease activity or drug 
responses. If validated, protein modification and cellular response markers could help 
clinicians achieve remission earlier. 
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The term “autoimmune disease” (AD) is an 
overarching de- scription of a vast range of chronic 
conditions in which an abnormal immune response 
is established. There are over 80 ADs that range 
from problems in the joints in rheuma- toid arthritis 
(RA) and systemic lupus erythematosus (SLE) to skin 
conditions such as vitiligo and psoriasis [1]. The eti- 
ology of autoimmunity has been widely researched 
but the exact mechanisms remain elusive. Previous 
studies have sug- gested the role of bacterial infection 
[2], environmental factors [3], and genetics as potential 
risk factors of AD [4], however knowledge is 
incomplete. 
The prevalence of AD is specific to each condition, 
for example  RA  affects  0.5–1%  of  the  adult  
population  [5]. 
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receptor; IFN, interferon; IgG0, agalactosylated IgG; IL, 
interleukin; ITIM, immunoreceptor tyrosine-based 
inhibitory motif; RA, rheumatoid arthritis;  Siglec,  sialic  
acid-binding  immunoglobulin-like  lectin; 
Epidemiological studies of AD suggest a prevalence of 
7.6–9.4%, however, only covering a subset of diseases 
[6]. Throughout AD, there is an average female 
predilection of 75% according to the American 
Autoimmune Related Dis- eases Association [7]. 
Treatment of AD is aimed at relieving symptoms and lim- 
iting damage, with the ultimate aim of improving 
patient quality of life. Medication is often prescribed in 
a disease- specific regimen, for example treatment of 
joint-related dis- eases such as RA primarily involves 
anti-inflammatory and immunosuppressive drug 
combinations early in disease. Re- sponse rates to 
treatment regimens can be low, for example disease-
modifying anti-rheumatic drugs used to treat RA re- port 
failure rates of 30% [8]. Additionally, nonresponse to 
glucocorticoid is common in SLE amongst other 
rheumatic conditions, and hence many patients 
experience relapse dur- ing dosage titration [9]. 
Sensitive biomarkers that can monitor response to treat- 
ment and subclinical disease activity are required. A 
reliable biomarker panel, descriptive of disease pathology 
could allow clinicians to determine treatment responses 
and switches to alternatives at an earlier time point. 
Furthermore, mon- itoring robust pathology 
descriptive biomarkers may be able to predict relapse 
and give the opportunity to limit damage.
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This review will focus on protein glycosylation 
pathways, their ability to directly impact upon 
treatment outcomes in RA and other ADs, and their 
potential as biological markers of key pathological 
processes. The review will also discuss the cellular 
context of these pathways in immune response, 
autoimmunity, drug resistance, and disease 
persistence. 
Two members of the sialic acid-binding 
immunoglobulin- like lectin (Siglec) family offer 
examples of key glycosylation- dependent pathways, 
which could contribute to AD pathology and drug 
resistance [10]. Siglec-1 (CD169) is a macrophage- 
restricted cell surface receptor that has been shown to 
drive proinflammatory processes and is related to 
disease persis- tence [11]. Siglec-2 (CD22) is a B-cell 
restricted molecule that negatively regulates B-cell 
receptor (BCR) and subsequent im- mune response 
and has been implicated in drug resistance [12]. 
 
 
2 Protein glycosylation fluctuations in AD 
 
Glycosylation is an important post-translational 
modification observed in over 70% of human proteins 
[13] and is specific to age, gender, and environmental 
and biochemical factors [14]. Fluctuations in 
expression and activity of glycosyltransferase and 
glycosidase enzymes associated with the progression 
of disease can lead to aberrant glycosylation [15,16]. 
Alteration of glycans can sterically disrupt interactions 
between cognizant lectins and glycoproteins, which 




2.1 Acute-phase response proteins 
 
The glycosylation patterns of several acute-phase 
plasma pro- teins differ in AD patients compared to 
healthy individuals, which suggests a pathogenic role. 
A study focused on alter- ations in sera proteins of 
RA patients discovered an abnor- mal elevation of 
fucosylation [18]. Similarly, a recent study by Higai et 
al. [19] found increased numbers of biantennary and 
alpha 1, 3-fucosylated glycans at glycosylation sites of 
a.1-acid glycoprotein in patients with acute 
inflammation compared to healthy controls. 
Other sera proteins, such as Haptoglobin have been 
of interest in association of RA [20]. Saroha et al. 
[21] re- ported a unique monosaccharide pattern of 
Haptoglobin and acid glycoprotein to be specifically 
linked with RA pathogenesis. 
 
 
2.2 Agalactosylated  immunoglobulin 
 
Patients with RA express a higher concentration of 
agalacto- sylated IgG (IgG0). This concentration 
positively correlates with disease severity in RA  patients,  
suggesting  a  poten- tial role of IgG0 as a biomarker 
for disease activity [22, 23]. IgG0 also shows good 
correlation with biomarkers of AD in 
general, including inflammatory markers Interleukin-6 
(IL-6) and C-reactive protein, which increase in early 
disease [24]. Pasek et al. [25] suggested the use of 
IgG0 as a marker for disease severity, as levels return 
to normal after anti-TNF monotherapy. 
RA patients undergoing Methotrexate and Infliximab 
combination therapy exhibit decreased levels of IgG0 
as well as clinically improved symptoms of the disease 
[26]. These changes in glycosylation may amplify the 
autoimmune re- sponse, by specific activation of 
macrophages, T cells, and B cells, contributing to the 




3 Key cells in disease pathogenesis 
 
Numerous studies have investigated molecular 
signatures in AD that may have the potential to 
distinguish response to treatment. However, despite 
a large volume of genetic biomarker-based studies, 
there remains no definitive genetic signature to 
differentiate response to therapy. Focusing on cellular 
interactions could prove to be a valuable means to 
differentiate responders. This section summarizes the 
main cells involved in inflammation, primarily 
monocytes, T cells, and B cells as biological indicators 
of disease activity or sever- ity [28]. 
Macrophages play a central role in AD pathogenesis, 
trig- gering the production of proinflammatory 
mediators, such as cytokines TNF-a. and IL-1 [29]. 
The numbers of circulat- ing monocytes increase in 
AD patients, which highlights the importance of their 
role in disease pathogenesis [30–32]. 
Monocytes circulate in the blood stream  and  differen- 
tiate into mature macrophages on entering  inflamed  
tis- sue. Macrophages are found in large numbers within 
the cartilage–pannus junction of RA patients. At this 
location, they display signs of activation including 
expression of the major histocompatibility complex, 
class II (MHC-II), and se- cretion of proinflammatory 
and regulatory cytokines [33, 34]. Macrophage 
activation positively correlates with progression of joint 
destruction, evidenced by radiological examination 
[35]. Synovial macrophages can differentiate into 
subpopula- tions that trigger the activation of T cells and 
proinflammatory cytokines, leading to more damage 
and further progression of the disease [36, 37]. 
Macrophages have also been investi- gated as key 
players in other ADs, such as Lupus Nephritis, a 
kidney-related complication of SLE. Lupus Nephritis 
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dis- ease activity positively correlates with monocyte 
infiltration and macrophage differentiation [32]. A 
subsequent section describes the macrophage-specific 
pathways influenced by variable glycosylation and 
discusses its association with dis- ease persistence in 
AD. 
B cells orchestrate autoimmune responses in adaptive 
im- munity by the production of autoantibodies and 
antigen pre- sentation [38]. Section 4.3 will focus on 
how protein glyco- sylation influences the BCR and 
could ultimately determine immune tolerance and the 
















Figure 1. Selected sialic acid linkage sequences and relative affinities of Siglec-1 and Siglec-2. (A–F) represent terminal 
sequences of glycan structures of human (A, B, C, D, and F) and murine (E) glycoproteins and glycolipids that interact with 
Siglecs. (A) represents a.2-3 sialic acid linkage; (B) and (E) display a.2-6 linkage; (C) displays a.2-8 linkage; while both (D and F) 
represent sulfated a.2-3 sialic acid linkage. Table (G) displays the relative affinity of Siglec-1 and Siglec-2 for each glycan structure 
(A–F). (+++) represents greatest binding affinity, (+) represents low binding affinity, and (*) indicates binding affinity not tested. 
NeuAc, N-acetylneuraminic acid (sialic acid); NeuGc, N-glycolylneuraminic acid (murine sialic acid); GlcNAc, N-acetylglucosamine; 
Gal, galactose; Sul, sulfate; Fuc, fucose
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T cells are also implicated in AD pathogenesis, where 
their activation leads to the release of cytokines such as 
TNF-a. and IL-4 [39]. CD4+CD25+ regulatory T cells, 
also known as sup- pressor T cells or Tregs, are a 
subset of T cells that play an important role in 
autoimmune responses. Tregs are involved in self-
tolerance by  suppressing  the  destructive  functions 
of CD4+CD25− effector T cells (Teffs) during the 
immune response [40]. 
Recent research has highlighted a critical 
relationship between Tregs and macrophages in the 
context of RA. In particular, Siglec-1 positive 
macrophages cause a negative regulation of Tregs 
[40]. Xiong et al. [11] demonstrated that the 
frequency of Siglec-1 in peripheral blood 
mononuclear cells was greater in RA patients, than that 
of healthy controls. 
 
 
4 Glycosylation-dependent pathways in 
autoimmunity 
 
Siglecs are sialic acid-binding immunoglobulin-like 
lectins that are involved in cell–cell interactions and 
signaling func- tions. There are several Siglec 
isoforms, differing in biolog- ical function and 
affinity for specific sialic acids [41]. There 
is substantial evidence that Siglec-1 and -2 in particular are 
involved in disease persistence and treatment resistance in 
RA and potentially other ADs. 
 
 
4.1 Siglec-1 (CD169) 
 
Siglec-1, also known as Sialoadhesin or CD169 is a cell sur- 
face receptor restricted to macrophages and their mono- 
cyte precursors, with high expression found in secondary 
lymphoid tissues. The structure of Siglec-1 comprises 17 
immunoglobulin-like domains including one V-set domain 
through which it binds ligands, and 16 C2-set domains, which 
elongate the binding site away from the surface of the cell 
[42] (Fig. 1). Siglec-1 performs many functions, most im- 
portantly cell adhesion, accommodated by the elongation of 
the C2-set domains (Fig. 1) [43]. It binds to granulocytes, B 
cells, erythrocytes, and a subset of CD8 T cells [44]. It also 
acts as an endocytic receptor by internalization of sialic acid- 
tagged pathogens [45]. Hartnell et al. [44] also found Siglec-1 is 
highly conserved in the extracellular region between mouse 
























Figure 2. The structure and expression of highly conserved siglecs. Siglecs are type-I mem- brane proteins made up of a variable 
number (1–16) of extra- cellular C2-set immunoglobulin domains and an  amino terminal V-set domain  that mediates sialic acid 
binding. Siglec-1 lacks intracellular tyrosine-based signaling motifs and has a poorly conserved cytoplasmic tail. Siglec-2’s (CD22) 





The lack of immunoreceptor tyrosine-based inhibitory 
sig- naling motif (ITIM) in the cytoplasmic domain 
strongly sug- gests Siglec-1 functions primarily via cell–
cell and cell–matrix interactions [44]. It may also play a 
role in anti-viral and anti- bacterial activity as its 
regulation is subject to type I and type II interferon 
(IFN) induction [46]. Siglec-1 increases in a num- ber 
of ADs associated with IFN signaling, including SLE, 
type 1 diabetes, and systemic sclerosis [47–49]. In a 
study measur- ing IFN biomarkers, Siglec-1 
expression was increased in 86% SLE patients [50]. 
These findings suggest Siglec-1 is a marker of 
prospective disease activity in AD. 
Most Siglecs show a binding preference in either a.2,3 
or 
a.2,6 glycosidic linkage (the numbers here indicate 
the spe- cific carbons with the hexose ring) . Siglec-1 has 
a predilection for a.2,3, accommodated by 
glycosyltransferase and glycosi- dase enzymes (Fig. 2) 
[16]. It can also bind in a.2,8 linkage, but with weak 
affinity [51]. X-ray crystallography shows the binding 
of Siglec-1 is accommodated by a salt bridge formed 
between an arginine residue in the V-set domain 
and the carboxylate of the sialic acid [52]. 
Siglec-1 is described as a candidate biomarker for 
RA disease activity due to its increased expression 
on periph- eral blood monocytes in patients relative 
to healthy controls [11]. RA patients also exhibited a 
decrease in average Siglec- 
1 levels during successful treatment with DMARDs 
[11]. Xiong et al. also found an increased frequency 
of Siglec-1 mRNA within monocytes of RA patients 
during active dis- ease and were able to correlate their 
findings with other dis- ease predictors including 
DAS28, erythrocyte sedimentation rate, rheumatoid 
factor, and C-reactive protein levels. A pre- vious 
study demonstrated similar results, where a strong 
correlation was observed between levels of Siglec-1 
posi- tive monocytes and clinical parameters for 
patients with the disease [53]. 
4.2 Siglec-1 interacts with Tregs 
 
Siglec-1 positive macrophages negatively regulate 
Tregs [40] (Fig. 3). In vitro experiments demonstrate 
that Siglec-1 KO macrophages trigger the 
production of Tregs at a higher rate than wild-type 
macrophages, therefore confirming that Siglec-1 
positive macrophages suppress the proliferation of 
Tregs. Importantly, a decrease in the number of Siglec-
1 pos- itive macrophages leads to an increase in Tregs, 
which leads to a lower disease activity in an RA model 
[40]. 
The interaction between Siglec-1 and Tregs is believed 
to occur through the T-cell surface receptor, CD43. 
This sialy- lated glycoprotein has been identified as a 
counter receptor for Siglec-1 [54, 55]. In vivo 
experiments show a direct inter- action between the 
two receptors, however the mechanism through 
which this occurs remains unclear and warrants fur- 
ther investigation [56]. 
 
 
4.3 Siglec-2 (CD22) and BCR 
 
BCR plays an important role in immune tolerance. 
BCR is negatively regulated by Siglec-2 [12] (Fig. 4). 
Siglec-2 is widely expressed by the majority of 
peripheral mature B cells [57], however its expression 
is lost during B-cell differentiation into plasma cells. It is 
expressed at high levels on B cells in the fol- licular, 
mantle, and marginal zones of the spleen, but weakly 
expressed by B cells in the germinal center [58]. In 
resting B cells, the majority of Siglec-2 is localized in 
clatherin-enriched microdomains [59]. 
Lanoue et al. [60] demonstrated Siglec-2 mediated 
sup- pression of BCR by in vitro studies of 
glycoconjugate ligands binding in a.2-6. The study 
highlighted that BCR activation by antigen-expressing 









Figure 3. The inhibitory role of 
siglec-1 on CD4+ Treg cells, 
subsequent increase in CD4+ 
Teff cell proliferation, and en- 
hanced inflammatory response. 
(A) demonstrates the inhibitory 
role CD4+ Tregs on CD4+ Teff 
proliferation and subsequent 
proinflammatory response. (B) 
Kidder  et   al.   demonstrated an 
increase in J3-galactoside a.-
2,3-sialyltransferase (ST3Gal) 
mRNA expression and a.2-3 sia- 
lylation of CD4+ Treg cells in a 
murine model of SLE. (C) Kidder 
et al. also demonstrated siglec-1 
positive macrophages induced 
the death of CD4+ Treg cells, 
expressing sialic acid in a.2-3 
linkage, by an unknown mecha- 
nism. The subsequent reduction 
in Treg numbers resulted in an 




cells co-expressed a.2-6 sialic acid glycoconjugates. 
This find- ing eludes to a potential role for Siglec-2 in 
the maintenance of tolerance and the development of 
autoimmunity. 
The importance of ligand binding in the maintenance 
of B-cell homeostasis has also been investigated by Poe 
et al. [61]. This study showed that knock-in mice 
expressing one of the two Siglec-2 mutations 
abrogating ligand binding displayed higher rates of 
turnover in peripheral and recirculating bone marrow 
B cells in vivo. 
Activation of the BCR signaling cascade leads to an 
increase in calcium  ions  (Ca2+)  released  from  
intracellu- lar stores through the phosphorylation and 
activation of a range of signaling molecules, including 
BtK, BLNK/SLP65, and PLC')'2 [12].  BCR  
activation  also  initiates  an  influx of extracellular Ca2+ 
through the calcium release activated channel. Rapid 
phosphorylation of Siglec-2 ITIMs by the Src kinase, 
Lyn, occurs following BCR cross-linkage [62]. The ty- 
rosine phosphatase SHP-1 is then recruited and binds 
to two phosphorylated ITIMs. Then, SHP-1 dampens 
BCR signaling through the depletion of endoplasmic 
reticulum Ca2+ stores and activation of the Ca2+ pump 
PMCA4 [12] (Fig. 5). 
Siglec-2 null mice display increased intracellular Ca2+ 
sig- 
naling following BCR activation [63–66], as well as a 
more rapid B-cell turnover, reduced numbers of 
circulating blood and bone marrow B cells, and 
enhanced BCR-induced B- cell apoptosis [61, 65–67]. 
The mechanisms behind decreased Ca2+ levels as a result 
of Siglec-2 binding remain unclear. However,  studies  
suggest  that  therapies  targeting  Siglec- 
2 could increase BCR activation, thus improving 
patient outcome [68]. 
Two independent Siglec-2 null mouse strains display 
in- creased autoantibody production against single- 
and double- stranded DNA and histone complexes 
[64, 69, 70]. These findings suggest Siglec-2 may play 
a key role in the antibody- mediated autoimmunity 
characteristic of AD. Additionally this pathway may 
be responsible for antidrug antibodies pro- duction, 
which play a causal role in secondary non-response to 
therapy [71]. 
Siglec-2 polymorphisms have been associated with 
au- toimmunity in a number of mouse strains [72], 
most of which occur within the ligand-binding 
domain [58]. SHP- 
1 null and SHP-1 mutant mice display a similar hy- 
perresponsive phenotype to the Siglec-2 null mouse 
[67, 73], and demonstrate increased levels of 
spontaneous au- toantibody production [74, 75]. As 
autoantibody produc- tion has been shown to 
influence treatment  responses [71], this further 
suggests Siglec-2 may contribute to non- response 





               
 
Figure 4. The effect of normal and defective SIAE function on Siglec-2 regulation of BCR activation. (A) demonstrates normal sialic 
acid acetylesterase (SIAE) function. SIAE is responsible for the removal of 9-O-acetyl groups from sialic acid molecules in sialylated 
glycoconju- gates. Glycoproteins containing sialic acid in a.2-6 linkage are capable of binding to and activating Siglec-2, both in cis-, 
as demonstrated, and trans- interactions. The activation of Siglec-2 inhibits BCR activation and subsequent immune response. (B) 
demonstrates defective SIAE function, resulting in increased 9-O-acetylated sialic acid. Siglec-1, -2, and -3 are incapable of binding 
ligands containing 9-O-acetylated sialic acid. A defective SIAE system will therefore result in reduced Siglec-2 suppression of BCR 
activation. This can result in increased autoreactive BCR signaling and immunogenicity. 
 
 
polymorphisms within Siglec-2 and its ligands or 
down- stream intracellular pathways may increase the 
susceptibility of developing antidrug antibodies and 
subsequently subthera- peutic response to therapy. 
However, further research into the effects of these 
polymorphisms within patient populations is required. 
4.4 A role for sialyltransferases in autoimmunity? 
 
A large number of  sialyltransferases  are  responsible  for the  
generation  of  sialic  acids,  ligands  of  the   Siglecs. Sialic acids 
are created in a.2-3, a.2-6, and a.2-8 linkage, depending  on  
















Figure 5. The downregulation of BCR 
signaling caused by cross-linking of Siglec-2. 
(A) BCR becomes phosphorylated and 
activated due to PLCy2, BLNK/SLP65, and BTK 
signal- ing  molecules.  This  leads  to an 
increase in calcium ions (Ca2+ ) from 
endoplasmic retic- ulum (ER). Calcium  ions  are 
also   brought   into   the   cell via the calcium 
release acti- vated channel (CRAC). (B) Af- ter 
cross-linking between BCR and Siglec-2, ITIMs 
of Siglec-2 become phosphorylated by the Src 
kinase, Lyn. This leads to the recruitment of 
SHP-1 tyro- sine phosphatase that subse- 
quently binds to two phospho- rylated ITIMs. 
Calcium stores are depleted within intracellular 








N-glycan, O-linked mucin, or glycolipid [76]. J3-
Galactoside a.-2,6-sialyltransferase-I (ST6Gal-I) is the 
sialyltransferase re- sponsible for creating sialic acids in 
a.2-6 linkage. It has been implicated in the regulation 
and induction of B-cell tolerance and subsequently 
autoimmunity through its role in creating a.2-6 sialic 
acid ligands for Siglec-2. ST6Gal-I deficient mice do 
not mimic the enhanced BCR activation seen in the 
Siglec- 2 null mouse, but do display impaired immune 
responses to thymus-dependent and thymus-
independent antigens [77]. Further research is required 
to elucidate the mechanisms behind this phenotype. 
A recent study by Liu et al. [78] demonstrated that 
ST6Gal- I inhibits TNF-a. mediated macrophage 
apoptosis via sialyla- tion of the TNF receptor 1 and 
downregulation of ST6Gal- 1 enhanced TNF-a. 
mediated macrophage apoptosis. The 
evidence to date suggests that ST6Gal-I may play a key role in 
autoimmunity and subsequent response to TNF-a. targeted 
biological therapy. 
ST3Gal is the sialyltransferase responsible for produc- ing 
a.2-3 linked sialic acids. In the Kidder et al. [79] study, T cells 
expressing the Siglec-1 ligand had increased ST3Gal- III and 
ST3Gal-VI transcript expression. a.2-3 sialylation was also 
found to be essential for Siglec-1 binding and modula- tion 
of T-cell activation (illustrated in Fig. 3). Siglec-1 defi- cient 
mice display an increase in CD8+ T cells within the spleen 
and lymph nodes [80], however ST3Gal-I null mice ex- hibit a 
phenotype displaying relatively reduced levels of CD8+ T cells 
[81]. Again, further research is required to elucidate the 
relationship between ST3Gal, Siglec-1, and circulating T cells 
as well as other immune cell populations. 
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Existing unguided approaches to therapy result in high 
rates of non-response to autoimmunity treatments. 
The mecha- nisms behind non-response are poorly 
understood, limiting the ability to tightly control 
disease and establish remission in a timely fashion. 
This review summarizes evidence of two key protein 
glycosylation-driven pathways of the immune re- 
sponse in ADs. We postulate that perturbed protein 
glycosy- lation observed in autoimmune patients, leads 
to an adverse imbalance of T-cell subsets that can be 
measured as a sur- rogate of non-response or 
resistance to drug therapy. With a clearer knowledge 
of these pathways, it is foreseeable that novel 
monitoring tools could be developed for early stratifica- 
tion of patients onto the most suitable treatment 
regimen. 
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